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Platelets play a fundamental role in thrombosis, but they are increasingly regarded as 
discrete immune cells due to their pro-inflammatory actions on leukocytes and the 
endothelium.  The P2Y12 receptor is responsible for amplifying and sustaining platelet 
activation.  As a result, P2Y12 inhibitors, such as ticagrelor and clopidogrel, form an essential 
component of acute coronary syndrome treatment in preventing thrombotic events.  
Furthermore, P2Y12 receptors have also been identified on vascular smooth muscle cells 
where they mediate cell contraction and mitogenic responses.  This thesis investigates the 
role of P2Y12 in mediating the vessel wall response to injury and to inflammation, specifically 
in atherogenesis, and considers the use of P2Y12 inhibitors in modulating these effects. 
 
I have shown, using a murine ferric chloride injury model, that platelet P2Y12 is crucial in 
mediating thrombus and neointima formation following vessel injury, and that P2Y12 
inhibition at the time of injury was sufficient to prevent their formation. 
 
To investigate the role of P2Y12 in atherogenesis, a novel ApoE/P2Y12 double knockout 
mouse strain was generated and fed a high-fat western diet for 12 weeks, before assessing 
atherosclerotic burden.  Compared to ApoE
-/-
 controls, P2Y12-deficency led to a moderate 
reduction in lesion area, particularly in areas of the vasculature prone to turbulent blood flow, 
such as the aortic arch.  These vessels exhibited characteristics of established disease, with 
advanced lesions, and so atheroma was also assessed after 4 weeks on a western diet.  I 
demonstrated, using bone marrow transplantations, that platelet P2Y12-deficiency profoundly 
reduced platelet reactivity compared to ApoE
-/-
 controls, but had no effect on atheroma; 
whereas vessel wall P2Y12-deficiency significantly attenuated lesion area and led to a less 
mature lesion phenotype.  Treating mice with ticagrelor or clopidogrel for 4 weeks achieved 
effective platelet P2Y12 inhibition, compared to mice treated with mannitol as a control, but 
did not block the vessel wall P2Y12 effect on atherogenesis. 
 
These data describe a previously unknown role for vessel wall P2Y12 in potentiating early 
atherogenesis.  Despite its major contribution to platelet reactivity, platelet P2Y12 had no 
effect at this early stage, and yet is vital in later disease in atherothrombosis and modulating 
neointima formation following vessel injury.  This work emphasises the complexity of cellular 
roles within atherogenesis, and how the impact of these cell populations may change as 
disease evolves.  Further work is required to clarify the extent to which vessel wall and 
platelet P2Y12 influence atherogenesis throughout disease progression, in order to provide a 
clearer understanding of potential pharmacological targets in the prevention and 
management of atherosclerosis. 
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PF4   Platelet factor 4 
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PGI2   Prostaglandin I2 (Prostacyclin) 
PI3K   Phosphoinositide 3-kinase 
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TNF-α   Tumour necrosis factor-α 
TRAP   Thrombin receptor activating protein 
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1.1 The cardiovascular system 
The vertebrate cardiovascular system is a remarkably intricate, versatile, and yet robust 
network.  Our understanding of the heart and its vessels has grown from the very first 
speculations of Aristotle (384 BC), suggesting the heart was the source of all blood vessels, 
to our modern understanding of a closed circulatory system, first described by William 
Harvey (1578-1657). 
 
Prior to Harvey, the concept of blood ‘circulating’ was inconceivable.  The established 
doctrine of Galen (130-199), promoted an open-ended vascular system, whereby blood 
moved from the right to left ventricle via invisible pores in the septum, and slowly ebbed to 
tissues when needed.  This dogma remained unchallenged for nearly 1500 years until, in 
1628, William Harvey published the findings of his extensive experiments, defining the 
closed vascular system we understand today.  He demonstrated that blood must form a 
circuit, with the right ventricle pumping blood to the lungs, via the pulmonary artery, and 
returning to the left ventricle by the pulmonary vein, although he never favoured the idea of a 
direct link.  Nevertheless, just 4 years after Harvey’s death, Malpighi demonstrated the 
existence of capillaries using light microscopy, proving Harvey’s theory conclusively (Aird 
2011). 
 
1.1.1 Diseases of the circulatory system 
Beating continuously over 2.5 billion times on average in a lifetime (based on a life 
expectancy of 80 years), the heart is a truly resilient organ.  However, it is not surprising, 
given the intensive nature and crucial role for the circulatory system, coupled with a modern 
lifestyle that cardiovascular diseases (CVD) remain the leading cause of death in the world, 
accounting for 30% of the 57 million deaths annually.  Estimated at 17.3 million a year, 
deaths from CVD outstrip cancer over two-fold (7.6 million), and this figure is expected to 
rise to 23.6 million by 2030 (WHO 2008). 
 
Although a disease primarily associated with the ageing and wealthier West, this is a 
misconception as over 80% of cardiovascular deaths occur in low and middle income 
regions of the world and is the leading cause of death, second only to lower respiratory 
infections in the lowest income countries (WHO 2008).  An epidemiologic transition is 
evident in these areas, with a shift in deaths from infectious diseases to chronic non-
communicable diseases such as CVD.  Changes in lifestyle and improved nutrition, coupled 
with inadequate access to appropriate healthcare, have led to increased obesity and 
diabetes, particularly in countries such as India, China, and East Asia.  As a result, 
1 Introduction 
2 
 
cardiovascular deaths are rising, and at a faster rate than can be explained by demographic 
changes alone, posing a potential time bomb for developing nations (Yusuf et al. 2001). 
 
Advances in medical treatment and emerging pharmaceuticals have begun to impact in high 
income regions and slow rates of cardiovascular-related death.  Despite this, cardiovascular 
disease still accounts for 50% of deaths in Europe (WHO 2008) and a third of those in the 
UK.  A confounding issue is that of obesity, which is an increasing problem with age and one 
which continues to rise year on year.  In the school year 2008/2009, 23% of reception 
children were either obese or overweight, and by year 6 this rose to 33%.  By the age of 65 
to 74 years, 85% of men and 75% of women are either overweight or obese (Scarborough et 
al. 2010). 
 
Perhaps another factor to consider is the economic cost of tackling cardiovascular disease.  
Estimated at £30 billion a year in the UK, treatment and care for these diseases, with obesity 
rising, could stretch NHS resources to breaking point.  Therefore, development of more 
effective treatments, with a focus on prevention, is a very desirable prospect. 
 
In the face of such stark statistics, the battle against cardiovascular diseases clearly has a 
long way to go, and without intervention is set to become a global epidemic. 
 
1.1.2 Coronary heart disease and acute coronary syndromes 
Cardiovascular disease is a term which covers a broad spectrum of diseases, including 
ischaemic heart and cerebrovascular diseases, cardiomyopathies, and rheumatic and 
hypertensive heart disease.  Although the aetiology of these conditions may vary, the 
majority stem from vascular dysfunction as a direct result of the inflammatory disease 
atherosclerosis, in which vessels become stenosed from the development of complex, fatty 
lesions within the vessel wall.  Coronary heart disease (CHD), also termed coronary artery 
disease (CAD), specifically refers to lesions within the coronary vessels, which compromise 
the lumen and restrict blood flow to the myocardium resulting in diminished cardiac function.  
Of all the cardiovascular diseases, coronary heart disease has the highest mortality, 
accounting for 48% of total deaths from CVD in the UK (Scarborough et al. 2010). 
 
Ischaemia caused by stenosed vessels in CHD manifests as angina, acute chest pain 
experienced upon strenuous activity.  However, as disease develops, lesions can become 
unstable, increasing the risk of thrombosis, which is the dominant cause of acute coronary 
syndromes (ACS) such as myocardial infarction (MI).  The formation of non-occlusive 
thrombus in coronary vessels may present as either unstable angina or non-ST-elevation 
myocardial infarction (NSTEMI).  Both have similar onset, but prolonged ischaemia in MI 
causes tissue necrosis, which is not seen in unstable angina (Cannon and Braunwald 2008; 
Cannon and Lee 2008).  Occlusive thrombus formation is ultimately more life threatening.  It 
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is estimated that approximately 70% of fatal MIs and sudden coronary deaths are as a result 
of atherosclerotic plaque rupture and formation of an occlusive thrombus (Naghavi et al. 
2003).  Complete vessel blockage can cause catastrophic damage to the myocardium from 
transmural necrosis, severely compromising cardiac function.  This type of MI often 
manifests as an ST-elevation myocardial infarction (STEMI), so-called due to an abnormal 
electrocardiogram (ECG) output in the ST segment of the wave. 
 
1.1.3 Risk factors 
A large number of risk factors are associated with coronary heart disease (see Table 1.1).  
These are proven to have causative effect and are the basis on which predictive models, 
such as the Framingham risk score, calculate cardiovascular risk.  Although seen as the 
gold standard for many years, the Framingham score is now outdated and demonstrated 
poor calibration to actual outcomes (Anderson et al. 1991).  In 2010, the UK National 
Institute for Health and Care Excellence (NICE) withdrew its recommendation of using the 
score, leaving the choice of risk model to local organisations (Dent 2010).  More recently, 
the QRISK2 model (Collins and Altman 2012), developed and validated in the UK, includes 
additional variables such as ethnicity and socio-economic deprivation, and shows superior 
calibration and discrimination over Framingham. 
 
In addition to conventional risk factors, a variety of molecular biomarkers are closely linked 
with CHD, including C-reactive protein (CRP), homocysteine, lipoprotein(a), and fibrinogen 
levels.  However, the usefulness of these biomarkers is intensely debated, as a close 
association between the molecule and CHD may not necessarily translate into improved risk 
estimation.  Furthermore, proving a causal effect of these molecules on CHD can often be 
confounded by other factors such as inflammation, although this may not detract from their 
overall value as a biomarker.  Nevertheless, questions have been asked as to what 
advantage they bring to existing prediction models and further investigation is necessary 
(Dent 2010). 
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Table 1.1 – Risk factors for coronary heart disease. 
 
Many risk factors are associated with the development of atherosclerosis and, in particular, 
coronary heart disease.  These can be described as either behavioural or medical risk 
factors, and are used in predictive models to calculate cardiovascular risk (Yusuf et al. 2001; 
Dent 2010; Dent 2010; Scarborough et al. 2010). 
 
Medical  Behavioural 
Elevated LDL cholesterol * Diet 
Low HDL-cholesterol * Smoking * 
Hypertension * Physical inactivity 
Overweight and obesity Alcohol consumption 
Diabetes mellitus *  
Genetic susceptibility  
Infection (e.g. Chlamydia pneumonia)  
*Framingham risk factors  
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1.2 Atherogenesis 
Through his extensive investigations and dissections of the heart, Leonardo da Vinci (1452-
1519) was the first to describe atherosclerotic vessels.  He noted, “the coat thickens so 
much as to close up and stop the movement of blood” and attributed this as a result of, 
“absorbing increased nourishment from the blood” (Keele 1951).  Da Vinci’s observations 
were astonishing for the time, and his hypothesis echoes with a surprising similarity to the 
hypercholesterolaemia (elevated blood cholesterol) theory of recent times. 
 
Supported by abundant data, the link between hypercholesterolaemia and atherosclerosis 
led it to be described simply as a lipid-storage disease for many years.  It was not until the 
1970s, when fundamental work by Russell Ross began to uncover the complex nature of 
atherogenesis, involving cells of the vessel wall and platelets.  Further research by others in 
the 1980s and 90s, established the intrinsic role of the immune system and network of 
signalling pathways involved. Atherosclerosis is now understood to be a chronic 
inflammatory disease influenced by many factors, and involving a vast array of inflammatory 
cells, cytokines, and pathways (Ross 1999; Libby 2002). 
 
1.2.1 Aetiology 
The pathogenesis of atherosclerosis is influenced by a multitude of lifestyle choices, along 
with medical conditions, and the haemodynamics of blood flow itself.  It is a chronic disease 
which develops over a lifetime.  Lesions can take many years, even decades to develop, 
with those affected often remaining symptomless for the majority of their lives, unaware of 
underlying disease.  Evidence shows the process can even begin before birth, with the 
discovery of fatty streaks and intimal accumulation of low density lipoprotein (LDL) in foetal 
aortas aged 5-7 months (Napoli et al. 1997).  This was enhanced with maternal 
hypercholesterolaemia and is a clear example of how lifestyle can translate into disease.  
However, despite the many factors and elements to atherogenesis, all begin with an initial 
insult to the artery wall. 
 
1.2.2 Response to injury hypothesis 
The concept of atherogenesis as a response to injury is not a new one.  Rudolph Virchow, in 
1856, was among the first to suggest, “an inflammation of the inner arterial coat to be the 
starting point of the so-called atheromatous degeneration” as a result of an initial ‘irritation’ 
(Virchow 1971).  However, 120 years later, Ross and Glomset proposed a modified and 
more detailed response-to-injury hypothesis, which has since become the cornerstone of 
atherosclerosis research.  This suggested lesions develop as a result of subtle injury to the 
vasculature caused by a range of factors such as mechanical injury, chemical factors, 
infection, or the effects of chronic hyperlipidaemia on the vascular endothelial cells  (Ross 
and Glomset 1976). 
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Their initial hypothesis suggested that injury may alter cells of the vessel wall, possibly 
leading to their detachment altogether.  Platelet adherence and aggregation would ensue, 
permitting infiltration of platelet-derived factors and lipoproteins at the site of injury, and 
initiating vascular smooth muscle cell (VSMC) mitogenesis (Ross et al. 1977).  
Investigations in later years favoured endothelial dysfunction over denudation.  One such, in 
a rat model of hypercholesterolaemia, observed leukocytes adhering to the endothelium at 
sites where atherosclerotic plaques later formed (Joris et al. 1983).  Crucially, no endothelial 
denudation was seen, and so concluded it was not necessary in the pathogenesis.  Thus, in 
the early 1990s, the response to injury hypothesis was modified to describe endothelium 
dysfunction following injury, and include the key role of inflammatory cells such as 
monocytes, macrophages, and T lymphocytes in lesion formation (Ross 1993).  The concept 
of stem and progenitor cell involvement in atherogenesis has also been considered (Sata et 
al. 2002).  This has gained increasing attention, with a recent study suggesting MI can 
instigate stem cell release from the bone marrow and elicit a secondary inflammatory 
response by enhancing monocyte recruitment, consequently accelerating atherosclerosis 
(Dutta et al. 2012).  Likewise, increasing evidence of platelet interactions with the 
inflammatory system has generated great interest in their involvement in atherogenesis.  As 
the focus of this thesis, platelet biology, and the specific role of platelets in inflammation and 
atherogenesis will be discussed later in detail from section 1.4 onwards.  However, I will first 
describe the established cell roles and processes involved in lesion formation and 
atherothrombosis. 
 
1.2.3 Endothelial activation 
The healthy endothelium acts as a protective barrier, separating surrounding tissues from 
circulating blood, and controlling the passage of cells and molecules across its surface.  It 
has natural anti-thrombogenic properties (Rosenberg and Rosenberg 1984), and crucially 
resists the attachment of cells to its surface.  When dysfunction ensues following injury, the 
endothelium loses these properties and becomes pro-thrombotic, has increased permeability 
to circulating cells, and begins to express adhesion molecules on its surface. 
 
The selectins (E, L and P), along with their ligands, are among the first to be expressed, and 
mediate leukocyte capture and rolling on the endothelial surface (Alon et al. 1995).  
Specifically monocytes, T lymphocytes and neutrophils are captured, as well as platelets.  
Initial tethering is via either P-selectin (CD62P), found on the endothelium and activated 
platelets, or L-selectin (CD62L), expressed constitutively on all leukocytes, which binds to 
CD34 on the endothelium (Baumhueter et al. 1994).  P-selectin glycoprotein ligand-1 
(PSGL-1), present on all leukocytes and activated platelets, and upregulated in activated 
endothelial cells, enables leukocyte capture and platelet adherence via P-selectin (Norman 
et al. 1995; Frenette et al. 2000).  PSGL-1 is also a ligand for E-selectin (CD62E), expressed 
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on the endothelium, and is important in slow rolling, an essential step for firm leukocyte 
adhesion (Asa et al. 1995; Ley et al. 1998). 
 
Integrins and cell adhesion molecules (CAM) are expressed on a variety of cell types, and 
permit cells to bind to each other, as well as to extracellular matrix (ECM).  They are 
responsible for the firm arrest of leukocytes on to the endothelium where integrins, such as 
very late antigen-4 (VLA-4), bind to their respective CAMs, including vascular cell adhesion 
molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1), expressed on the 
activated endothelial surface (Springer 1995).  In addition, ICAM-1 has a binding domain for 
fibrinogen (D'Souza et al. 1996), which is converted by thrombin into fibrin as part of the 
coagulation cascade, thus enhancing the procoagulant properties of the dysfunctional 
endothelium.  
 
Once adherent to the endothelium, leukocytes migrate to the vessel intima through 
endothelial cell junctions as the final stage of the leukocyte adhesion cascade (diapedesis).  
This is facilitated by adhesion molecules such as platelet/endothelial cell adhesion molecule-
1 (PECAM-1), expressed on leukocytes, endothelial cells, and platelets (Muller 1995), and 
ICAM-1 (Shaw et al. 2004). 
 
1.2.4 Predisposed sites 
The location of VCAM-1 and ICAM-1 expression in the vasculature corresponds to the areas 
prone to lesion development, as demonstrated in animal models of atherogenesis (Li et al. 
1993; Nakashima et al. 1998).  Presence of these adhesion molecules are an early indicator 
of endothelial dysfunction, preceding fatty streak formation (Nakashima et al. 1998), and are 
rapidly upregulated in response to injury.  In a rabbit model of hypercholesterolaemia, focal 
VCAM-1 expression was evident after only 1 week of feeding on a high-fat diet (Li et al. 
1993). 
 
Elevated cholesterol is a systemic issue, yet atherosclerosis is a phenomenon that is often 
only seen at very specific points in the vasculature, typically the branches, bifurcations, and 
curvatures of vessels.  These predisposed sites correspond to areas of disturbed blood flow, 
characterised by oscillatory flow and recirculation of blood, resulting in low and fluctuating 
wall shear stress (Ku et al. 1985; Asakura and Karino 1990).  Where blood flow is steady 
and unidirectional, laminar shear stress is exerted across the artery wall.  Endothelial cells 
can transduce these haemodynamic forces into cellular responses, and are thought to detect 
shear stress via receptors such as PECAM-1 (Tzima et al. 2005). 
 
In response to laminar shear stress, nitric oxide synthase (NOS) and cyclooxygenase-2 
(COX-2) are upregulated (Topper et al. 1996).  These have a role in regulating vascular tone 
by producing nitric oxide (NO) and prostaglandin I2 (PGI2), which are potent vasodilators.  
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NO also has an athero-protective role, as it has been shown to significantly inhibit VCAM-1, 
ICAM-1, and E-selectin expression, as well as suppress leukocyte chemoattractant 
secretion, such as interleukin-6 (IL-6) and 8 (CXCL8).  The effects of shear stress on gene 
expression are thought to be regulated by flow-responsive transcription factor activity (De 
Caterina et al. 1995; Peng et al. 1995; Tsao et al. 1996). 
 
Therefore in areas of disturbed blood flow and resulting low shear stress, athero-protective 
mechanisms of the endothelium are no longer initiated and adhesion molecule expression is 
upregulated.  The endothelium then takes on a pro-inflammatory profile, which promotes 
leukocyte adhesion to the endothelial surface. 
 
1.2.5 Modified LDL 
Uptake and retention of LDL within the vessel wall is a potent stimulus for atherogenesis 
(Schwenke and Carew 1989).  Native LDL is taken into the endothelium, via the LDL 
receptor (LDL-R) (Brown and Goldstein 1986), and becomes progressively oxidised by free 
radicals (Morel et al. 1984) and lipoxygenases (Harats et al. 2000).  Oxidised LDL (ox-LDL) 
is chemotactic for monocytes (Quinn et al. 1987), and can induce pro-inflammatory cytokine 
secretions, such as monocyte chemotactic protein-1 (MCP-1/CCL2) (Cushing et al. 1990) 
and macrophage colony stimulating factor (M-CSF) (Rajavashisth et al. 1990).  Furthermore, 
ox-LDL stimulates expression of endothelial adhesion receptors, including VCAM-1 (Khan et 
al. 1995) and P-selectin (Gebuhrer et al. 1995), thereby enhancing leukocyte recruitment 
and adhesion to the endothelium. 
 
1.2.6 Early lesion development 
Monocytes and macrophages 
Stary et al. astutely described the distinct morphological and histological changes observed 
during atherogenesis, as lesions develop.  The very earliest vascular changes seen are 
subtle, characterised by small clusters of lipid-laden macrophages (foam cells) confined to 
the intima (Stary et al. 1994) (see Figure 1.1).  This signifies one of the main consequences 
of endothelial dysfunction, with expression of adhesion receptors enabling leukocytes, 
primarily monocytes, to bind to the endothelium.  Once adherent, monocytes migrate 
between endothelial cells in response to chemokines, such as MCP-1 and IL-8, secreted 
from monocytes and endothelial cells, respectively (Papadopoulou et al. 2008).  In the 
intima, macrophage M-CSF augments the differentiation of monocytes into macrophages 
(Clinton et al. 1992), thus enabling the uptake of LDL via scavenger receptors, and leading 
to foam cell formation.   
 
Leukocyte attachment to the endothelium results in activation of both cells and initiates a 
cascade of events, such as the expression of adhesion receptors and secretion of a vast 
array of pro-inflammatory cytokines and enzymes.  The intention of this immune response is 
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to recruit further cytokine-releasing leukocytes to the site of inflammation, and so a positive 
feedback loop is established.  Innate cytokines IL-1 and tumour necrosis factor (TNF)-α, 
released from monocytes, macrophages, and endothelial cells, are central mediators of 
these inflammatory mechanisms, and are involved in cell activation, proliferation, production 
of further cytokines, and upregulation of adhesion receptors (Loppnow et al. 2011).  
Secreted chemokines MCP-1 and IL-8 have been shown to have an additional role in 
leukocyte recruitment, triggering firm arrest of monocytes to the endothelium (Gerszten et al. 
1999).  Furthermore, mice deficient in TNF-α (Ohta et al. 2005), MCP-1 (Boring et al. 1998), 
M-CSF (Smith et al. 1995), and IL-1 (Kirii et al. 2003; Kamari et al. 2007), or its receptor IL-
1R1 (Chamberlain et al. 2009), all exhibit significantly reduced atherosclerotic lesion 
formation, demonstrating the important role of these cytokines in the early pathogenesis of 
atherosclerosis. 
 
T Lymphocytes 
MCP-1 has also been shown to be a strong chemoattractant for T lymphocytes (Carr et al. 
1994; Roth et al. 1995), which are present in early lesions (Hansson et al. 1989), albeit in 
smaller numbers than macrophages.  Another T cell chemokine RANTES (regulated upon 
activation, normal T cell expressed and secreted/CCL5) is released from activated T cells to 
aid further leukocyte recruitment (Schall et al. 1990). 
 
Neutrophils 
Despite being the most abundant white blood cell, little is known of the involvement of 
neutrophils in atherosclerosis.  Although rarely detected, neutrophils are present in lesions 
(Rotzius et al. 2010), and are recruited via IL-8 and RANTES release.  It is postulated that 
neutrophils may contribute to atherogenesis via their activation and degranulation, causing 
release of leukocyte chemokines such as cathepsin G (Drechsler et al. 2011). 
 
CD40/CD40L 
Among this potent cocktail of inflammatory cytokines involved in atherogenesis, is a 
receptor-ligand pair of particular importance in cell cross-talk.  CD40 and its ligand 
(CD40L/CD154) mediate signalling between virtually all cells within this inflammatory 
system.  Both present on endothelial, smooth muscle, and T cells, macrophages, and 
platelets, CD40 and CD40L initiate many inflammatory responses, and are expressed in 
atherosclerotic lesions (Mach et al. 1997).  Blockade of CD40 signalling inhibits lesion 
formation (Mach et al. 1998; Schonbeck et al. 2000), and in existing atherosclerosis, 
promotes plaque stability (Lutgens et al. 2000).  Ligation of CD40 evokes VCAM-1 and P-
selectin expression in endothelial cells (Kotowicz et al. 2000), and IL-1β release (Schonbeck 
et al. 1997). 
  
10 
 
 
Figure 1.1 – Summary of the key features of lesion progression, which occur during 
atherogenesis. 
 
In the healthy vessel, factors such as laminar blood flow and high shear stress promote 
athero-protective mechanisms in the vessel wall.  These include an increase in nitric oxide 
production, which supresses the expression of adhesion receptors on endothelial cells.  
Upon an insult to the vessel wall, such as high levels of circulating LDL, the endothelium 
becomes activated and begins to express a range of selectins, integrins, and cell adhesion 
molecules.  These permit leukocytes, lymphocytes and platelets to adhere to the vessel 
wall, which in turn causes the release of further cytokines to recruit additional inflammatory 
cells to the area.  Monocytes migrate into the vessel intima where they differentiate into 
macrophages, and begin to phagocytosis LDL, after which they become foam cells.  The 
continued release of cytokines and growth factors promotes the migration and proliferation 
of further cells into the intima, including vascular smooth muscle cells from the vessel 
media.  An accumulation of these lipid-laden cells, and the synthesis of collagen and other 
extracellular matrix components, cause the intima to thicken and protrude into the vessel 
lumen.  Cell apoptosis and necrosis leads to the formation of a lipid-rich necrotic core and 
the release of matrix metalloproteinases, which degrade the extracellular matrix and de-
stabilise the lesion.  Plaque erosion, fissure, or rupture ensues, and causes the pro-
thrombotic contents of the lesion to be exposed to circulating blood, initiating 
atherothrombosis.  Platelets rapidly activate and aggregate to form a thrombus, which may 
then block the vessel and lead to an acute coronary syndrome. 
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1.2.7 Advanced lesion development 
So-called ‘early’ atherosclerotic lesions do not necessarily occur early in life, like their name 
may suggest, as these lesions can be found in the vessels of adults and children alike.  
Atheroma growth itself is by no means a continuous process, with periods of stabilisation 
followed by bursts of growth.  Indeed, lesion progression is not automatic and may halt, 
requiring further stimulus for growth to proceed.  It is thought that progression to so-called 
‘advanced’ lesions requires an added impetus, such as other CVD risk factors (see section 
1.1.3), or areas of disturbed blood flow (Stary et al. 1994; Libby 2002). 
 
Characteristics of advanced lesions, as defined by Stary et al., include accumulations of 
cells, lipid, and matrix components, and thickening of the intima causing deformity of the 
arterial wall (see Figure 1.1).  In addition, the build-up of products from apoptosis and 
necrosis lead to the formation of a necrotic core.  These now complex, fibrotic and 
sometimes calcified lesions, completely obliterate the once normal cell and matrix structure 
of the original vessel wall (Stary et al. 1995).  Despite these extensive changes to the 
vessel, lumen area may not initially be affected due to outward remodelling of the artery, and 
consequently individuals can remain symptomless (Glagov et al. 1987; Clarkson et al. 1994).  
However, these lesions may still be clinically significant since, with or without vessel 
stenosis, they are prone to fissures and rupture that can lead to thrombosis and acute 
coronary syndromes. 
 
Vascular smooth muscle cells 
VSMCs play a role throughout all stages of atherosclerosis as they too express adhesion 
receptors (Braun et al. 1995) and release an array of cytokines when activated, such as IL-1, 
TNF-α, M-CSF, and MCP-1, contributing to leukocyte recruitment.  Yet their ability to 
migrate, proliferate, and to synthesise and deposit collagen and extracellular matrix make 
VSMCs particularly important in transforming atherosclerotic lesions from early to mature 
plaques (Ross 1999; Raines and Ferri 2005). 
 
Induction of migration and proliferation is driven through release of growth factors, such as 
platelet-derived growth factor (PDGF) and transforming growth factor (TGF) β, from 
activated cells in the vessel wall.  As the name suggests, PDGF was first identified as a 
platelet releasate that demonstrated mitogenic effects on cultured VSMCs (Ross et al. 
1974).  However, various isoforms (PDGF A-D) are also released from macrophages 
(Shimokado et al. 1985) and endothelial cells (DiCorleto and Bowen-Pope 1983), as well as 
smooth muscle cells themselves, acting in an autocrine manner (Nilsson et al. 1985).  Action 
of cytokines, such as IL-1 and TNF-α, can also influence VSMC proliferation through 
induction of PDGF secretion (Hajjar et al. 1987; Raines et al. 1989).  Indeed, the expression 
of PDGF and its receptors have been found to be increased in atherosclerotic lesions 
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(Barrett and Benditt 1987; Rubin et al. 1988), and in vivo models blocking the action of 
PDGF have clearly shown a reduction in atheroma (Lamb et al. 2001; Sano et al. 2001). 
 
TGF-β is another growth regulatory molecule, which tightly controls cell proliferation and 
differentiation in many cell types, including VSMCs (Bobik 2006).  Cellular expression levels 
of TGF-β determine either its inhibitory, or stimulatory effect on VSMC proliferation via 
PDGF.  Low concentrations of TGF-β induce endogenous secretion of PDGF from smooth 
muscle cells, creating an autocrine loop.  In contrast, high levels limit proliferation via down 
regulation of the PDGF receptor (Battegay et al. 1990). 
 
Extracellular matrix deposition 
In addition to their effects on proliferation, TGF-β and PDGF are also potent inducers of 
collagen and proteoglycan production in VSMCs (Amento et al. 1991; Schonherr et al. 
1993).  Indeed, TGF-β-mediated matrix deposition is crucial in plaque progression, fibrosis, 
and stabilisation.  Inhibition of TGF-β signalling, via a soluble recombinant TGF-β receptor, 
dramatically altered plaque composition to a pro-inflammatory phenotype prone to 
haemorrhage, characterised by large lipid cores and decreased fibrosis (Lutgens et al. 
2002).  Moreover, analysis of TGF-β expression in human carotid lesions noted a 3-fold 
increase in asymptomatic lesions compared with those of patients presenting with stroke, 
further supporting the role of TGF-β in plaque stabilisation (Cipollone et al. 2004). 
 
VSMC phenotype 
Vascular smooth muscle cells demonstrate great plasticity, and have the ability to modulate 
their phenotype in response to environmental cues.  VSMCs are largely described as 
switching between either quiescent, ‘contractile’ or proliferative, ‘synthetic’ states; however, 
these fall at opposite ends of the spectrum with many intermediate phenotypes in between.  
Subtle or profound changes in migratory and mitogenic responses, matrix production, 
expression of cell markers and adhesion receptors, and secretion of cytokines result in a 
widely heterogeneous population (Owens et al. 2004). 
 
Contractile cells of the media migrate to the intima in response to inflammatory stimuli.  In 
doing so, VSMCs switch to a synthetic phenotype and down regulate their characteristic 
contractile markers, including α-smooth muscle actin (α-SMA), desmin, and smooth muscle 
myosin heavy chain (SM-MHC).  So-called ‘synthetic’ VSMCs are able to migrate and 
proliferate, and have increased capacity for ECM deposition and cytokine secretion (Owens 
et al. 2004).  Key mediators of phenotypic modulation include PDGF (Chen et al. 2006), 
TGF-β (Hautmann et al. 1997), ECM (Thyberg and Hultgardh-Nilsson 1994), shear stress 
(Reusch et al. 1996), and lipids (Pidkovka et al. 2007).  
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As VSMCs proliferate in the lesion, structural reorganisation occurs from ordered concentric 
layers, to a large jumbled mass of cells abundant in rough endoplasmic reticulum and golgi 
bodies, a clear indicator of ECM synthesis (Ross and Klebanoff 1971; Thyberg et al. 1983).  
Accumulation of ECM, and fibrous cap formation, alter the mechanical properties of the 
lesion and arterial wall.  VSMCs that are incorporated in the cap, revert back to a contractile 
phenotype and contribute to the stabilisation of the plaque (Babaev et al. 1990; van der Loop 
et al. 1997). 
 
The concept that lesional VSMCs originate from the vessel media is an issue which is hotly 
debated.  Whilst several studies have identified the recruitment of bone marrow-derived 
progenitor cells as an additional, alternative source (Sata et al. 2002; Tanaka et al. 2003; Yu 
et al. 2011), others dispute the involvement (Hu et al. 2002; Bentzon et al. 2006) and lineage 
of these cells (Iwata et al. 2010), and so the matter continues to be contested. 
 
1.3 Atherothrombosis 
Classically, acute coronary events were thought to be caused by the rupture of thin capped 
atheromas with a large lipid-rich core.  Although this is true, clinicians now understand many 
different types of lesions can led to coronary events and be vulnerable not only to rupture, 
but erosion and fissure also.  A wide spectrum of lesions, including those with evidence of 
previous thrombus or intra-plaque haemorrhage, and those with fibrotic, calcified, and 
critically stenotic plaques, are all at risk of atherothrombosis (Naghavi et al. 2003; Schaar et 
al. 2004). 
 
1.3.1 The vulnerable lesion 
Plaque disruption is facilitated by a loss of structural integrity within the plaque due to 
degradation of extracellular matrix proteins by matrix metalloproteinases (MMP), a process 
that is then further fuelled by apoptosis and necrosis. 
 
The accumulation of macrophages and their eventual death occurs throughout lesion 
progression.  In early disease, macrophage apoptosis is thought to be beneficial and limits 
lesion growth (Liu et al. 2005); however, in advanced disease, the phagocytosis of these 
apoptotic cells becomes impaired (Schrijvers et al. 2005), leading to necrosis and the 
formation of a necrotic core (Ball et al. 1995; Tabas 2005).  This impaired clearance of 
apoptotic macrophages further promotes inflammation via the release of cytokines, including 
TNF-α (Grainger et al. 2004), which has itself been shown to stimulate macrophage-induced 
VSMC apoptosis (Boyle et al. 2003) and induce MMP expression (Galis et al. 1994).   
 
Matrix metalloproteinases are a group of proteases consisting of collagenases, gelatinases, 
and stromelysins, amongst other subclasses, which catalyse the breakdown of ECM.  MMPs 
are elaborated from macrophages, endothelial, and vascular smooth muscle cells in 
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response to cytokines, such as IL-1 and TNF-α (Galis et al. 1994; Saren et al. 1996), and T 
lymphocyte-mediated CD40 ligation (Mach et al. 1997; Mach et al. 1999; Schonbeck et al. 
1999; Horton et al. 2001).  Collagenases (MMP-1, 8 and 13) are responsible for collagen 
fibre degradation, and have been found to be expressed at rupture-prone sites in 
atherosclerotic plaques (Galis et al. 1994; Sukhova et al. 1999; Herman et al. 2001), along 
with stromelysins (MMP-3 and 11), and gelatinases (MMP-2 and 9) (Henney et al. 1991; 
Galis et al. 1994; Schonbeck et al. 1999), which degrade other ECM proteins.  The action of 
these MMPs, coupled with a reduction in matrix-producing VSMC due to apoptosis, lead to a 
dramatic loss of ECM within the lesion.  Fuelled by macrophage apoptosis and necrosis, it is 
therefore not surprising that these processes are all associated with unstable lesions and 
sites of plaque rupture (Galis et al. 1994; van der Wal et al. 1994; Bauriedel et al. 1999). 
 
1.3.2 The pro-thrombotic lesion 
Just as in early atherogenesis where they were among the driving forces of inflammation, 
macrophages and VSMCs are equally influential in advanced disease by increasing the 
thrombogenicity of the lesion.  Wilcox et al. were the first to identify the presence of tissue 
factor (TF), a potent catalyst of the coagulation cascade, within the media of healthy vessels, 
but noticed that atherosclerotic lesions had much higher levels, which was localised to 
macrophages, the necrotic core, and ECM (Wilcox et al. 1989).  Others later discovered that 
macrophage apoptosis and TF content both correlated with the thrombogenicity of the lesion 
(Kaikita et al. 1997; Toschi et al. 1997; Hutter et al. 2004). 
 
As mentioned previously, CD40 and its ligand are expressed on many cells within the lesion 
(Mach et al. 1997).  In addition to potentiating atheroma, CD40 ligation has also been shown 
to induce TF expression on the surface of macrophages (Mach et al. 1997) and VSMCs 
(Schonbeck et al. 2000), rendering the lesion pro-thrombotic.  Furthermore, microparticles 
shed from apoptotic cells within the lesion have been found to not only contain TF, but also 
bear the phospholipid phosphatidylserine (PS) on their surface, which also promotes 
thrombosis (Mallat et al. 1999). 
 
1.3.3 Thrombosis 
Plaque disruption is understood to be brought about by either the physical forces of blood 
flow acting on weaker areas of the lesion, or as a result of internal destabilisation of the 
lesion, although perhaps the more likely scenario is a combination of both (Fuster et al. 
2005).  Upon rupture, the TF-rich contents of the plaque are released into the blood, 
initiating the extrinsic pathway of the coagulation cascade and contributing to thrombosis.  
Platelets (Schwertz et al. 2006; Panes et al. 2007), leukocytes (Giesen et al. 1999), and their 
microparticles (Rauch et al. 2000) are known to be additional sources of TF. 
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Exposure of collagen in the damaged vessel wall, as well as activated platelets, initiate the 
intrinsic coagulation pathway, which later converges with the extrinsic pathway in the final 
common steps which lead to thrombin and fibrin generation.  Platelets rapidly activate in 
response to thrombin, a potent platelet agonist, or upon adhering to vessel collagen, and 
quickly form platelet aggregates.  These become incorporated within the developing fibrin 
matrix, along with trapped leukocytes and red blood cells (RBC), to form a large platelet and 
fibrin-rich thrombus capable of occluding vessels.  In addition, activated platelets further 
promote thrombosis by enabling thrombin generation on their outer membrane, following the 
exposure of PS on their surface (Dahlback 2000). 
 
In the following section, platelet biology, activation and aggregation, and the role of the 
P2Y12 receptor in these processes will be discussed in greater detail. 
 
1.4 Platelets 
In 1865, German anatomist Max Schultze (1825-74) was the first to describe the presence of 
colourless ‘sphericules’, approximately 2 µm in diameter, in the blood (Schultze 1865).  
However, ground-breaking work by Giulio Bizzozero (1846-1901) discovered platelets were 
important in thrombosis and coagulation, and able to rapidly adhere to the vessel, forming a 
thrombus.  Bizzozero considered platelets as the third constituent of the blood, 
morphologically distinct from red, and white blood cells, as granulated anucleate cells or 
‘corpuscles’ (Bizzozero 1882; Brewer 2006). 
 
As Bizzozero correctly postulated, the primary physiological role of platelets is detecting 
vascular damage, via exposure of vessel substratum, and rapidly aggregating.  Platelet 
activation leads to thrombin generation, which activates the coagulation cascade and 
ultimately results in the development of a fibrin-rich haemostatic plug, halting any blood loss.  
Nevertheless, in addition to haemostasis, there is a growing appreciation of the important 
role of platelets in the innate and adaptive immune response (Semple et al. 2011). 
 
1.4.1 Production 
Platelets are derived from megakaryocytes in the bone marrow, and enter the bloodstream 
following a complex process of mass assembly and release.  A single megakaryocyte is 
capable of producing thousands of platelets, and does so by amplifying its DNA many times 
over.  The cells enlarge, and the cytoplasm fills with ribosomes, organelles, granules, and a 
vast membranous and tubular network (Patel et al. 2005). 
 
Now packed with platelet components, the megakaryocytes develop pseudopodia, which 
elongate into long pro-platelet strings.  Platelet granules, organelles, and membrane network 
are packaged into the pro-platelet ends, where platelets are assembled (Italiano et al. 1999).  
Pro-platelet formation is amplified by continual elongation and branching, driven by sliding of 
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the microtubules (Patel et al. 2005), until the entire megakaryocyte cytoplasm is converted 
into pro-platelets.  These are released, leaving an extruded nucleus behind.  Individual 
platelets are then liberated from the pro-platelet ends, and have a lifespan of 8 to 10 days 
(Patel et al. 2005).  With a normal platelet count between 150 and 400 x 10
9
 platelets per 
litre of blood, an average adult has approximately one trillion platelets circulating at any one 
time. 
 
1.4.2 Structure  
In their resting state, platelets circulate as small, oval, lentiform discs.  This shape is 
maintained by a specialised cytoskeleton which, upon platelet activation, can reorganise, 
altering the platelet structure into spiny spheres.  Inside the platelet, α granules, dense 
granules, and lysosomes act as storage compartments for a plethora of molecules, including 
inflammatory mediators, adhesive proteins, coagulation factors, and platelet agonists.  An 
immense intracellular membrane network, called the open canalicular system, permeates 
the cytoplasm and connects to the surface of the platelet, functioning as an exit route for 
granule contents.  In addition, the self-contained dense tubular system acts as an 
intracellular store for calcium, the release of which is important in many phases of platelet 
activation.  Surface receptors mediate platelet activation in response to a range of stimuli, 
including adhesion to matrix proteins, or exposure to soluble agonists, such as thrombin, 
adenosine diphosphate (ADP), and thromboxane A2 (TxA2) (see Figure 1.2) (White 2006). 
 
1.4.3 Adhesion 
Following plaque rupture, or other instances of vessel damage, ECM components, including 
collagen, von Willebrand factor (vWF), and fibronectin are exposed to blood flow.  Integrins 
and receptors mediate initial platelet tethering to these components, followed by platelet 
activation via receptor-mediated signalling.  Downstream events from these pathways 
include calcium release from intracellular stores, platelet shape change, granule secretion, 
and ultimately activation of platelet integrins, GPIaIIa (α2β1) and GPIIbIIIa (αIIbβ3), enabling 
firm adhesion and aggregation (Nieswandt et al. 2011). 
 
Due to their small size, platelets naturally accumulate and flow adjacent to the vessel walls 
by a process called margination.  This positioning is beneficial to their role in haemostasis; 
however, flowing at high shear, platelets need to be slowed prior to firm adhesion and 
activation.  Initial platelet attachment to the sub-endothelium occurs via collagen-bound 
vWF, and platelet receptor GPIb, part of the receptor complex GPIb-IX-V (also referred to as 
GPIb-IX).  High shear flow rates stretch the platelet membrane around GPIb, bound to vWF, 
to form elongated tethers, which may break, but ultimately slow the platelet to allow 
activation and firm adherence (Dopheide et al. 2002). 
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Figure 1.2 – Ultrastructure of a resting platelet. 
 
The lentiform shape of a resting platelet is maintained by the specialised cytoskeleton 
and microtubule coil.  Lysosomes, dense, and α granules act as storage compartments, 
releasing their contents upon platelet activation.  The open canalicular system permeates 
the cytoplasm, and is connected to the plasma membrane, which provides an exit route 
for granule contents during release.  Intracellular calcium is stored in the dense tubular 
network, and is rapidly mobilised upon platelet activation.  Membrane receptors initiate 
these activation responses, following platelet adhesion or exposure to soluble agonists. 
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Tethered platelets are then able to interact with collagen, the most reactive ECM 
component, via the Ig receptor GPVI.  Ligation of this receptor elicits an intracellular 
signalling response, leading to firm arrest of the platelet through activation of integrins 
GPIaIIa, which binds to collagen, and GPIIbIIIa, enabling both vWF and fibrinogen binding 
(Nieswandt and Watson 2003).  In the absence of GPVI signalling, mouse platelets were 
unable to adhere to collagen in either static or flow conditions, despite normal expression of 
GPIb-IX and the platelet integrins; therefore, demonstrating the essential role of GPVI in 
platelet activation and adhesion (Nieswandt et al. 2001). 
 
1.4.4 Activation and receptor signalling 
Platelets are able to respond to a range of agonists due to the wide variety of receptors 
present on their membranes (see Figure 1.3).  Activation can occur via adhesion to ECM, as 
described above, or by exposure to soluble agonists, signalling via G protein-coupled 
receptors (GPCR).  The activation response can be viewed as a 2-step process, with initial 
receptor signalling followed by secondary amplification from the release of endogenous 
agonists stored within the dense granules (Li et al. 2010). 
 
A network of signalling pathways lie between the initial activating stimulus of receptor 
ligation, and their end-point responses of shape change, granule secretion, and platelet 
aggregation.  These pathways are complex, involve multiple feedback loops, and are 
interlinking, with phospholipase C (PLC), calcium (Ca
2+
) mobilisation, and Src family kinase 
forming common intermediary steps for signal transduction through many receptors.  In 
addition, several GPCRs are coupled to the same G protein, for example thrombin, TxA2, 
serotonin (5HT), and ADP all signal via Gq (see Figure 1.4). 
 
1.4.5 Shape change 
The earliest physiological response to activation is platelet shape change, brought about by 
rearrangement of the actin cytoskeleton.  Regulatory proteins control the dynamics of the 
cytoskeleton, and mediate the disassembly of actin filaments upon platelet activation.  
Platelets take on a spherical form, and the reassembly of new actin filaments result in finger-
like protrusions extending from the plasma membrane.  If adhered to a surface, the platelets 
then flatten and spread (Hartwig 2006). 
 
Initiation of this cascade of events is mediated by Ca
2+
 mobilisation (Rosenberg et al. 1981), 
and phosphorylation of myosin II, a cytoskeleton regulatory protein, by myosin light chain 
kinase (MLCK) (Daniel et al. 1994).  Virtually all platelet receptors result in Ca
2+
 mobilisation 
from the dense tubules due to the activation of PLCβ or γ in their signalling pathways.  
However, investigations by Paul et al. demonstrated that shape change can also occur in the 
absence of calcium, via activation of RhoA and its kinase, which can stimulate MLCK and 
myosin II phosphorylation independently of calcium (Paul et al. 1999).  
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  Figure 1.3 – Overview of platelet receptors and activation responses. 
 
Platelets possess many surface receptors for a variety of ligands capable of inducing 
platelet activation.  GPIb-IX and VI initiate activation responses via adhesion to the 
vessel wall to either collagen, or von Willebrand factor (vWF).  Soluble mediators, such 
as thrombin, serotonin (5HT), and thromboxane (TxA2), act via their respective receptors 
shown.  Platelet activation results in shape change, granule release, and aggregation.  
Dense and α granules release their contents, including platelet agonists and 
inflammatory mediators.  Adenosine diphosphate (ADP) released from the dense 
granules acts on the purinergic receptors P2Y1 and 12, shown in bright blue.  P2Y12 is of 
particular importance, as this plays a key role in amplifying the activation response.  This 
includes the transformation of integrin GPIIbIIIa (αIIbβ3) from a low to high affinity state, 
enabling it to bind fibrinogen, and form platelet aggregates. Adapted from Storey (2006). 
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Figure 1.4 – Summary of platelet receptor signalling pathways. 
 
Platelets become activated upon adhesion to extracellular membrane proteins, via 
receptors GPIb-IX and GPVI, or by exposure to soluble agonists, signalling via G protein-
coupled receptors.  A network of signalling pathways lie between the initial activating 
stimulus of receptor ligation, and their end-point responses of shape change, granule 
secretion, and platelet aggregation.  These complex pathways involve multiple feedback 
loops, and have a degree of cross-over, with phospholipase C (PLC), calcium (Ca
2+
) 
mobilisation, and Src kinases forming common intermediary steps for signal transduction 
through many receptors.  In addition, several G protein-coupled receptors are coupled to 
the same protein, for example thromboxane (TxA2), thrombin, serotonin (5HT), and 
adenosine diphosphate (ADP) all signal via Gq.  The important role of P2Y12 signalling in 
platelet activation is highlighted by the blue arrows.  P2Y12 is coupled to Gi and inhibits 
adenylyl cyclase (AC) activity.  P2Y12 works in a synergistic manner with P2Y1 to bring 
about ADP-induced platelet aggregation, through phosphoinositide 3-kinase (PI3K) 
activity and integrin αIIbβ3 (GPIIbIIIa) activation, leading to irreversible platelet 
aggregation.  Importantly, P2Y12 also amplifies and sustains platelet activation in 
response to other platelet agonists, including thrombin, TxA2 and collagen, demonstrating 
its crucial role in platelet reactivity. 
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1.4.6 Secretion 
An activation response common to all signalling pathways is platelet secretion, including the 
release of granule contents, incorporation of granule membranes with the plasma 
membrane, and the generation and secretion of TxA2.  Platelets contain a variety of storage 
vesicles, which are pre-packaged with a vast array of proteins, receptors, and molecules 
capable of inducing pro-thrombotic, atherogenic, and bactericidal effects upon exocytosis 
(see Table 1.2).  The dense and α granules are the most abundant of these vesicles, and 
play an important role in the amplification of platelet activation, coagulation, and the 
inflammatory response.  In particular, the release of platelet agonists ADP and 5HT from the 
dense granules, leads to activation of their respective receptors, amplifying the activation 
response (Rendu and Brohard-Bohn 2001).  Lysosomes also secrete their contents upon 
platelet activation (Ciferri et al. 2000), but will not be discussed further in this thesis. 
 
Granule release is initiated by many signalling events (see Figure 1.4), including calcium 
release, the mitogen-activated protein kinase (MAPK) pathway, phosphoinositide 3-kinase 
(PI3K), and protein kinase C (PKC).  These events regulate the activity of soluble N-
ethylmaleimide-sensitive factor activating protein receptor (SNARE) and GTPase proteins, 
which augment the docking and fusion of granules with the open canalicular system and 
plasma membranes.  Granule contents such as ADP, cytokines, and coagulation factors are 
released into the extracellular compartment, whilst granule membrane components, 
including P-selectin (CD62p) and CD40L, are then expressed on the platelet surface (Rendu 
and Brohard-Bohn 2001; Blair and Flaumenhaft 2009; Li et al. 2010). 
 
Other activation events include the generation and secretion of TxA2 via the activity of 
phospholipase A2 (PLA2), which liberates arachadonic acid from the plasma membrane, 
and is converted to TxA2 by cyclooxygenase-1 (COX-1) and thromboxane synthase.  
Released TxA2 is able to activate platelets via the thromboxane receptor (TPα), and 
provides another route for amplification of the activation response.  Blockade of TxA2 
production is the mechanism by which the COX-1 inhibitor, aspirin, irreversibly inhibits 
platelet activation (Paul et al. 1999). 
 
1.4.7 Aggregation 
Receptor-mediated integrin activation is important, not only for firm adhesion to the vessel 
wall, but also for platelet aggregation, and subsequent thrombus formation.  Of all platelet 
integrins, GPIIbIIIa (αIIbβ3) is the most abundant, and is able to bind fibrinogen, vWF, and 
several other matrix proteins, allowing interactions with the vessel wall and, crucially, 
between platelets.  GPIIbIIIa is found in a low affinity state on the surface of resting platelets, 
unable to bind to any of its ligands.   Following platelet activation, intracellular ‘inside-out’ 
signalling induces a conformational change in the integrin, transforming it from a low to high 
affinity, ‘activated’ state.  This is mediated by the binding of talin and kindlin cytoskeletal
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Table 1.2 - Platelet granule contents and membrane components. 
 
A summary of the main α, dense, and lysosomal granule contents and membrane 
components, with a particular focus on those elements highlighted in this thesis and relating 
to atherogenesis (McNicol and Israels 1999; Rendu and Brohard-Bohn 2001; Nurden). 
 
 Contents Membrane components 
α granules Adhesive proteins: vWF, 
fibrinogen, fibronectin, laminin, 
vitronectin 
Coagulation factors: V, XI 
Cytokines and growth factors: IL-
1, IL-8, MCP-1, RANTES, TGF-β, 
PDGF, PF4 
Fibrinolytic factors: Plasminogen, 
PAI-1 
Proteases: MMP-1, 2, 4, 9, 
ADAMTS13 
Anti-microbial proteins 
Immunoglobulins 
Glycoproteins: Ib-IX, VI, IIbIIIa 
CD40L 
CD63 
P-selectin (CD62p), PSGL-1 
PECAM-1 
Dense granules ADP, ATP, 5HT, calcium Glycoproteins: Ib, IIbIIIa 
P-selectin 
Lysosomes Acid proteases, glycohydrolases CD63, LAMP1,2 
*All abbreviations are in the full text except: a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif (ADAMTS)13; adenosine triphosphate (ATP); lysosomal-associated membrane protein 
(LAMP); plasminogen activator inhibitor-1 (PAI-1) and platelet factor 4 (PF4).  
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proteins to the cytoplasmic domain of the β3 subunit.  Integrin ligation, via fibrinogen or vWF, 
augments platelet-platelet interactions through GPIIbIIIa, forming platelet aggregates and 
initiating further signalling events.  This so-called ‘outside-in’ signalling results in granule 
secretion, platelet spreading, and clot retraction (Shattil and Newman 2004; Li et al. 2010).   
 
1.5 Platelet purinergic receptors 
The P2Y12 receptor belongs to a larger family of membrane-bound molecules, the purinergic 
(P2) receptors, which are important in mediating extracellular signalling.  P2 receptors are 
expressed on a variety of cells throughout the body, and are activated by nucleotides, such 
as ADP and adenosine triphosphate (ATP).  They are divided into two groups, ATP-gated 
ion channels (P2X) and G-protein-coupled receptors (P2Y), of which there are several 
subtypes.  Platelets possess three P2 receptors; P2X1, P2Y1, and P2Y12 (Erlinge and 
Burnstock 2007). 
 
1.5.1 P2X1 
ATP released from damaged cells or platelet dense granules, causes a rapid influx of 
extracellular Ca
2+
 via P2X1 (MacKenzie et al. 1996), and this is considered to prime 
activation of the P2Y receptors by working in a synergistic manner to enhance intracellular 
Ca
2+
 signalling, and its effects (Vial et al. 2002).  P2X1 has also been shown to amplify 
collagen-induced granule secretion, aggregation (Oury et al. 2002), and contribute to 
thrombus formation (Hechler et al. 2003). 
 
1.5.2 P2Y1 
As part of a duo of ADP receptors found on platelets, P2Y1 mediates a rapid ADP-induced 
platelet activation response, which is then amplified and sustained by its counterpart, P2Y12 
(Storey et al. 2000).  P2Y1 is coupled to Gq and, when activated, causes a rapid rise in 
intracellular Ca
2+
 through PLCβ, resulting in platelet shape change (see Figure 1.4) 
(Offermanns et al. 1997; Jin et al. 1998).  Furthermore, P2Y1 is essential for initiating ADP-
induced platelet aggregation, and it also potentiates aggregation to other agonists such as 
collagen (Fabre et al. 1999; Leon et al. 1999); however, P2Y1 stimulation alone results in 
only a small, reversible aggregation response that requires P2Y12 activation for completion 
(Hechler et al. 1998; Jin and Kunapuli 1998). 
 
1.5.3 P2Y12 
The identity of the second platelet ADP receptor was elusive for some time, but much was 
discovered about its activity prior to its eventual cloning (Foster et al. 2001; Hollopeter et al. 
2001).  It was known to be coupled to Gi (Ohlmann et al. 1995), and Daniel et al. 
demonstrated that this mystery receptor, referred to previously as P2T, P2TAC, P2YADP, or 
P2Ycyc, inhibited adenylyl cyclase (AC) activity, but did not induce shape change as did P2Y1 
and therefore must be a distinct receptor (Daniel et al. 1998).  P2Y12, as it’s now known, is 
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required, along with P2Y1, to achieve complete ADP-induced aggregation (Jin and Kunapuli 
1998).  However, the importance of P2Y12 lies in its ability to amplify and sustain platelet 
activation responses to not only ADP, but also other platelet agonists, including TxA2, 
thrombin, and collagen, since activation of platelets by these agonists inevitably lead to 
release of ADP from dense granules (Storey et al. 2000).  This capacity to enhance platelet 
reactivity, regardless of the initiating stimulus, is why P2Y12 inhibition has been established 
as, and continues to be, a vital treatment for preventing thrombotic events following ACS or 
percutaneous coronary intervention (PCI). 
 
1.5.4 P2Y12 in platelet activation 
Although a relatively weak agonist compared to thrombin and collagen, which are markedly 
more potent, ADP acts a vital co-factor in the platelet activation response.  ADP is released 
from the dense granules, following platelet activation in response to various agonists, 
including thrombin, and stimulates the P2Y receptors on the source, and neighbouring 
platelet(s).  As a result, this nucleotide, when bound to the P2Y12 receptor, initiates the Gi 
signalling pathway, and brings about irreversible GPIIbIIIa activation and complete 
aggregation in response to any platelet agonist (Dorsam and Kunapuli 2004; Storey 2006).  
Accordingly, synergistic activation of the Gq (Quinton et al. 2002), G13 (Nieswandt et al. 
2002), GPVI (Ohlmann et al. 2000), or GPIb-IX (Turner et al. 2001) pathways, in addition to 
Gi stimulation, is required for these effects.  Thus, in the absence of P2Y12 activation, 
platelet aggregation is readily reversible, with GPIIbIIIa reverting to its inactive form (Jin and 
Kunapuli 1998; Quinton et al. 2002). 
 
P2Y12 potentiates these activation responses by sustaining elevated Ca
2+
 levels within the 
platelet, which would otherwise diminish (Storey et al. 2000).  This is thought to be mediated 
by inhibition of AC activity and stimulation of PI3K (Hardy et al. 2004).  Induced via 
endothelial PGI2, adenylyl cyclase regulates platelet activity in vivo by the production of 
cyclic adenosine monophosphate (cAMP), which inhibits intracellular Ca
2+
 release 
(Smolenski 2012).  Consequently, P2Y12 inhibition of AC removes the inhibitory effects of 
cAMP on Ca
2+
 mobilisation; however, Hardy et al. demonstrated this was only partially 
responsible for the calcium levels.  P2Y12-mediated activation of PI3K was also shown to 
contribute the sustained Ca
2+
 levels (Hardy et al. 2004) via activation of PLC (van der 
Meijden et al. 2008). 
 
PI3K activity is also responsible for P2Y12-induced TxA2 and granule secretion (Dangelmaier 
et al. 2001; Garcia et al. 2010), as well as irreversible aggregation (Trumel et al. 1999; 
Kauffenstein et al. 2001).  Other agonists, such as thrombin, are known to induce PI3K 
activity.  Yet, thrombin stimulation alone results in reversible aggregation, not stable 
aggregates as seen following P2Y12 activation.  These P2Y12 specific effects, it appears, are 
mediated by the generation of a particular PI3K product, phosphatidylinositol 4,5-
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bisphosphate (PIP2), which is linked to irreversible aggregation (Trumel et al. 1999).  
Furthermore, P2Y12-induced PI3K is also involved in platelet spreading on immobilised 
fibrinogen (O'Brien et al. 2012).  In addition, P2Y12 activation is associated with GTPase 
Rap1 activity, a key mediator of GPIIbIIIa integrin activation (see Figure 1.4), although it can 
be activated independently of P2Y12 also (Larson et al. 2003). 
 
In summary, the P2Y12 receptor is extremely influential in platelet activation, by potentiating 
platelet secretion and aggregation (Storey 2006).  Furthermore, P2Y12 activation also 
promotes procoagulant responses by enhancing surface membrane PS expression (Leon et 
al. 2003), and contributing to platelet microparticle formation (Storey et al. 2000; Kahner et 
al. 2008), which are another source of PS and TF (Owens and Mackman 2011).  As a result, 
P2Y12 activity plays an important role in thrombosis. 
 
1.5.5 P2Y12 in thrombosis 
The effects of P2Y12 antagonists, such as clopidogrel, on reducing thrombotic events in ACS 
patients had been known for some time (CAPRIE 1996).  Similarly animal models had 
shown P2Y12 antagonist treatment prolonged bleeding time and reduced thrombus formation 
(Samama et al. 1992; Herbert et al. 1998; Huang et al. 2000), but how these drugs provided 
a therapeutic benefit was less apparent.  However, cloning of the P2Y12 receptor (Hollopeter 
et al. 2001) enabled the development of P2Y12
-/-
 mice (Foster et al. 2001), and permitted the 
study of its role in thrombosis in vivo. 
 
Foster et al. were the first to generate P2Y12
-/-
 mice and demonstrated that their platelets 
displayed P2Y12-deficient characteristics as expected, such as reduced aggregation in 
response to ADP, collagen, and thrombin.  In addition, they showed this translated into 
substantially prolonged bleeding times following tail tip transection (Foster et al. 2001).  
Further studies on P2Y12
-/-
 mice revealed, using arterial injury models, that P2Y12 controls 
both thrombus growth and stability (Andre et al. 2003). 
 
1.5.6 Other cells expressing P2Y12 
The P2Y12 receptor was first identified on platelets; however, its expression has since been 
discovered in other cell types, although often little is known of its role in these tissues, and 
its function remains to be fully elucidated in some cases (see Table 1.3).  The most notable 
and well-documented roles for P2Y12, outside of the platelet, are in VSMCs and microglia. 
 
Wihlborg et al. revealed that P2Y12 receptors on VSMCs mediated cell contraction in 
response to ADP.  In addition, he discovered that the P2Y12 antagonist cangrelor, but not 
clopidogrel, was able to block ADP-induced contraction in denuded vessels (Wihlborg et al. 
2004).   A more recent study showed ticagrelor is also capable of inhibiting this response,
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Table 1.3 - P2Y12 receptor expression. 
 
An overview of the tissues and cell types in which the P2Y12 receptor has been identified, 
including its function in these cells, if known. 
 
 
  
Tissue Cell Function  
Blood Platelets Amplification of platelet activation (Storey et al. 2000) 
 Dendritic cells Enhance T-cell activation (Ben Addi et al. 2010) 
Vessel 
wall 
Vascular smooth 
muscle cells 
Cell contraction and promote pro-
inflammatory and mitogenic 
responses 
(Wihlborg et al. 2004; 
Rauch et al. 2010) 
 Endothelial cells Unknown (Shanker et al. 2006) 
Brain Microglia Chemotaxis in response to injury (Sasaki et al. 2003; 
Haynes et al. 2006) 
Liver Cholangiocytes Postulated to act as chemosensors 
detecting biliary nucleotides 
(Masyuk et al. 2008) 
Pancreas Islet cells Postulated to stimulate insulin 
secretion 
(Lugo-Garcia et al. 
2008) 
Spleen Splenic sinus 
endothelial cells 
Unknown (Uehara and Uehara 
2011) 
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but prasugrel, another thienopyridine-class drug similar to clopidogrel, had no effect (Grzesk 
et al. 2012).  Furthermore, in vitro studies in cultured VSMCs revealed that P2Y12 receptors 
are linked to mitogenic and pro-inflammatory responses in VSMCs, through a thrombin-
induced pathway (Rauch et al. 2010). 
 
Microglia are the macrophages of the brain, and their role is to detect injury, infection, 
remove apoptotic cells, and in addition, they are also important in brain development 
(Schlegelmilch et al. 2011).  P2Y12 receptors are involved in microglia activation, and 
mediate chemotaxis in response to injury (Haynes et al. 2006); however, their involvement in 
other microglia functions is unknown.  
 
1.6 Antiplatelet drugs in CVD 
For those presenting with an ACS following atherothrombosis, antiplatelet drugs form a 
dominant part of the treatment strategy, in addition to revascularisation via PCI, usually 
involving the insertion of a metal stent, or coronary artery bypass graft (CABG) surgery.  
These are followed by long-term antiplatelet drug treatment as an outpatient, to reduce the 
risk of further thrombotic events (Capodanno et al. 2013). 
 
1.6.1 Percutaneous coronary intervention 
Balloon angioplasty, as a method of coronary revascularisation, was developed by Andreas 
Gruentzig, who performed the first human coronary angioplasty in 1977 (Gruntzig 1978).  
This paved the way for the development of the balloon expandable Palmaz-Schatz stent 
(Schatz et al. 1991), which became the forebear of modern stents due its improved 
outcomes (Fischman et al. 1994).  Over 80,000 stenting procedures are now carried out 
annually in the UK (Scarborough et al. 2010). 
 
For patients with multiple diseased vessels and complicating conditions, such as diabetes, 
CABG is traditionally the favoured procedure, demonstrating a lower mortality in comparison 
with PCI (Hlatky et al. 2009). 
 
1.6.2 Dual antiplatelet therapy 
Since platelet activation is central to thrombus formation, the drugs which inhibit this 
activation are crucial in the treatment and prevention of ACS.  Aspirin is a COX-1 inhibitor 
that irreversibly blocks the production of platelet agonist TxA2 from arachadonic acid, and 
was the first such antiplatelet drug to be used (Patrono 1994).  Several clinical studies 
demonstrated that both acute and long-term aspirin treatment reduced the risk of MI or 
death in unstable patients (Theroux et al. 1988; Wallentin 1991; 
Antiplatelet_Trialists'_Collaboration 1994).  However, the prolonged use of aspirin is also 
associated with an increased incidence of gastrointestinal bleeding (Roderick et al. 1993). 
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The P2Y12 antagonist clopidogrel offered an alternative to aspirin, and demonstrated not 
only superior platelet inhibition, but also an enhanced reduction in thrombotic events 
(CAPRIE 1996).  Combination of the two drugs, however, offered the greatest risk reduction 
(Yusuf et al. 2001), and as a result this dual antiplatelet therapy of aspirin plus P2Y12 
antagonist continues to be the cornerstone of ACS treatment and prevention (Hamm et al. 
2011). 
 
1.6.3 Clopidogrel 
Clopidogrel and its predecessor, ticlopidine, belong to a group of drugs called 
thienopyridines.  These are pro-drugs that first require metabolism by various isoforms of the 
hepatic cytochrome P450, in a 2-step process to produce the active metabolite, which then 
binds irreversibly to the P2Y12 receptor (Cattaneo 2012).  Platelet inhibition, denoted as 50% 
inhibition of aggregation, is achieved within 2-4 hours of administration and, due to its 
irreversible binding, these inhibitory effects are apparent for 3-10 days, dependent on 
platelet turnover (Hamm et al. 2011).  Drug metabolism is therefore directly linked to its 
activity, and genetic polymorphisms of the cytochrome P450 isoforms have now been linked 
to poor clopidogrel response in some individuals (Shuldiner et al. 2009).  Furthermore, they 
are also associated with an increased risk of thrombotic events (Mega et al. 2010). 
 
Although an effective platelet inhibitor, ticlopidine use was limited due to its severe side 
effects, which were less evident in its more potent replacement, clopidogrel (Bertrand et al. 
2000).  Since its introduction, the efficacy of clopidogrel, in combination with aspirin, has 
been tested by various clinical studies.  The CURE study set out to test combination therapy 
versus aspirin alone for 3-12 months in ACS patients, and found that the addition of 
clopidogrel reduced the incidence of adverse events, including MI or death.  This did, 
however, also come with a moderately increased risk of major, but not fatal, bleeding (Yusuf 
et al. 2001).  In an extension of this study, PCI-CURE revealed that dual clopidogrel and 
aspirin treatment prior to PCI and for prolonged treatment afterwards, for an average of 8 
months, reduced MI and death by 31% versus aspirin treatment alone (Mehta et al. 2001).  
Later, the CREDO study found that dual treatment for up to 1 year, versus 30 days, after PCI 
reduced adverse events by 27%, and that a loading predose of clopidogrel at least 6 hours 
prior to PCI may be advantageous and reduce further events (Steinhubl et al. 2002). 
 
1.6.4 Ticagrelor 
Development of the orally active P2Y12 antagonist ticagrelor offers an alternative for poor 
clopidogrel responders.  It belongs to a new drug class of cyclopentyltriazolopyrimidines, 
and binds directly and reversibly to the P2Y12 receptor (Capodanno et al. 2013).  As 
ticagrelor is orally active, its onset of action is more rapid compared to clopidogrel, and 50% 
platelet inhibition is typically achieved after 30 minutes of administration.  Drug activity is 
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linked to ticagrelor plasma levels and, with a half-life of approximately 12 hours, the duration 
of effect lasts 3-4 days (Hamm et al. 2011). 
 
A comparison of the efficacy of ticagrelor versus clopidogrel treatment in ACS patients was 
investigated in the PLATO study.  This revealed that ticagrelor treatment led to a significant 
reduction in MI, stroke, or death compared to clopidogrel, and had no effect on procedure-
related major bleeding rates.  An increase in non-procedure-related bleeding was, however, 
noted (Wallentin et al. 2009).  In addition, the PLATO substudy clearly demonstrated that 
ticagrelor achieved a superior level of platelet inhibition to clopidogrel, including immediately 
following a single loading dose (Storey et al. 2010).  The pharmacodynamic profile of these 
drugs was further investigated in the ONSET/OFFSET study, which showed ticagrelor had a 
more rapid onset of inhibitory action and wore off more quickly compared to clopidogrel, 
making it advantageous for use when antiplatelet drugs need to be halted prior to surgical 
procedures (Gurbel et al. 2009).  
 
In light of its superior inhibitory effects and improved clinical outcomes, ticagrelor is now 
recommended for all patients.  Only in cases where ticagrelor and other P2Y12 antagonists, 
such as prasugrel (see section 1.6.5), are unsuitable, should clopidogrel be considered as 
an alternative.  In all cases, the use of a P2Y12 antagonist, in addition to aspirin, is 
recommended to be given for a period of 12 months (Hamm et al. 2011). 
 
Non-P2Y12-mediated effects of ticagrelor have been noted, but currently are not fully 
understood.  Recently van Giezen et al. demonstrated that ticagrelor inhibits adenosine 
reuptake by erythrocytes (van Giezen et al. 2012).  Adenosine is a purine that is known to 
have anti-inflammatory effects on the vessel wall (Smits et al. 1995; Dubey et al. 1998).  In 
addition, the PLATO study revealed that ticagrelor led to an unexpected reduction in total 
mortality, to a greater extent than could be explained by cardiovascular deaths alone, raising 
questions about the mechanisms behind this mortality reduction (Wallentin et al. 2009).  
Further analyses of the PLATO findings showed that ticagrelor-treated patients were also 
less likely to have pulmonary adverse events, such as infection and sepsis (Storey et al. 
2012). 
 
1.6.5 Other P2Y12 antagonists 
Prasugrel, another thienopyridine class drug, has emerged as a potent alternative to 
clopidogrel.  It is similar to clopidogrel in that it too is a pro-drug and requires metabolism to 
form the active metabolite, which binds irreversibly to P2Y12; however, this process is much 
more efficient leading to its enhanced antiplatelet effects and rapid onset (Sugidachi et al. 
2007; Capodanno et al. 2013).  The TRITON-TIMI 38 study compared prasugrel versus 
clopidogrel treatment in ACS patients undergoing PCI and revealed that prasugrel reduced 
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the incidence of adverse events, such as MI and death, but was associated with an increase 
in major and fatal bleeding, although overall mortality was unchanged (Wiviott et al. 2007). 
 
Cangrelor is an ATP-analogue drug given via intravenous (i.v.) infusion, which achieves 
effective platelet inhibition within seconds and, due to a short half-life of 3-6 minutes, 
enables recovery of platelet function within 60 minutes after cessation of treatment 
(Capodanno et al. 2013).  Pharmacodynamic studies have revealed that cangrelor 
demonstrates superior platelet inhibition compared to clopidogrel (Storey et al. 2002), but 
this did not translate to significantly improved outcomes in patients undergoing PCI in the 
CHAMPION-PCI and –PLATFORM studies (Bhatt et al. 2009; Harrington et al. 2009).  
However, despite the later CHAMPION-PHEONIX and BRIDGE studies showing cangrelor 
was superior to clopidogrel in reducing ischaemic events (Bhatt et al. 2013), and sustaining 
platelet inhibition during procedures (Angiolillo et al. 2012), cangrelor is not yet approved for 
clinical use and its future is still unsure. 
 
1.7 Platelets in restenosis 
1.7.1 Neointimal hyperplasia 
Ironically, PCI as a treatment for CHD can itself lead to a recurrence of symptoms due to 
restenosis, i.e. the re-occlusion of the vessel, caused by growth of neointima.  Restenosis is 
viewed as a wound healing response gone awry, with excessive neointima formation 
(hyperplasia) in response to injury (Steele et al. 1985; Forrester et al. 1991; Schwartz et al. 
1992), similar to that described by Russell Ross in the initiation of atherosclerosis (Ross 
1993).  Neointima formation is brought on by vascular injury incurred at the site of stent 
deployment, with the severity of restenosis directly correlated to the degree of vessel injury 
sustained (Schwartz et al. 1992; Farb et al. 2002).  Endothelial denudation followed swiftly 
by platelet adhesion and thrombus formation, are all precursors of early neointima (Steele et 
al. 1985; Harker 1987; Chandrasekar and Tanguay 2000).  Leukocyte recruitment (Farb et 
al. 2002), VSMC proliferation (Komatsu et al. 1998; Christen et al. 2001), and ECM 
synthesis (Glover et al. 2002) fuel neointimal growth, which is characterised by the re-
organisation of mural thrombus (Steele et al. 1985; Richter et al. 2000; Glover et al. 2002).  
More recent studies have shown that stem cells also contribute to neointimal growth, 
suggesting that not all endothelial and smooth muscle cells in neointima originate from the 
vessel wall (Tsai et al. 2012). 
 
1.7.2 Treatment and prevention 
Initial restenosis rates following balloon angioplasty or bare metal stent (BMS) implantation 
have been documented at between 30 and 40% (Holmes et al. 1984; Fischman et al. 1994).  
Developments, particularly in the field of stent design and the use of anti-proliferative and 
immunosuppressive drug-eluting stents (DES), have significantly reduced restenosis rates.  
Promising results from clinical studies of sirolimus- and paclitaxel-eluting stents showed 
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dramatic reductions in the incidence of restenosis when compared to BMS, reporting rates of 
3.2% vs. 35.4% for sirolimus DES versus BMS at 6 months post-PCI (Moses et al. 2003), 
and 7.9% vs. 26.6% for paclitaxel-eluting stents after 9 months (Stone et al. 2004).  Many 
other DES have since been developed, including zotarolimus- (Fajadet et al. 2006) and 
everolimus-eluting stents (Palmerini et al. 2012).  Despite limiting neointima, DES also delay 
the formation of an intact endothelium.  Safety concerns have since arisen following the 
BASKET-LATE study results, showing an increased risk of late stent thrombosis with DES 
(4.9%) compared to BMS (1.3%) following discontinuation of antiplatelet therapy (Pfisterer et 
al. 2006), and this continues to be a major complication. 
 
1.7.3 Platelets and antiplatelet drugs in restenosis 
Many animal studies have highlighted the close relationship between platelet activation, 
aggregation, and restenosis.  Platelet, rather than endothelial, P-selectin has been shown to 
be important in promoting neointima formation (Manka et al. 2004) through deposition of 
platelet RANTES onto leukocytes and the endothelium, thereby enhancing leukocyte 
recruitment (Schober et al. 2002).  Further studies have demonstrated platelets also 
facilitate neointimal hyperplasia via platelet MCP-1-dependent monocyte recruitment 
(Schober et al. 2004), and through PDGF release (Ferns et al. 1991).  In addition, blockade 
of platelet activation via thrombin (Unterberg et al. 1995), collagen (Konishi et al. 2002), 
TxA2, serotonin and ADP (Willerson et al. 1991; Anderson et al. 2001), or increased cAMP 
levels (Faxon et al. 1984) also lead to reduced neointimal hyperplasia.  However, translation 
of these studies into humans has not always offered such positive results.  Combined 
inhibition of platelet integrins GPIIbIIIa and αvβ3 led to attenuated neointima formation in a 
hamster model of vessel injury (Matsuno et al. 1994), but this was not reflected in human 
studies, such as ERASER, which showed that integrin blockade had no effect on restenosis 
post-PCI (ERASER 1999). 
 
Investigations into the direct impact of P2Y12 antagonists on restenosis are limited, and offer 
differing results.  The ISAR clinical study demonstrated that ticlopidine treatment did not 
reduce restenosis (Kastrati et al. 1997).  In addition, low clopidogrel responsiveness has 
been shown to have no effect on restenosis, compared to those patients who achieved high 
levels of P2Y12 inhibition (Schulz et al. 2010).  Yet other studies of ticlopidine in humans 
(Nagaoka et al. 2001), and clopidogrel with nitroaspirin in mice (Momi et al. 2005), indicate 
beneficial effects of these inhibitors on neointimal thickening.  Furthermore, reductions in the 
rate of target vessel revascularisation following large-scale clinical studies of P2Y12 
antagonists clopidogrel (Steinhubl et al. 2002), ticagrelor (Wallentin et al. 2009), and 
prasugrel (Wiviott et al. 2007) suggest a positive impact of these drugs on reducing 
restenosis rates, although these trials were not powered to prove such an effect. 
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1.7.4 Murine model of vascular injury and restenosis 
Murine models have been used extensively to investigate the vascular response to injury, 
primarily studying thrombosis using various injury methods, such as wire injury, ligation, 
laser injury, and ferric chloride (Westrick et al. 2007).  In the study of restenosis, few murine 
models of stent implantation exist due to the technical difficulties posed by small vessel size 
(Chamberlain et al. 2010).  Wire injury is an alternative method, which results in neointimal 
hyperplasia following mechanical endothelial damage caused by the repeated insertion of a 
metal wire into a vessel (Westrick et al. 2007).  Other chemical methods, such as the topical 
application of ferric chloride, achieve endothelial injury and neointima formation with the 
vessel remaining physically intact. 
 
The ferric chloride injury method was originally developed as an in vivo model of arterial 
thrombosis (Kurz et al. 1990); however, due to the 2-stage nature of the vessel wall 
response, it has also been used to study neointima formation (Schafer et al. 2002).  Topical 
application of a ferric chloride solution to the outer surface of an intact vessel causes 
localised endothelial denudation, VSMC, and endothelial damage, and collagen exposure 
due to oxidative damage (Woollard et al. 2009; Eckly et al. 2011).  Ferric ions are 
transported through the vessel wall via an endocytosis/exocytosis pathway, resulting in the 
generation of reactive oxygen species that disrupt the vessel wall (Tseng et al. 2005).  The 
resulting damage leads to exposure of vessel wall TF, which further promotes thrombosis by 
triggering the coagulation cascade (Wang et al. 2009).   
 
Kurz et al. discovered that applying a piece of ferric chloride-soaked filter paper (5-65% w/v) 
to the carotid artery of a rat resulted in the rapid formation of an occlusive platelet and fibrin-
rich thrombus.  In addition, the total vessel occlusion time was related to the ferric chloride 
concentration in a dose-dependent manner (Kurz et al. 1990).  Further investigation in mice 
revealed lower concentrations (2-10% w/v) would be more sensitive to unmask anti-
thrombotic effects, with concentrations greater than 5% w/v achieving consistent vessel 
occlusion (Wang and Xu 2005).  Several studies have adopted the same method of 10% w/v 
ferric chloride solution applied to the carotid artery for 3 minutes to investigate both 
thrombus (Farrehi et al. 1998; Konstantinides et al. 2001), and neointima formation (Zhu et 
al. 2001; Schafer et al. 2002). 
 
1.8 Platelets in atherogenesis 
Even in the early days of atherosclerosis research, platelets were linked to atherogenesis 
and observed as having mitogenic effects.  In 1974, Ross noted that platelets activated with 
thrombin released a ‘serum factor’, later identified as PDGF, which stimulated the 
proliferation of arterial smooth muscle cells in vitro (Ross et al. 1974).  We now understand 
that the role of platelets extends far beyond haemostasis; however, the full extent and 
impact of their role in atherogenesis is becoming clearer with the help of animal models. 
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1.8.1 Interactions with leukocytes and the endothelium 
Upon activation, platelets release a cocktail of pro-inflammatory cytokines from their 
granules, and express a variety of adhesion receptors and proteins (Rendu and Brohard-
Bohn 2001), which facilitate interactions with both leukocytes and the endothelium.  Among 
these are P-selectin (CD62p) and its ligand PSGL-1, which enable platelets to adhere to 
reciprocal proteins on endothelial cells (Frenette et al. 1998; Frenette et al. 2000), and form 
platelet-leukocyte conjugates (Larsen et al. 1989; Diacovo et al. 1996; Storey et al. 2002).  
Platelet P-selectin and endothelial PSGL-1 ligation causes P-selectin release from Weibel-
Palade bodies, and thereby enhances leukocyte rolling on the endothelium (Dole et al. 2005; 
Dole et al. 2007).  In addition, activated platelets have been shown to further promote 
leukocyte recruitment via the deposition of the chemokines RANTES and platelet factor 4 
(PF4/CXCL4) on the surface of endothelial cells and leukocytes, in a process which is 
platelet P-selectin dependent (von Hundelshausen et al. 2001; Schober et al. 2002; Huo et 
al. 2003).  Microparticles shed from activated platelets similarly contribute to RANTES 
delivery (Mause et al. 2005).  Activated platelets also modulate pro-inflammatory responses 
via IL-1 release (Lindemann et al. 2001), which causes MCP-1 release and ICAM-1 
expression in endothelial cells (Gawaz et al. 2000).  In addition, MCP-1 also binds to 
adherent platelets and triggers leukocyte arrest onto these cells (Schober et al. 2004). 
 
Animal experiments conducted to assess the contribution of platelets in atherosclerotic 
lesion development demonstrated, using transgenic mice, that platelet P-selectin enhanced 
lesion growth, and promoted an advanced lesion phenotype (Burger and Wagner 2003).  
Similarly, Huo et al. found that circulating activated platelets readily formed platelet-
leukocyte conjugates and exacerbated atherosclerotic lesion development.  Furthermore, 
these effects were attributed to platelet P-selectin-mediated chemokine deposition (Huo et 
al. 2003).  This is supported by findings showing that mice treated with a RANTES receptor 
antagonist demonstrated reduced neointimal lesions after injury (Schober et al. 2002).  
Likewise, PF4
-/-
 mice also showed significantly attenuated atheroma (Sachais et al. 2007). 
 
Platelet adherence can also occur independently of P-selectin through the GPIb-IX receptor 
complex and endothelial P-selectin (Romo et al. 1999), membrane attack complex (MAC)-1 
on leukocytes (Wang et al. 2005), or vWF (Andre et al. 2000).  Indeed blockade of GPIb in 
mice, by use of an antibody, led to a significant reduction in atheroma, demonstrating a clear 
role for platelet adhesion in atherosclerosis (Massberg et al. 2002).  Likewise, GPVI antibody 
treatment had a similar limiting effect on lesion progression (Bultmann et al. 2010). 
 
CD40-CD40L signalling between platelets, leukocytes, and endothelial cells plays an 
important role in atherogenesis by mediating cytokine release and adhesion molecule 
expression (Lievens et al. 2009).  Platelets possess both proteins, they constitutively 
express CD40 (Inwald et al. 2003), but also CD40L upon activation (Henn et al. 1998).  
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CD40 ligation provides another mechanism for platelet activation, and also results in 
RANTES release (Danese et al. 2004).  However, platelet CD40L triggers inflammatory 
responses in other cells.  Henn et al. demonstrated that CD40L upregulated VCAM-1, ICAM-
1, and E-selectin expression in endothelial cells, and also led to IL-8 and MCP-1 release 
(Henn et al. 1998).  Furthermore, CD40L mediates platelet-leukocyte conjugate formation, 
and has a direct impact on leukocyte recruitment and adherence to the endothelium 
(Lievens et al. 2010).  In this in vivo model, atherosclerotic mice were injected with CD40L-
deficient platelets and, in addition to diminished platelet-leukocyte interactions, also 
displayed reduced atherosclerosis.  Earlier studies have shown similar findings, 
demonstrating that CD40L is important in promoting lesion development, as well as an 
unstable lesion phenotype (Mach et al. 1998; Lutgens et al. 1999; Lutgens et al. 2000; 
Schonbeck et al. 2000). 
 
1.8.2 Mitogenic effects on the vessel wall 
PDGF and TGF-β are known to regulate VSMC mitogenesis and synthesis of ECM proteins, 
both of which are important processes in advanced lesion development (Raines and Ross 
1993).  When activated, platelets release these growth factors, inducing VSMC migration 
and proliferation (Schini-Kerth et al. 1997; Massberg et al. 2003), and collagen synthesis 
(Amento et al. 1991).  Consequently in vivo rabbit and mouse models, where the action of 
PDGF was blocked by use of an antibody, demonstrated reduced atheroma (Lamb et al. 
2001; Sano et al. 2001), and delayed the fibrous cap formation (Kozaki et al. 2002). 
 
1.8.3 Murine model of atherosclerosis 
Given the timescale in which atherosclerosis develops in humans, early research using 
animal models proved difficult as many species appeared resistant to the disease and did 
not develop spontaneous lesions.  Administration of a high-cholesterol diet enabled the 
study of fatty lesions in rabbits; however, such models had limited usefulness as these 
lesions were dissimilar to those observed in humans (Jawien et al. 2004).  Despite many 
mouse strains being highly resistant, it was noted that C57/BL6 mice fed a high-fat ‘Paigen’ 
diet developed small lesions (Paigen et al. 1985). 
 
The later development of the apolipoprotein E (ApoE)
-/-
 (Piedrahita et al. 1992) and LDL-R
-/-
 
mouse strains (Ishibashi et al. 1993) revolutionised research into this disease.  Given the 
rapidity of onset of atherogenesis in both strains, athero-progression from simple to complex 
lesions could be achieved in a matter of weeks, particularly with the addition of a paigen, or 
the less toxic ‘western’ diet (Jawien et al. 2004; Getz and Reardon 2006).  This has given 
rise to a second generation of double and triple knockout mouse lines, to investigate the role 
of various cells and proteins in atherosclerosis.   
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ApoE is a component of all the lipoproteins, with the exception of LDL, and is responsible for 
the trafficking of lipids between organs and cells.  It also acts as a ligand, and facilitates the 
excretion of lipids and cholesterol from the blood plasma via receptor-mediated pathways in 
the liver (Mahley 1988).  ApoE-deficient mice have demonstrated both spontaneous and 
diet-induced atherosclerotic lesions, and so they provide a well-characterised model for 
atherosclerosis (Zhang et al. 1992; Reddick et al. 1994).  In addition, the ApoE
-/-
 mouse 
strain is renowned for the development of complex fibrous lesions found throughout the 
arterial tree, similar to those observed in human disease (Nakashima et al. 1994).  LDL-R-
deficient mice, however, do not develop spontaneous lesions but, once fed a high-fat diet, 
can develop large lesions similar to those seen in ApoE-deficient mice (Jawien et al. 2004; 
Maeda 2011). 
 
1.9 Hypothesis and aims 
The classical role of platelets is thought to be in maintaining vascular integrity and 
haemostasis, in such processes as atherothrombosis, where they play a fundamental role.  
However, platelets are increasingly regarded as discrete inflammatory cells, and are known 
to interact with both the endothelium and leukocytes.  Given that platelets can, upon 
activation, elicit an inflammatory response in these cells, I hypothesised that the P2Y12 
receptor, which is crucial in amplifying platelet activation, would also be involved in 
modulating the vessel wall response to injury and inflammation. 
 
The aims of this thesis were to study the role of the P2Y12 receptor, using murine in vivo 
models of injury and atherogenesis, and specifically to: 
 
 Investigate the role of P2Y12 in thrombus and neointima formation following vessel 
injury, using the well-established ferric chloride injury model. 
 Generate an ApoE/P2Y12 double knockout colony to study the role of P2Y12 in 
atherogenesis, and to characterise the phenotype of this novel strain. 
 Assess the effect of P2Y12 deficiency on atherogenesis and lesion composition. 
 Investigate the role of platelet versus vessel wall P2Y12 in early atherogenesis using 
bone marrow transplantations (BMT). 
 Consider the use of P2Y12 antagonists, ticagrelor and clopidogrel, in modulating 
atherogenesis. 
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2.1 Preface 
This materials and methods chapter has been organised into main themes of work, to 
provide a clear and distinct description of the methods, and to avoid repetition.  As certain 
techniques have been used throughout the work, each has been described in detail once 
and referred to in all other sections.  The order of this chapter has also been designed to 
form a logical progression through the project. 
 
2.2 Animals 
2.2.1 Licensing 
All experimental procedures were approved by The University of Sheffield Ethics Committee, 
and were performed in accordance with UK and European legislation under the Animals 
(Scientific Procedures) Act 1986 and European Directive 2010/63/EU.  Work was carried out 
under project licence PPL 40/3307 (previously 40/2732), and personal licence PIL 40/8420. 
 
2.2.2 Husbandry 
Animals were housed in a controlled environment with a 12 hour light/dark cycle at 22°C and 
a constant air pressure.  Where possible, littermates were housed together with a maximum 
of 6 animals per cage.  All cages were provided with environmental enrichment, and animals 
were fed standard laboratory chow (Harlan 18% protein rodent diet) ad libitum, unless 
otherwise stated.  See Appendix I (section 10.1) for diet ingredients and specification. 
 
2.2.3 Breeding 
2.2.3.1 Established colonies 
Transgenic mice were obtained from in-house colonies derived from breeding pairs sourced 
externally. P2Y12
-/-
 and genetically matched wild-type P2Y12
+/+
 mice were derived from 
breeding pairs provided by Schering Plough Research Institute, NJ (courtesy of Dr M 
Chintala).  ApoE
-/-
 breeding pairs (JAX 2052) were supplied by Jackson Laboratories (Bar 
Harbor, ME).  Both the ApoE and P2Y12 strains were developed on a C57BL/6 background 
and backcrossed 10 generations (Piedrahita et al. 1992) (Foster et al. 2001). 
 
2.2.3.2 Generation of ApoE/P2Y12 double knockout colony 
An ApoE/P2Y12 double knockout (DK) colony was developed by cross breeding of the in-
house ApoE and P2Y12 colonies.  ApoE
-/-
 mice were crossed with P2Y12
-/-
 mice to produce 
an F1 generation of heterozygotes.  Offspring were crossed to produce a subsequent F2 
generation, of which 1 in 16 were expected to be the desired genotype (see Table 2.1).  
Mice from all generations were ear clipped and genotyped by polymerase chain reaction 
2 Materials and methods 
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(PCR) to identify double knockouts for further breeding.  Prior to processing, ear clips were 
stored in the freezer at -25°C until needed. 
 
2.3 Genotyping 
2.3.1 Materials 
DNEasy® blood and tissue kit was purchased from Qiagen (Crawley, UK).  Ethidium 
bromide and PCR primers were from Sigma-Aldrich (Poole, UK).  BioMix™ Red and 
agarose was from Bioline (London, UK).  GoTaq® DNA polymerase, and all other PCR 
buffers and markers, were produced by Promega (Southampton, UK). 
 
2.3.2 DNA extraction from murine tissue 
The DNEasy® blood and tissue kit was used for all samples to extract purified DNA from the 
mouse ears clips.  DNA was extracted as per the kit protocol handbook (Purification of total 
DNA from animal tissues – Spin-column Protocol, page 28).  In summary, this involved 
incubating the ear clips in lysis buffer and proteinase K overnight at 56°C to digest the 
tissue.  The following day, samples underwent a series of wash and centrifugation steps in 
spin columns, ending with an elution of purified DNA into AE buffer (supplied with kit). 
 
2.3.3 Polymerase chain reaction for genotyping 
Extracted DNA was subsequently amplified by PCR to determine the genotype of each 
animal.  ApoE and P2Y12 PCRs were analysed separately, to determine whether each 
animal was a homozygote or heterozygote for the ApoE and P2Y12 gene.  Primers specific to 
the ApoE or P2Y12 gene were used to amplify the particular gene of interest in each case.  
The sequences of the primers used are shown in Table 2.2.  All primers were reconstituted 
in sterile water to 100 µmol/L stock solutions, from which 20 µmol/L working solutions were 
made. These were added in differing volumes to each of the PCRs to provide optimum DNA 
amplification for each gene.  All PCRs were carried out in a G-Storm GS1 thermocycler (GRI 
Ltd, Braintree, UK). 
 
2.3.3.1 ApoE PCR reaction conditions 
PCR reaction tubes were prepared for each individual DNA sample, as detailed in Appendix 
II (section 10.2.1).  ApoE primers were used to a final concentration of 0.4 µmol/L in the 
reaction mix.  BioMix™ Red contained 2 mmol/L MgCl2, nucleotides, DNA polymerase, and 
a red dye, eliminating the need to use a loading dye when running the gel following PCR.  
BioMix™ was used to increase efficiency and reduce variability.  Sterile water was then 
added to the reaction mix to make a final volume 25 µL for each sample.  The reaction tubes 
were placed in a G-Storm thermocycler, and the PCR was carried out using the cycle 
program also detailed in Appendix II. 
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Table 2.1 – Genotype outcomes of the ApoE/P2Y12 colony F2 generation. 
 
A summary of all possible genotype outcomes of the ApoE/P2Y12 colony F2 generation, 
achieved from crossing the F1 generation of heterozygotes (ApoE
+/-
P2Y12
+/-
). 
 
 AP Ap aP ap 
AP AAPP AAPp AaPP AaPp 
Ap AAPp AApp AaPp Aapp 
aP AaPP AaPp aaPP aaPp 
ap AaPp Aapp aaPp aapp 
 
A - ApoE wild-type allele P - P2Y12 wild-type allele 
a - ApoE knockout allele p - P2Y12 knockout allele 
 
 
Table 2.2 – List of ApoE and P2Y12 primers used for polymerase chain reaction. 
 
Primer Name Sequence (5’-3’) 
ApoE 180 GCCTAGCCGAGGGAGAGCCG 
 181 TGTGACTTGGGAGCTCTGCAGC 
 182 GCCGCCCCGACTGCATCT 
P2Y12 NEO ACGCGTCACCTTAATATGCG 
 DP308 GGCTGCCTTGAGAAATATCAAGT 
 DP310 GGCACTCTAGTGATGCTTTGCCTA 
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2.3.3.2 P2Y12 PCR reaction conditions 
PCR was performed according to methods provided by Schering Plough Research Institute, 
NJ.  Reaction tubes were prepared as detailed in Appendix II (section 10.2.2), using 
individual nucleotides, 1.5 mmol/L MgCl2, GoTaq® DNA polymerase, and GoTaq® green 
buffer.  Green GoTaq® buffer eliminated the need to use loading dye when running the gel.  
Sterile water was added to the reaction mix, to make a final volume of 25 µL.  PCR was 
carried out using the cycle program also detailed in Appendix II. 
 
2.3.4 Agarose gel electrophoresis and analysis 
ApoE PCR products were electrophoresed in 1.5% w/v agarose gels, and P2Y12 PCR 
products in 2% w/v gels; in addition, each contained 10 µL of ethidium bromide.  Gels were 
submerged in TAE buffer (40 mmol/L Tris, 1 mmol/L EDTA, 0.1% v/v glacial acetic acid; 
section 10.2.4) prior to sample loading.  For all PCR products, 10-15 µL of sample was 
loaded into each well.  As described previously, loading dyes were not required as the PCR 
mix already contained either a red or green dye.  To determine the length of DNA fragments 
in each sample, a Phix174/HAEIII DNA marker (see section 10.2.5) was added to the first 
well of each row.  Agarose gels were run at 90 volts for 1-2 hours. 
 
When completed, gels were viewed under ultraviolet (UV) light in a ChemiGenius
2
 
transilluminator (Syngene, Cambridge, UK) to assess the migration of DNA.  An image of the 
gel was captured using Syngene GeneSnap Bio imaging software.  DNA migration patterns 
were compared in relation to the DNA markers, to determine the sizes of the bands.  For 
ApoE PCR products, a lower (smaller) band of 155 bp indicated a wild-type genotype 
(ApoE
+/+
).  An upper (larger) band of 245 bp specified a knockout (ApoE
-/-
).  The presence of 
both bands denoted a heterozygote, ApoE
+/-
.  For P2Y12 PCR products, a lower band of 510 
bp similarly indicated a wild-type (P2Y12
+/+
).  An upper band of 650 bp showed a knockout 
(P2Y12
-/-
), and both bands denoted a heterozygote (P2Y12
+/-
). 
 
2.4 Ferric chloride injury model for rodents 
2.4.1 Materials 
Clopidogrel (Plavix®) was purchased from Bristol Myers Squibb Pharmaceuticals Ltd 
(Uxbridge, UK).    Ferric chloride was from Sigma-Aldrich (Poole, UK) and used at 10% w/v 
dissolved in sterile water.  Saline (0.9% w/v NaCl2) was from Baxter Healthcare Ltd 
(Thetford, UK).  Whatman® grade 1 filter paper was purchased from Whatman International 
(Maidstone, UK).  Hypnorm® was purchased from VetaPharma Ltd (Leeds, UK); Midazolam 
(Hypnovel®) was from Roche (Welwyn Garden City, UK). 
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2.4.2 Animals 
Male P2Y12
-/-
 mice and genetically matched wild-types, P2Y12
+/+
, underwent ferric chloride 
injury.  All mice were aged between 8 and 12 weeks, and weighed 22-28 g at the time of 
surgery. 
 
2.4.3 Pharmacological inhibition of P2Y12 
To examine the effects of P2Y12 inhibition on thrombus and neointima formation following 
arterial injury, some P2Y12
+/+
 mice were also treated with the P2Y12 antagonist clopidogrel, or 
sterile water as a control.  Clopidogrel was prepared as a suspension in 200 µL of sterile 
water, at a dose of 20 mg/kg, and administered orally by gavage, a method of delivering a 
substance directly to the stomach via a tube or needle. 
 
Mice were scruffed in an upright position and a blunt, curved 18-gauge needle, 
approximately 2 inches in length, passed slowly down the oesophagus to the neck of the 
stomach.  The drug suspension or vehicle control was deployed from the syringe into the 
stomach, and the needle carefully removed.  This particular method of drug delivery was 
employed to ensure swift, timely, and accurate dosing of the drug to each mouse. 
 
Both long- and short-term clopidogrel treatment regimens were investigated.  For long-term 
treatments, mice were gavaged 24 hours before ferric chloride injury, with either clopidogrel 
or water, followed by a second dose, 1-2 hours before surgery.   Some mice were sacrificed 
at 30 minutes post injury to investigate thrombus formation. The remaining mice were 
allowed to recover from the procedure, and then continued to be gavaged once daily.  At 21 
days post injury the mice were sacrificed to examine neointima formation. 
 
For short-term clopidogrel treatment, mice were gavaged 4 hours before injury, followed by a 
second dose 24 hours after surgery.  These mice were not gavaged again for the duration of 
the procedure, and were sacrificed at 21 days post injury. 
 
2.4.4 Bone marrow transplants in P2Y12 mice 
Bone marrow transplantation (BMT) is a procedure in which bone marrow is taken from a 
donor mouse, and transplanted into a lethally irradiated recipient mouse.  The purpose is to 
isolate the role of bone marrow-derived circulating cells, such as platelets, from the 
constituent genotype of the body.  Further detailed description of the entire BMT procedure, 
including irradiation dosing and chimera generation, can be found later in section 2.6. 
 
Briefly, male P2Y12
+/+
 and P2Y12
-/-
 mice, aged 4-6 weeks old, underwent bone marrow 
transplantation prior to ferric chloride injury.  Mice received a lethal dose of whole body 
irradiation, followed by an i.v. tail vein injection of bone marrow cells from donor females.  
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Mice were kept in ventilated caging and treated with antibiotic water for 5 weeks after 
transplantation, prior to ferric chloride injury.  Animals were sacrificed at 21 days post injury.   
 
2.4.5 Surgical procedure for ferric chloride injury 
Animals were anaesthetised by intraperitoneal (i.p.) injection of an anaesthetic solution 
(0.008 mL/g), consisting of Hypnorm® (fluanisone 2.5 mg/mL; fentanyl citrate 0.07875 
mg/mL) and midazolam (1.25 mg/mL). 
 
An incision, approximately 1 cm in length, was made to the right of the midline of the neck, 
and the salivary glands were separated by blunt dissection.  The right common carotid artery 
was then exposed and carefully isolated from the surrounding tissues using forceps.  
Subsequently a piece of Whatman® grade 1 filter paper (1 mm x 2 mm) was soaked in 10% 
w/v ferric chloride solution and placed on the artery, just below the bifurcation into the 
internal and external carotid arteries, where it was left for 3 minutes (see Figure 2.1).  The 
artery was then washed with saline and the dermis sutured with 5/0 silk.  At 30 minutes post-
injury, some mice were sacrificed to study thrombus formation, whilst the others were 
allowed to recover in order to study neointima (Evans et al. 2009).  These animals were 
placed in a hospital cage within an incubator set to 30°C.  Upon recovery from anaesthesia, 
mice were monitored for any signs of stroke before being returned to standard housing.  Any 
sick animals were culled.  The combined incidence of death, during procedure, and stroke, 
leading to the animal being culled, was 8%. 
 
2.4.6 End of procedure 
Mice were killed at either 30 minutes or 21 days post-injury, and the right common carotid 
arteries harvested, as detailed later in section 2.8, followed by histological analysis (see 
section 2.9). 
 
2.5 Atherogenesis studies 
2.5.1 Materials 
Western diet was purchased from Special Diet Services (SDS; Witham, UK).  This is a high-
fat, no cholate diet used specifically to study diet related diseases, and contains 
supplementary cholesterol to aid induction of atherosclerosis.  Chow diet was a Teklad 
Global diet from Harlan (Indianapolis, IN).  See Appendix I (section 10.1) for diet ingredients 
and specification.  D(+) glucose was obtained from Sigma-Aldrich (Poole, UK) and 
Actrapid® human insulin purchased from Novo Nordisk (Crawley, UK). 
 
2.5.2 Animals 
ApoE
-/-
 and ApoE/P2Y12 DK mice were fed ad libitum either standard laboratory chow or 
western diet for 12 weeks.  All mice used were male, and aged between 8 and 10 weeks 
upon commencement of feeding.    
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Figure 2.1 – Ferric chloride injury surgical procedure. 
 
The right common carotid artery was isolated by blunt dissection using forceps.  A piece 
of filter paper, 2 mm x 1 mm in size, was soaked in 10% w/v ferric chloride solution and 
placed on the artery, carefully avoiding contact with the surrounding tissue.  The filter 
paper was left in place for 3 minutes, causing injury to the vessel.  After 3 minutes the 
paper was removed, the vessel washed with saline, and the dermis sutured.  
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2.5.3 Weight measurements 
Mice were ear clipped to identify individual mice within a cage.  Weekly weight 
measurements were taken for both chow and western fed ApoE
-/-
 and ApoE/P2Y12 DK mice.  
Readings were taken at the start of each week over 12 weeks, beginning with a baseline 
weight before feeding commenced and a final weight after 12 weeks of feeding.  
Measurements were taken to the nearest 0.1 g.  Individual weights each week were 
combined to give a mean weight for each genotype and diet. 
 
2.5.4 Food consumption 
Over a period of 12 weeks, the food consumption of a cage of 4 ApoE
-/-
 and 4 ApoE/P2Y12 
DK mice on western diet was measured.  Bags of food were weighed out (140 g each) and 
added to a cage, one at a time, when the food hopper was empty.  All food added to a cage 
was recorded, and no food was removed or thrown away.  At the end of 12 weeks, any 
remaining food in the hopper was weighed and subtracted from the total weight of food 
added to each cage over the course of 12 weeks. 
 
2.5.5 Blood pressure measurements 
Daily blood pressure readings were taken of ApoE
-/-
 and ApoE/P2Y12 DK mice on western 
diet via a tail cuff device on the Bp-2000 blood pressure analysis system (Visitech Systems 
Inc, Apex, NC).  Individual mice were identified by ear clips and were trained for one week 
on the equipment prior to commencement of the study.  To help reinforce this daily routine, 
readings were always taken by the same operator, at the same time each day.  Efforts were 
also made to ensure similar lighting levels, room temperature, and low noise levels.  
Following training, baseline readings were taken whilst mice were on standard chow, the 
week prior to feeding.  Mice were then switched to western diet at the start of week 1, and 
readings were taken thereafter until the end of week 12.  The system was calibrated daily 
using a manometer and the cuff elastic changed on a weekly basis to ensure consistent 
experimental conditions. 
 
Specimens were placed on a heated platform at 34°C ± 0.5°C and secured in a magnetic 
holder.  The tail was threaded through the cuff and secured with tape, and finally the sensor 
positioned on top of the tail.  A total of 30 readings were taken for each mouse, every day, 
with the first 10 readings discarded.  The final 20 readings were taken to calculate the mean 
blood pressure and pulse rate for each animal.  These values were also used to generate a 
weekly mean blood pressure for each genotype. 
 
2.5.6 Metabolic studies 
Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were carried out after 10 and 
11 weeks, respectively, of feeding on a western diet.  These studies were carried out on 
ApoE
-/-
 and ApoE/P2Y12 DK mice undergoing daily blood pressure readings. 
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Mice were restrained on the heated blood pressure platform, and a small sample of blood 
was obtained by puncturing the tail vein using a 21-gauge needle.  Blood glucose levels 
were measured using an Optium Xceed portable glucose meter and disposable test strips 
(Abbott Laboratories Limited, Maidenhead, UK).  Measurements were given in mmol/L. 
 
2.5.6.1 Glucose tolerance test 
Fed baseline glucose levels were taken 1-2 days prior to starting the metabolic studies and 
each mouse weighed.  All mice were fasted from 5pm the evening before the GTT, and a 
fasted blood glucose level was taken the following morning. 
 
Mice received an i.p. injection of 20% w/v D(+) glucose in sterile water, at a dose of 10 µL/g 
(2 mg/g).  Blood glucose readings were taken at 30, 60, 90, and 120 minutes post injection 
(Crossey et al. 2000; Wheatcroft et al. 2004; Zhang 2011).  When blood glucose levels had 
returned to baseline levels, mice were returned to their cages. 
 
2.5.6.2 Insulin tolerance test 
The week following glucose tolerance testing, the same mice were weighed again, and a fed 
baseline glucose level was taken.  Each mouse received Actrapid® human insulin at a dose 
of 0.75 U/kg by i.p. injection.  Blood glucose readings were taken at 20, 40, and 60 minutes 
post injection (Wheatcroft et al. 2004).  Mice were monitored throughout for signs of 
hypoglycaemia, upon which a glucose injection would have been administered.  When blood 
glucose levels had risen to baseline levels, mice were returned to their cages. 
 
2.5.7 End of procedure 
Mice were sacrificed after 12 weeks of feeding on western or chow diet.  Blood was taken by 
cardiac puncture, either for plasma or flow cytometry. Various tissues were harvested for 
histological analysis, including the brachiocephalic and right common carotid arteries, the 
aortic sinus, the aorta, and major organs (see section 2.8 and 2.9). 
 
2.6 Detailed method for bone marrow transplantations 
2.6.1 Materials 
RPMI-1640 (modified, with sodium bicarbonate, without L-glutamine and without phenol red) 
was purchased from Sigma-Aldrich (Poole, UK).  FBS was from Lonza (Slough, UK).  HBSS 
was purchased from Thermo Scientific (Epsom, UK).  Acetic acid was from VWR 
International Inc. (Lutterworth, UK).  Neomycin trisulphate salt hydrate and polymyxin B 
sulphate salt were obtained from Sigma-Aldrich (Poole, UK). 
 
2.6.2 Animals and chimeras generated 
Transplanting bone marrow between strains of transgenic mice generates chimeras (see 
section 2.4.4), a mouse which is composed of 2 genetically distinct cell populations or 
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tissues.  The chimeras generated in the following studies are detailed in Tables 2.3 and 2.4.  
The method described is based on a protocol which has successfully been used previously 
by my group (Chamberlain et al. 2006; Evans et al. 2009; West et al. 2014). 
 
2.6.2.1 Ferric chloride studies 
BMT was carried out on male P2Y12
+/+
 and P2Y12
-/-
 mice, aged 4-6 weeks old, to create 2 
chimeras and 2 control groups (see Table 2.3).  Female mice were used as donors in a ratio 
of 1 donor to 2 recipient mice.  After BMT, mice underwent ferric chloride injury, as 
described earlier in section 2.4. 
 
2.6.2.2 Atherogenesis studies 
ApoE
-/-
 and ApoE/P2Y12 DK mice were used to create the chimeras detailed in Table 2.4.  
Females were used as donors, where possible, and recipient males were aged 8-10 weeks 
at the time of transplantation. 
 
All mice were housed in individually ventilated caging (IVC), fed standard chow and given 
neomycin (1 mmol/L, final concentration) and polymyxin B (1000 USP units/mL) in drinking 
water, provided in covered bottles (see Appendix I, section 10.1).  In addition, atherogenesis 
mice were switched to western diet 5 weeks after transplantation, and maintained on this 
diet for 4 weeks until the end of the procedure. 
 
2.6.3 Total body irradiation 
Recipient mice were given a lethal dose of whole body irradiation totalling 11 Gy (1100 rad).  
This was split into 2 doses of 5.5 Gy (550 rad), 4 hours apart.  Following the final irradiation, 
mice were placed in an incubator at 35°C for 1 hour prior to receiving donor bone marrow via 
a tail vein injection. 
 
2.6.4 Bone marrow cell preparation and transplantation 
Donor mice were killed by cervical dislocation, and the femurs and tibias removed under 
aseptic conditions.  Bone marrow was flushed from the bones with RPMI-1640 media + 10% 
v/v fetal bovine serum (FBS) using a syringe and 26-gauge needle.  The cell-media solution 
was passed through a 40 µm cell strainer, and then centrifuged at 500 x g for 5 minutes.  
The supernatant was removed and the small cell pellet resuspended in Hank’s buffered salt 
solution (HBSS) + 10% v/v FBS.  Cells were counted on a haemocytometer, using 1% v/v 
acetic acid to lyse the RBCs, and then placed on ice until the tail vein injections.  Each 
preparation produced an average yield of 20 x 10
6
 cells/mL. 
 
Mice were injected with 200 µL of whole bone marrow via the tail vein.  Each mouse 
received between 2 and 4 x 10
6
 cells in total and were monitored daily, on day 0-6 after 
transplant and twice daily on day 7-14, for signs of non-engraftment.  Mortality due to this 
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Table 2.3 – P2Y12 chimeras generated from bone marrow transplantations for ferric chloride 
studies. 
 
Chimera Donor Recipient 
1 P2Y12
+/+
 P2Y12
+/+
 
2 P2Y12
-/-
 P2Y12
+/+
 
3 P2Y12
-/-
 P2Y12
-/-
 
4 P2Y12
+/+
 P2Y12
-/-
 
 
 
Table 2.4 – ApoE/P2Y12 chimeras generated from bone marrow transplantations for 
atherogenesis studies. 
 
Chimera Donor Recipient 
1 ApoE
-/-
 ApoE
-/-
 
2 ApoE/P2Y12 DK ApoE
-/-
 
3 ApoE/P2Y12 DK ApoE/P2Y12 DK 
4 ApoE
-/-
 ApoE/P2Y12 DK 
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cause was 0% for these experiments, although an incidence of up to 30% can be expected 
for bone marrow transplantations. 
 
2.6.5 End of procedure 
For atherogenesis studies, mice were killed at 9 weeks post-transplant, after 4 weeks of 
feeding on western diet.  Blood was taken by cardiac puncture, either for plasma or flow 
cytometry.  The brachiocephalic and right common carotid arteries, aortic sinus, aorta, and 
major organs were harvested for histological analysis (see section 2.8 and 2.9). 
 
2.7 Pharmacological inhibition of P2Y12 in a model of early 
atherogenesis 
2.7.1 Materials 
Ticagrelor (Brilique™) was supplied by AstraZeneca UK Ltd (Luton, UK) and clopidogrel 
(Plavix®) was from Bristol Myers Squibb Pharmaceuticals Ltd (Uxbridge, UK).  Mannitol was 
obtained from Sigma-Aldrich (Poole, UK).  Hartley’s blackcurrant flavoured concentrated jelly 
was used in these experiments.  
 
2.7.2 Animals 
ApoE
-/-
 and ApoE/P2Y12 DK male mice were fed western diet for 4 weeks, in addition to 
either twice-daily doses of ticagrelor (100 mg/kg), daily clopidogrel (20 mg/kg), or mannitol 
(control) in jelly.  This method of voluntary drug delivery was adapted from a published 
method by Zhang (Zhang 2011).  The doses of ticagrelor and clopidogrel were based on 
previous studies that established these as optimal for providing a high, sustained level of 
platelet P2Y12 inhibition (Evans et al. 2009).  Mannitol is a main constituent of ticagrelor and 
clopidogrel tablets, and was therefore selected as a control. 
 
2.7.3 Preparation of drug doses 
Ticagrelor and clopidogrel tablets had the film coating removed and were crushed into 
powder.  Ticagrelor, clopidogrel, or mannitol powder was weighed into separate shallow 
moulds according to the appropriate doses for each drug, weighing 12 doses per mould.  
Flavoured jelly was dissolved in hot water, according to the manufacturer’s instructions, and 
allowed to cool, then poured into each mould and mixed with the drug to achieve an even 
suspension.  Moulds were placed immediately in a freezer and later cut into 12 equal cubes, 
measuring approximately 1 cm
3
, containing a single dose of drug. 
 
2.7.4 Dosing strategy 
Mice were housed individually and fed a chow diet during one week of training, where mice 
received twice-daily meals of jelly only.  Mice were then switched to a western diet upon 
commencing drug treatment.  Due to the short half-life of ticagrelor, mice were dosed twice-
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daily with ticagrelor and mannitol.  Clopidogrel-fed mice were given one dose of clopidogrel 
and one dose of mannitol.   Mice received daily doses approximately 9 hours apart and were 
observed daily to monitor jelly consumption. 
 
2.7.5 End of procedure 
Mice were killed after 4 weeks of drug treatment and western diet.  Blood was taken by 
cardiac puncture for flow cytometry.  In addition, various tissues were harvested for 
histological analysis, including the brachiocephalic artery, aortic sinus, and whole aorta (see 
section 2.8 and 2.9). 
 
2.8 Harvesting of tissues 
2.8.1 Materials 
Sodium pentobarbital was provided by J M Loveridge Ltd (Southampton, UK).  Hirudin (900 
anti-IIa units/mL, 5 µg/mL) was purchased from Canyon Pharmaceuticals™ (Basel, 
Switzerland).  Sodium citrate was supplied from Sigma-Aldrich (Poole, UK).  PBS was 
purchased from Oxoid (Basingstoke, UK).  All fixative reagents were from VWR International 
Ltd (BDH brand, Lutterworth, UK), except sodium phosphate, which was supplied from 
Sigma. 
 
2.8.2 Sacrifice of animals and blood withdrawal 
At the end of the procedure, mice were killed by injection of 0.2 mL sodium pentobarbital 
(200 mg/mL) given i.p.  If blood was required, cardiac puncture was performed following 
pentobarbital injection, and prior to cessation of breathing. 
 
Blood was taken directly from the heart through the chest wall into a 1 mL syringe, following 
loss of the pedal reflex.  For plasma, blood was taken into a heparinised syringe and 
centrifuged at 2000 x g for 5 minutes at room temperature in a Beckman microfuge® R 
(Beckman Coulter, High Wycombe, UK).  For platelet flow cytometry, blood was taken into 
10% v/v hirudin at a final concentration in the blood of 1%.  Blood was kept at room 
temperature and processed for flow cytometry immediately (see section 2.10.4).  For 
coagulation studies (see section 2.10.5), blood was taken into 3.8% w/v sodium citrate at a 
ratio of 1 part anticoagulant to 9 parts blood, as used in previous murine studies (Palm et al. 
1997; Bolliger et al. 2010). 
 
2.8.3 Perfusion fixation 
Once breathing had ceased, the abdominal cavity was exposed and the lower aorta cut to 
provide a route for blood loss.  The chest cavity was then opened, and the circulation 
perfused via intraventricular injection of 1 mL phosphate buffered saline (PBS), followed by 1 
mL of 10% v/v buffered formalin (33.3 mmol/L NaH2PO4, 50 mmol/L Na2HPO4, 10% v/v 
formaldehyde; see Appendix III, section 10.3.1). 
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2.8.4 Tissue excision 
2.8.4.1 Carotid artery 
An incision was made into the neck and the right carotid artery carefully dissected from the 
surrounding tissue.  A segment of the vessel, approximately 1 cm in length, was excised 
originating from the bifurcation.  For ferric chloride injuries, this included the entire injured 
area and some surrounding healthy tissue.  The arteries were fixed in 10% v/v buffered 
formalin before processing for histological analysis (see section 2.9). 
 
2.8.4.2 Organs 
The spleen, liver, and lungs were taken from ApoE
-/-
 and ApoE/P2Y12 DK mice to assess 
differences in organ weights between the genotypes.  Organs were removed by blunt 
dissection and placed in 10% v/v buffered formalin.  
 
2.8.4.3 Dissection of the aortic tree 
To expose the aortic tree, the rib cage, lungs, thymus, and oesophagus were removed.  
Beginning at the descending aorta, above the diaphragm, and working towards the aortic 
arch, fat was carefully dissected from the aorta, breaking any small branching vessels along 
its length.  The vena cava was then broken to expose the upper aorta.  The arch and its 3 
main vessels, the brachiocephalic, left common carotid, and left subclavian arteries, were 
dissected free of the surrounding tissue.  The brachiocephalic artery was then excised from 
its origin at the aortic arch, to the bifurcation into the right common carotid and right 
subclavian arteries, and placed in 10% v/v buffered formalin. 
 
The left common carotid and left subclavian arteries were cut at the arch, and the aorta 
excised from its origin at the heart, ending at the diaphragm.  The aorta was placed in a petri 
dish with PBS, and blunt forceps were used to remove any remaining adventitial fat from the 
vessel.  Sprung vanus scissors were used to open the vessel and expose the inside surface.  
Vessels were cut along the outside curve of the arch, ending at the top of the descending 
aorta and along the inside curve for its entire length (see Figure 2.2).  Aortae were then 
placed in 4% w/v paraformaldehyde in PBS (PFA; see Appendix III, section 10.3.1). 
 
The heart was removed by blunt dissection from any surrounding tissue, and transected 
along the midline below the atria at a slight angle (see Figure 2.2).  Both pieces of heart 
were placed in 10% v/v buffered formalin. 
 
All tissues were stored at 4°C and kept in either 10% v/v buffered formalin or 4% w/v PFA for 
24 hours, and then transferred to PBS for longer term storage.  Tissues were processed for 
histological analysis, as described below. 
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Figure 2.2 – Aortic dissection. 
 
These images show the chest cavity (a) before and (b) after removal of the lungs, 
thymus, and oesophagus.  The aorta and arch (c) were then dissected free of the 
surrounding tissue, before the entire aorta was removed (d).  The aorta was then stripped 
of any remaining adventitial fat and cut open using vanus scissors (e) to expose the 
inside surface of the aorta (f).  Diagram (g) shows the aortic arch and the branching 
vessels.  The green dashed lines indicate the point at which the brachiocephalic artery 
was excised.  Diagram (h) shows the heart from a front (i) and lateral (ii) view.  The red 
dashed ellipse indicates the position of the aortic sinus, and the green dashed lines show 
the position and angle at which the heart was transected. 
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2.9 Histology, immunohistochemistry and morphometry 
2.9.1 Materials 
All histological cassettes, moulds and paraffin wax were purchased from Raymond A Lamb 
Ltd (now Thermo Fisher Scientific, Epsom, UK).  Alcohols and xylene were also from 
Thermo Fisher Scientific.  All stains, Polysine™ glass slides, coverslips and DPX resin were 
purchased from VWR International Ltd (Lutterworth, UK).  Whatman® grade 1 filter paper 
was obtained from Whatman International (Maidstone, UK).  Fine insect pins (#26002-20) 
were from Fine Science Tools (Heidelberg, Germany).  Primary antibodies: mouse 
monoclonal anti-human α-smooth muscle actin (M0851; clone 1A4) and mouse monoclonal 
anti-human MAC387 (M074701) were supplied by Dako (Ely, UK), rat anti-mouse F4/80 
(ab6640) was purchased from Abcam (Cambridge, UK), and rabbit polyclonal anti-P2Y12 
(APR-012) was from Alomone Labs (Jerusalem, Israel).    Secondary antibodies: biotinylated 
goat anti-mouse IgG and goat anti-rat IgG were purchased from Vector Labs (Peterborough, 
UK), Alexa Fluor® 488 goat anti-mouse IgG H+L (A-11034) and Alexa Fluor® 594 goat anti-
rabbit IgG H+L (A-11037), both highly cross adsorbed, were supplied by Invitrogen™ Life 
Technologies (Paisley, UK).  Vectastain® ABC-HRP kit and Vectorshield® mounting media 
with DAPI (H-1200) was also from Vector Labs.  Hydrogen peroxide (30% v/v), Triton X-100, 
SigmaFAST™ 3,3′-Diaminobenzidine tablets, and Tris buffered saline (TBS) powder (0.05 
mol/L Tris, 0.138 mol/L NaCl, 2.7 mmol/L KCl) were from Sigma-Aldrich (Poole, UK).  
Trypsin 250 was obtained from BD Biosciences (Oxford, UK).  Citric acid monohydrate was 
purchased from Alfa Aesar (Ward Hill, MA).  Commercially available Marvel skimmed milk 
powder was used for immunohistochemistry. 
 
2.9.2 Tissue preparation 
2.9.2.1 Carotid and brachiocephalic arteries 
Arteries (except aortae, see section 2.9.5.1) were removed from formalin or PBS, and each 
laid on a sheet of Whatman® grade 1 filter paper, straightened and a second sheet of filter 
paper placed on top, leaving the artery sandwiched in between.  Each sample was labelled 
and placed in a plastic histological cassette for processing.  Arteries were dehydrated 
through graded alcohols and xylene, prior to embedding in paraffin wax for cutting.  Details 
of the dehydration protocol can be found in Appendix III (see section 10.3.2). 
 
2.9.2.2 Aortic sinus and other tissues 
Tissues were weighed prior to processing for histological analysis.  Each organ was 
removed from formalin or PBS and gently shaken to remove excess liquid.  Gross wet 
weights were measured on fine scales in micrograms (mg).  Some tissues were also 
processed for histology. 
 
As described in section 2.8.4.3, hearts were excised and transected along the midline below 
the atria.  Both pieces of tissue were kept and weighed on fine scales to find the total heart 
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weight.  The bottom half was then discarded and only the top half, containing the aortic 
sinus, retained and placed in a plastic cassette with filter paper. Organ tissues were first cut 
into 0.5 cm slices, using a scalpel blade, and 2 or 3 pieces placed in a cassette with filter 
paper.  These were then dehydrated as outlined in Appendix III (see section 10.3.2). 
 
2.9.3 Embedding in wax 
2.9.3.1 Carotid and brachiocephalic arteries 
The next day, following dehydration, in which samples were left overnight in molten wax, 
cassettes were taken from the oven.  The arteries were removed and each placed 
horizontally at the base of a shallow plastic mould.  Molten paraffin wax was then poured 
around the vessel and allowed to cool for 2-3 hours.  Once set, the wax block was removed 
and trimmed down to a small cuboid shape containing the artery.  This was then rotated and 
placed vertically in the centre of a deeper mould, placing the artery perpendicular to the 
base (see Figure 2.3).  Fresh molten wax was then poured into the mould, around the cube, 
and a microtome block placed on top.  The wax was left overnight to set.  This process 
corrects the orientation of the artery in preparation for sectioning. 
 
2.9.3.2 Aortic sinus and other tissues 
For all other tissues, cassettes were removed from the oven, and each piece of tissue 
placed in the bottom of a shallow plastic mould with the flat surface facing down.  In the case 
of the aortic sinus, this positioned the heart correctly to allow entire cross-sections of the 
sinus, including all 3 valve leaflets.  Molten wax was then poured around the tissue and a 
microtome block placed on top.  The blocks were allowed to set and harden overnight. 
 
2.9.4 Tissue sectioning 
Wax blocks were pressed from the moulds, and placed on ice for at least 1 hour prior to 
cutting on a Leica RM2135 microtome (Leica Microsystems, Wetzlar, Germany).  Overnight 
storage of the wax blocks in a fridge can also aid the cutting process, particularly when 
sectioning in a warm room. 
 
All vessel sections were cut to a 5 micron (µm) thickness and floated out on a water bath, 
heated to approximately 35°C, to flatten the sections.  Aortic sinus and organ sections were 
cut slightly thicker, at 7 µm, to help ensure the tissue remained intact during transfer to the 
water bath.  Sections were then mounted on Polysine™ glass slides by using the slide to 
‘pick up’ the sections from the surface of the water bath.  The slides were first allowed to air 
dry in racks, before placing them in an oven at 40°C overnight to dry completely and adhere 
to the coated slide surface.  The following day, slides were removed from the drying oven 
and stored at room temperature until staining. 
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Figure 2.3 – Embedding of vessels. 
 
To facilitate sectioning of vessels, a 2-step embedding process is needed to correctly 
orientate the vessels.  First vessels were laid along the bottom of a plastic mould (a) and 
molten wax poured around the tissue.  Once set, the block was removed from the mould 
and the excess wax trimmed away, leaving only a small cube containing the vessel.  
Next, this was rotated 90° (b) and placed in the bottom of another mould, with the vessel 
perpendicular to the base (c).  Molten wax was poured around the block and finally a 
microtome blocked placed on top.  Once set, the block was pressed from the mould and 
was ready for sectioning. 
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2.9.4.1 Carotid and brachiocephalic arteries 
Cross-sections were taken at intervals along the full length of the artery.  Typically 10 x 5 µm 
sections were mounted onto 4 slides, encompassing a 50 µm length of vessel.  An interval of 
100 µm was then left between each set of 10 sections.  This method of sectioning allowed 
assessment of the entire artery, and encompassed either the site of injury (ferric chloride 
injuries), or areas of atherosclerotic lesion (atherogenesis studies). 
 
2.9.4.2 Aortic sinus 
Blocks were cut until the appearance of the valve leaflets of the aortic sinus.  Sections were 
then collected continually from this point onwards until the end of the sinus and the 
beginning of the aorta, leaving no intervals. 
 
2.9.5 Histology 
2.9.5.1 En face oil red O staining of whole aortae 
Whole aortas were removed from PFA or PBS and stained en face with oil red O, an inert 
oil-soluble bis-azo dye for lipids.  This is a sensitive technique, and is commonly used to 
identify and measure areas of atherosclerotic lesion, as previously described (Nunnari et al. 
1989).  For details of the staining protocol, see Appendix III (section 10.3.3). 
 
Molten paraffin wax was poured into petri dishes and allowed to cool.  Once the wax had 
set, aortae were positioned to expose the inside of the vessels and pinned onto the surface 
using fine insect pins, approximately 0.2 mm in diameter (Fine Science Tools, Heidelberg, 
Germany), with the aid of a magnifying lamp.  When pinned, the vessels were covered with 
PBS before capturing images of each aorta. 
 
2.9.5.2 Histological staining of tissue sections 
Brachiocephalic artery, aortic sinus, carotid artery, and liver cross-sections were stained 
using histological dyes to identify tissue constituents and structure.  Briefly, slides were 
dewaxed and rehydrated through graded alcohols to water.  Sections were then stained 
using various protocols, including alcian blue/elastic van Gieson (EVG), haematoxylin and 
eosin (H&E), or martius scarlet blue (MSB).  For details of these staining protocols, see 
Appendix III (section 10.3.3).  Following staining, the tissue was dehydrated, and mounted 
with coverslips using DPX resin. 
 
2.9.6 Immunohistochemistry 
Aortic sinus sections were stained for α-smooth muscle actin (α-SMA), F4/80, and MAC387 
using standard immunohistochemical techniques.  Detailed protocols can be found in 
Appendix III (see section 10.3.4).  Briefly, sections were dewaxed, rehydrated and blocked 
for both endogenous peroxidases with hydrogen peroxide, and non-specific antibody binding 
with milk buffer.  Antigen retrieval was performed if necessary.  Sections were incubated 
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with primary antibody for 1 hour at room temperature, or overnight at 4°C, followed by 
incubation with biotinylated secondary antibody (1:200 dilution in PBS) for 30 minutes at 
room temperature.  Negative control sections were incubated in PBS only, followed by 
secondary antibody.  Positive staining was amplified using avidin-biotinylated enzyme 
complexes with horseradish peroxidase (HRP), and detected using SigmaFAST™ 3,3′-
diaminobenzidine tetrahydrochloride (DAB) as the substrate.  Tissue was then 
counterstained with Carazzi’s haematoxylin, dehydrated, and mounted with DPX. 
 
2.9.7 Immunofluorescence 
Aortic sinus sections were dual stained for α-SMA and P2Y12 using immunofluorescence.  A 
detailed protocol, including buffer constituents, can be found in Appendix III (section 10.3.5).  
Briefly, sections were dewaxed, rehydrated, and blocked for non-specific antibody binding 
with blocking buffer containing 5% v/v goat serum.  Sections were then incubated with α-
SMA (1:150) and P2Y12 (1:100) primary antibodies in dilution buffer at 4°C overnight.  
Sections were then incubated with Alexa Fluor® 488 anti-mouse IgG and Alexa Fluor 594® 
anti-rabbit IgG secondary antibodies (1:200) for 2 hours at room temperature in the dark.  
Tissue was mounted using Vectashield® mounting medium with DAPI, and sealed with nail 
varnish. 
 
2.9.8 Morphometry 
Images of stained sections were captured using a camera mounted to a light microscope, or 
dissecting microscope for whole aortae, and analysed on NIS-elements software (Nikon 
Instruments, Kingston upon Thames, UK).  Fluorescent images were captured using a Leica 
DM6000b fluorescence microscope with LMD BGR filter cube. 
 
2.9.8.1 Quantification of lesions in whole aortae 
Individual aortae were captured at x15 magnification, and the software was calibrated using 
an image of a ruler taken at the same magnification.  This ensured all subsequent 
measurements were accurate and in the appropriate units.  Total surface area of each aorta 
was measured by manually tracing the perimeter of the vessel.  Areas of positive oil red O 
staining were then selected using a threshold function with hue, saturation, and intensity 
(HSI) filters to identify red regions in the image.  Lesion area was quantified and expressed 
as a percentage of the total aortic surface area (see Figure 2.4).  This method was then 
used to assess lesion area in the aortic arch and descending aorta regions. 
 
2.9.8.2 Quantification of thrombus, neointima and lesions in vessels 
Carotid and brachiocephalic artery sections were captured at either x100 or x200 
magnification.  Typically one section per 150 µm interval (approximately) was assessed 
along the length of the artery, generating a mean area for each of the vessel parameters 
measured.  The internal and external elastic lamina area (IEL and EEL respectively) and
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Figure 2.4 – Quantification of en face oil red O staining of whole aortae. 
 
(a) Image of a whole aorta stained with oil red O, showing positively stained areas in red. 
Original image captured at x15 magnification. (b) NIS-elements analysis software was 
used to calculate the total vessel area by manually tracing the perimeter of the vessel 
(outlined in green). (c) The software was then used to select areas of positive staining by 
using hue, saturation and intensity filters.  Selected areas are highlighted in bright red. (d) 
The software then identified separate objects (outlined in green) and calculated the mean 
object area. (e) Shows a worked example of how the percentage lesion area was 
calculated.  NIS-elements software was calibrated using an image of a ruler taken at the 
same magnification as the vessels. Scale bars = 0.5 cm. 
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circumference were measured by manually tracing the outer perimeter of the structures (see 
Figure 2.5).  Due to the often fragmented nature of its structure, the thrombus, neointima, or 
lesion area were indirectly measured by quantifying lumen area, and subtracting this from 
the IEL.  Luminal area was determined using a threshold function with red, green, and blue 
filters (RGB) to select the white area of the lumen. 
 
Aortic sinus sections were captured at x40, x200, or x400 magnification.  Typically 5 
sections, each with 3 valves present, were assessed from each animal generating a mean 
area for each of the vessel parameters measured.  Due to the presence of the valve leaflets, 
it was not possible to calculate lesion area by indirect measurement of the lumen, as with 
arterial sections.  Instead, total lesion area was quantified by tracing around each individual 
lesion (see Figure 2.5). 
 
Using the assumption that the vessels were originally circular, the circumference 
measurements were then used to re-calculate the IEL and EEL areas, to correct for any 
distortion of the vessel during processing (see below for calculation).  Total cross-sectional 
area (CSA) of the vessel was attributed as c-EEL (corrected) area.  Medial area was 
determined by subtracting c-IEL from c-EEL.    Furthermore, to enable direct comparison 
between vessels of differing size, the thrombus:media (T/M), neointima:media (N/M) (Evans 
et al. 2009; Patil et al. 2010), and lesion:CSA (L/CSA) ratios (West et al. 2014) were also 
calculated. 
 
Calculation for corrected area (using formulas for circle area): 
 
Circumference (C) = 2πr   rearrange  r = C/2π 
Area of a circle = πr
2
 
Corrected area = π(C/2π)
2
 
 
2.9.8.3 Quantification of collagen and α-smooth muscle actin 
Collagen content of was determined using martius scarlet blue (MSB), and quantifying areas 
of blue positive staining within the lesions.  Smooth muscle actin content was determined by 
immunohistochemistry using DAB, in which positive cells were stained with a brown 
precipitate.  Similarly, as with oil red O, collagen and α-SMA content was measured using 
the threshold function with HSI filters to select areas of positive staining, which was then 
quantified and expressed as a percentage of the total lesion area. 
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Figure 2.5 – Measurement of vessel and aortic sinus parameters using image analysis. 
 
(a)(i) Original vessel image x100, scale bar = 100 µm. (ii) Using a polygon tool, the IEL 
(outlined in blue) and EEL (outlined in green) were manually traced. (iii) Lumen area was 
then selected using red, green, and blue (RGB) filters on the threshold function. Selected 
areas are highlighted in bright red. The software then measures the selected area 
(perimeter of area outlined in green).  (b)(i) Original sinus image x40, scale bar = 500 µm. 
(ii) Using a polygon tool, the total CSA of the sinus was manually traced (outlined in 
green).  (iii)  Lesions were then traced (outlined in blue) and the individual areas (1-4) 
combined to give a total lesion area. 
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2.10 In vitro assays 
2.10.1 Materials 
An ultra-sensitive mouse insulin ELISA kit was purchased from Crystal Chem Inc. (Downers 
Grove, IL).  PAR-4 TRAP peptide (AYPGKF) was synthesized by Almac Sciences (East 
Lothian, UK).  All HT buffer reagents, EDTA, and formaldehyde (37% w/v) containing 
methanol for FACS fix, were from Sigma-Aldrich (Poole, UK).  FITC anti-mouse CD62p and 
FITC isotype rat IgG1λ polyclonal antibodies were purchased from BD Pharmingen™ (BD 
Biosciences, Oxford, UK).  PE anti-mouse JON/A (CD41/61) was purchased from Emfret 
Analytics (Eibelstadt, Germany).  FACSFlow™ was obtained from BD Biosciences (Oxford, 
UK).  Dade® Actin® FS; Innovin® thromboplastin; thrombin reagent; Owren’s veronal buffer 
and standard human reference plasma (all Dade Behring, Liederbach, Germany) were 
supplied from Sysmex (Milton Keynes, UK). 
 
2.10.2 Blood biochemistry 
Plasma from ApoE
-/-
 and ApoE/P2Y12 DK mice fed on western and chow diet were sent to 
Sheffield Teaching Hospitals Biochemistry Department for analysis.  A full lipid profile 
including high and low density lipoproteins (HDL and LDL), triglycerides, and cholesterol 
levels were obtained, plus liver enzymes, aspartate transaminase (AST), and alanine 
transaminase (ALT). 
 
2.10.3 Insulin ELISA 
Plasma from ApoE
-/-
 and ApoE/P2Y12 DK mice fed on western diet for 12 weeks was 
analysed by enzyme-linked immunosorbent assay (ELISA) to determine plasma insulin 
levels.  Samples were prepared and processed according to the kit protocol for the low 
range assay (0.1 - 6.4 ng/mL), as previous data from our group showed insulin levels should 
fall within this range. 
 
In brief, 5 µL of plasma or mouse insulin standard was added to 95 µL of sample diluent in 
antibody-coated microplate wells and allowed to incubate for 2 hours at 4°C.  The plate was 
washed repeatedly before adding anti-insulin enzyme conjugate, and was allowed to 
incubate for a further 30 minutes at room temperature.  The plate was again washed, and 
the enzyme substrate solution added before the final 40 minute incubation at room 
temperature.  The reaction was stopped with 0.5 mol/L sulphuric acid and the absorbance 
measured at A450, with the reference at A630, on an Opsys MR™ plate reader (Dynex 
Technologies Ltd, East Grinstead, UK).  A standard curve was generated using the 
absorbance of the insulin standards and the plasma samples read from the curve. 
 
2.10.4 Platelet function studies 
A flow cytometry based platelet function assay was carried out on blood taken from ApoE
-/-
 
and ApoE/P2Y12 DK mice, to demonstrate either P2Y12 deficiency or inhibition.  Blood was 
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exposed to thrombin receptor activating protein (TRAP, AYPGKF), a potent platelet agonist 
of the protease-activated receptor (PAR)-4, to induce cell surface expression of P-selectin 
(CD62p) and activation of the receptor GPIIbIIIa (CD41/61), which are both markers of 
platelet activation.  The presence of these activation markers were detected and quantified 
by flow cytometry, a method of using fluorescently labelled antibodies which bind specifically 
to their target receptor or marker, in this case either P-selectin or activated GPIIbIIIa.   
 
Briefly, blood was collected via cardiac puncture into hirudin, as described in section 2.8.2.  
For each mouse 100 µL of blood was diluted into 1.9 mL HEPES-Tyrode’s (HT) buffer (129.6 
mmol/L NaCl, 8.8 mmol/L NaHCO3, 2.8 mmol/L KCl, 800.9 µmol/L KH2PO4, 5.7 mmol/L 
dextrose, 10 mmol/L HEPES; see Appendix IV, section 10.4.1) and 20 µL (100 mmol/L) 
CaCl2.  Tubes were prepared with 10 µL fluorescein isothiocyanate (FITC) anti-CD62p 
(1:200 dilution in HT buffer), 5 µL phycoerythrin (PE) JON/A (anti-CD41/61, used neat), 2 µL 
PAR-4 TRAP (0, 0.1, 0.3, 1 or 3 mmol/L), and 33 µL diluted blood.  Non-specific binding was 
determined by use of a FITC rat IgG1λ polyclonal isotype antibody in place of anti-CD62p, 
with no agonist.  For JON/A (anti-CD41/61), ethylenediaminetetraacetic acid (EDTA, 
100mmol/L, pH 8.0) was used in place of TRAP as an unstimulated control.  Tubes were 
incubated in the dark for 20 minutes at room temperature, before adding 500 µL of either 
FACSFlow™ or FACS fix (1% v/v formaldehyde in PBS) to each tube.  Samples were 
analysed on a BD™ LSRII flow cytometer using FACSDiva
TM
 software (BD Biosciences, 
Oxford, UK).  The platelet population was gated on forward versus side scatter plots and 
10,000 events were collected.  Expression was denoted as increase in median fluorescence 
of the entire platelet population over baseline values (Evans et al. 2009; West et al. 2014). 
 
2.10.5 Coagulation studies 
To determine any differences in thrombin and fibrin generation, activated partial 
thromboplastin time (aPTT) and prothrombin time (PT) were measured to assess the 
intrinsic (aPTT) and extrinsic (PT) coagulation pathways.  Fibrinogen levels were a measure 
of the final common coagulation pathway. 
 
Blood was taken, as described in section 2.8.2, from ApoE
-/- 
and ApoE/P2Y12 DK mice which 
had undergone BMT procedures.  Samples were sent to Sheffield Teaching Hospitals 
Coagulation Department within 2 hours of blood withdrawal, for centrifugation to obtain 
plasma, and subsequent analysis. 
 
Briefly, for aPTT, Dade® Actin® FS (containing phospholipids) was added to citrated plasma 
to activate the ‘intrinsic’ contact coagulation pathway, and the clotting time measured.  PT 
was measured by adding Dade® Innovin® thromboplastin (containing tissue factor) to 
citrated plasma to activate the extrinsic coagulation pathway, and the clotting time 
measured.  Finally, fibrinogen levels were determined by diluting citrated plasma in Dade® 
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Owren’s veronal buffer, before adding thrombin reagent.  Clotting time was measured and 
converted to a fibrinogen concentration by reference to a calibration curve of standard 
reference plasma.  All steps were carried out by a Sysmex coagulation auto-analyser 
CA1500 or CS2100i, which were cross-calibrated by the manufacturer to give equivalent 
results (Sysmex, Milton Keynes, UK). 
 
2.11 Statistics 
Data are expressed as mean values and presented with standard error of the mean (SEM), 
or as individual data.  Analyses were performed using Prism (Version 6; GraphPad, San 
Diego, CA) or SPSS software (Version 19; IBM, New York, NY). 
 
Levene’s test was performed on all data to assess for equality of variance.  Where the P 
value yielded >0.05, equal variances were assumed, and the data was analysed using 
parametric tests, including the independent samples t test, one-, or two-way analysis of 
variance (ANOVA).  The choice of post hoc test for one- and two-way ANOVA was 
dependent on the number of groups to be compared.  Bonferroni’s multiple comparison was 
used for datasets involving a small number of comparisons, whereas Tukey’s multiple 
comparison was applied to those which required a large number of comparisons to be made.  
Significance was attributed to P values <0.05. 
 
Where the Levene’s test yielded a P value <0.05, equal variances were not assumed and 
the data was analysed using the Mann-Whitney test.  In datasets involving multiple group 
comparisons, separate Mann-Whitney tests were performed for each group pair and the 
level of significance was adjusted to reflect the number of comparisons, such that 
significance was attributed to P values <0.01. 
 
Genotype frequencies of the ApoE/P2Y12 F2 generation, in Chapter 4, were analysed using 
the Pearson’s chi-squared test to assess whether this population followed the Hardy-
Weinberg principle and test the null hypothesis that genotype frequencies remain constant 
within a population.  Where the P value yielded <0.05, the null hypothesis was rejected. 
 
Power analyses determined that, in the vascular injury model, a sample size of 6 was 
required to have a 90% power of detecting a difference in neointima:media ratio of 0.8 
(standard deviation 0.4) with a 5% significance level.  In atherogenesis studies, a sample 
size of 8 was required to have a 90% power of detecting a difference in lesion:CSA ratio of 
0.05 (standard deviation 0.02) with a 5% significance level. 
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Studying the vessel wall response to injury, using in vivo models, offers a useful insight into 
the processes which may be important in vessel repair following PCI, restenosis, plaque 
rupture, and atherothrombosis, as well as the inflammatory response atherogenesis, 
commonly termed as a ‘response to injury’.  A better understanding of these processes is 
vital to delivering effective treatment and management, and may improve clinical outcomes. 
 
The development of neointima at the site of vascular injury is a wound healing response, 
preceded by the formation of an initial platelet-rich thrombus, which is remodelled primarily 
by invasion of smooth muscle and inflammatory cells (Steele et al. 1985; Harker 1987; 
Komatsu et al. 1998; Christen et al. 2001; Glover et al. 2002).  Moreover, platelets are 
thought to further enhance this process via the release of pro-inflammatory cytokines and 
growth factors.  Given that platelet activation is amplified and sustained by the P2Y12 
receptor (Storey et al. 2000), I hypothesised that P2Y12 would play a key role in thrombus 
and neointima formation.  In addition, I considered the use of the P2Y12 antagonist 
clopidogrel in modulating these processes.  Furthermore, P2Y12 is also expressed on 
vascular smooth muscle cells (Wihlborg et al. 2004), and so bone marrow transplantations 
were employed to investigate the role of platelet versus vessel wall P2Y12.    
 
In this chapter, I investigated the role of P2Y12 in thrombus and neointima formation using a 
murine ferric chloride injury model.  Ferric chloride solution was topically applied to the outer 
surface of the right common carotid artery, resulting in localised endothelial denudation.  I 
chose to use an established model, applying a 10% w/v ferric chloride solution for 3 minutes, 
which has been shown to produce occlusive thrombi within 10 minutes of application (Kurz 
et al. 1990; Farrehi et al. 1998; Konstantinides et al. 2001; Wang and Xu 2005), and 
neointima formation at 21 days post injury (Schafer et al. 2002). 
 
3.1 P2Y12 mediates thrombus and neointima formation 
following vessel wall injury 
P2Y12
+/+
 and P2Y12
-/- 
mice underwent ferric chloride injury, and carotid arteries were 
harvested at either 30 minutes post injury, to assess thrombus, or 21 days following injury, to 
quantify neointima formation.  For detailed methods refer to section 2.4. 
 
3.1.1 Thrombus 
At 30 minutes post injury, P2Y12
-/-
 mice demonstrated a significant reduction in thrombus 
compared to P2Y12
+/+
 controls (see Figure 3.1a and c): thrombus area was 0.039 ± 0.006 vs. 
0.003 ± 0.001 mm
2
 (+/+ vs. -/-; P<0.001).  Similarly, thrombus was significantly attenuated in 
3 Investigating the role of P2Y12 in the 
vessel wall response to vascular injury 
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P2Y12
+/+
 mice treated with clopidogrel (0.011 ± 0.003 mm
2
 vs. +/+; P<0.05).  As expected, 
luminal area was increased in those mice with reduced thrombus.  No difference was noted 
between the mean media area of each group; however, vessel CSA was significantly larger 
in clopidogrel-treated mice compared to both untreated groups. 
 
To minimise the effect of variations in vessel size, I also calculated thrombus:media ratio 
(T/M).   Mirroring the attenuated thrombus formation, as seen in Figure 3.1a and c, T/M ratio 
was significantly attenuated in P2Y12
-/-
 mice compared to P2Y12
+/+ 
controls (see Figure 3.1b): 
T/M ratio was 3.148 ± 0.379 vs. 0.257 ± 0.062 (+/+ vs. -/-; P<0.001).  Likewise, in P2Y12
+/+
 
mice treated with clopidogrel, T/M ratio was also significantly reduced (1.029 ± 0.300 vs. +/+; 
P<0.01). 
 
3.1.2 Neointima 
At 21 days post ferric chloride injury, neointima formation was quantified.  P2Y12
-/-
 mice 
showed a substantial attenuation in neointimal area compared to P2Y12
+/+
 control mice (see 
Figure 3.2a and c): neointima area was 0.061 ± 0.006 vs. 0.011 ± 0.001 mm
2
 (+/+ vs. -/-; 
P<0.001).  Pharmacological inhibition of P2Y12 in control mice with clopidogrel produced a 
similar reduction in neointima (0.003 ± 0.001 mm
2
 vs. +/+; P<0.001).  As a result, both 
P2Y12
-/-
 and P2Y12
+/+
 mice treated with clopidogrel exhibited a greater lumen area compared 
with untreated controls (P<0.001).  No difference was noted between the mean media area 
of each group; however, CSA was slightly increased in P2Y12
-/-
 mice compared to clopidogrel 
treated mice. 
 
The neointima:media ratio (N/M) was significantly attenuated in P2Y12
-/-
 mice compared to 
P2Y12
+/+
 controls (see Figure 3.2b): N/M ratio was 2.667 ± 0.273 vs. 0.4026 ± 0.029 (+/+ vs. 
-/-; P<0.001).  Similarly, N/M ratio was greatly reduced in clopidogrel-treated mice compared 
to untreated controls (0.111 ± 0.049 vs. +/+; P<0.001).  
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Figure 3.1 – Thrombus formation was attenuated in P2Y12
-/-
 mice, and clopidogrel-treated 
wild-types, at 30 minutes post ferric chloride injury. 
 
Carotid arteries were excised from P2Y12
+/+
 (n=5), P2Y12
-/-
 (n=5), and P2Y12
+/+
 mice 
treated with clopidogrel (n=3) at 30 minutes post ferric chloride injury.  Mice treated with 
clopidogrel were administered 20 mg/kg by gavage at 24 hours and 1-2 hours before 
surgery.  (a) Thrombus, media, lumen, and cross-sectional area (CSA), and (b) 
thrombus:media ratio were calculated for each vessel.  (c) Representative vessel cross-
sections are shown.  Images taken at x100 magnification, scale bar = 250 µm.  Data are 
mean ± SEM; *P<0.05, **P<0.01, ***P<0.001; (a) two-way and (b) one-way ANOVA with 
Tukey’s multiple comparison. 
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  Figure 3.2 – Neointima formation was attenuated in P2Y12
-/-
 mice, and clopidogrel-treated 
wild-types, at 21 days post ferric chloride injury. 
 
Carotid arteries were excised from P2Y12
+/+
, P2Y12
-/-
, and P2Y12
+/+
 mice treated with 
clopidogrel (all n=4) at 21 days post ferric chloride injury.  Mice treated with clopidogrel 
were administered 20 mg/kg by gavage at 24 hours and 1-2 hours before surgery, 
followed by single daily doses.  (a) Neointima, media, lumen, and cross-sectional area 
(CSA), and (b) neointima:media ratio were calculated for each vessel.  (c) Representative 
vessel cross-sections are shown.  Images taken at x100 magnification, scale bar = 250 
µm.  Data are mean ± SEM; *P<0.05, ***P<0.001; (a) two-way and (b) one-way ANOVA 
with Tukey’s multiple comparison. 
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3.2 Short-term blockade of P2Y12 attenuates neointima 
formation at 21 days post vessel injury 
Following either long- or short-term treatment with clopidogrel or water, neointima formation 
at 21 days post ferric chloride injury was quantified.  All mice treated with clopidogrel 
showed a non-significant trend towards reduced neointimal area compared to control mice 
given water (by gavage) (see Figure 3.3a): neointima area was 0.036 ± 0.011 in control 
mice, 0.006 ± 0.003 in short-term treated mice (P=0.056 vs. control), and 0.003 ± 0.001 mm
2
 
in long-term treated mice (P=0.032 vs. control).  Furthermore, mice given only short-term 
treatment with clopidogrel, at the time of injury, demonstrated a similar reduction in 
neointimal area compared to those mice treated daily throughout the duration of the study.  
As expected, luminal area was increased in those mice with reduced neointima; however, 
there was no difference between the media or CSA of each group. 
 
N/M was greatly reduced in clopidogrel-treated mice, compared to controls (see Figure 
3.3b): N/M ratio was 1.453 ± 0.5039 in control mice, 0.191 ± 0.073 in short-term treated mice 
(P=0.056 vs. control), and 0.111 ± 0.049 in long-term treated mice (P=0.063 vs. control).  As 
demonstrated in the neointimal areas, short-term treatment with clopidogrel was as effective 
as prolonged treatment in reducing neointima formation. 
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Figure 3.3 – Short-term clopidogrel treatment was as effective as prolonged treatment in 
attenuating neointima formation, at 21 days post ferric chloride injury. 
 
Carotid arteries were excised from P2Y12
+/+
 mice treated with water (n=5), short-term 
(n=5), or long-term clopidogrel treatment (n=4) at 21 days post ferric chloride injury.  For 
long-term treatments, mice were gavaged with either water or 20 mg/kg clopidogrel at 24 
hours and 1-2 hours before surgery, followed by a single daily dose thereafter.  Mice 
receiving short-term treatment were gavaged with clopidogrel 4 hours prior to injury 
followed by a final dose 24 hours after surgery.  (a) Neointima, media, lumen, and cross-
sectional area (CSA), and (b) neointima:media ratio were calculated for each vessel.  
Data are mean ± SEM; P=ns; Mann-Whitney test (adjusted level of significance P<0.01 
for multiple group comparisons). 
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3.3 Neointima formation is predominantly platelet, rather 
than vascular smooth muscle cell, P2Y12-mediated 
P2Y12
+/+
 and P2Y12
-/-
 mice underwent BMT to generate 2 control and 2 chimeric groups, 
deficient in either platelet or vessel wall P2Y12.  Ferric chloride injury was performed 5 weeks 
after transplantation, and neointima formation at 21 days post injury was assessed. 
 
Chimeric mice deficient in platelet, but not vessel wall, P2Y12 demonstrated a significant 
reduction in neointimal area compared to P2Y12
+/+
 controls (see Figure 3.4a): neointima area 
was 0.0233 ± 0.0067 in control mice and 0.001 ± 0.0004 mm
2
 in platelet P2Y12-deficient 
mice (P<0.05 vs. control).  As expected, neointima was also reduced in mice completely 
deficient in P2Y12 (0.0021 ± 0.001 vs. control; P<0.05).  Interestingly mice which did express 
platelet P2Y12, but were vessel wall P2Y12-deficient, did not demonstrate any significant 
effects on neointima formation compared to control mice (0.0171 ± 0.0062 vs. control; 
P=ns). 
 
This pattern of results was also mirrored when assessing N/M ratio, with mice deficient in 
platelet P2Y12 having a significantly attenuated N/M ratio compared to control mice (see 
Figure 3.4b):  N/M ratio was 0.9247 ± 0.2984 in control mice and 0.0343 ± 0.011 in platelet 
P2Y12-deficient mice (P<0.01 vs. control).  The N/M ratio was also reduced in mice 
completely deficient in P2Y12 (0.0796 ± 0.0352 vs. control; P=0.011).  Similarly, vessel wall 
P2Y12-deficiency alone did not have any significant effects on the N/M ratio (0.4996 ± 0.1653 
vs. control; P=ns). 
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Figure 3.4 – Bone marrow transplantation indicated neointima formation, following ferric 
chloride injury, was predominantly platelet, rather than vascular smooth muscle cell, P2Y12-
mediated. 
 
P2Y12 mice underwent bone marrow transplantation to generate chimeric groups: P2Y12
+/+
 into 
P2Y12
+/+
 (n=9), P2Y12
-/-
 into P2Y12
+/+
 (n=8), P2Y12
-/-
 into P2Y12
-/-
 (n=8), and P2Y12
+/+
 into P2Y12
-/-
 
(n=11).  Ferric chloride injury was performed 5 weeks following transplantation, and carotid 
arteries were excised 21 days post injury.  (a) Neointima and (b) neointima:media ratio were 
calculated for each vessel.  Data are mean ± SEM; *P<0.01, **P<0.001; Mann-Whitney test 
(adjusted level of significance P<0.01 for multiple group comparisons). 
70 
 
3.4 Summary 
This chapter has described the contribution of platelet P2Y12 receptor in the vessel wall 
response to injury, by examining thrombus and neointima formation following ferric chloride 
induced vascular injury.  In summary: 
 
 P2Y12-deficient mice had significantly less thrombus at 30 minutes after injury, 
compared to wild-type (P2Y12
+/+
) control mice. 
 Pharmacological inhibition of P2Y12 in wild-type mice, using clopidogrel, resulted in a 
similar reduction in thrombus compared to untreated animals. 
 Likewise, P2Y12 deficiency or inhibition also lead to significantly attenuated 
neointima formation compared to control, at 21 days following injury. 
 Further studies demonstrated that only short-term clopidogrel treatment, of 2 doses 
before and one immediately after injury, was required to cause a reduction in 
neointima at 21 days, as seen with prolonged (daily) clopidogrel treatment. 
 Bone marrow transplantations revealed platelet P2Y12-deficient mice had 
significantly attenuated neointima at 21 days, compared to P2Y12
+/+
 control mice, 
and demonstrated a similar reduction to mice completely deficient in P2Y12. 
 Vessel wall P2Y12-deficiency alone had little effect on neointima formation. 
 
3.5 Discussion 
The fundamental role of platelets, and specifically the P2Y12 receptor, in thrombosis is 
irrefutable, with P2Y12 inhibitors forming a key component of acute coronary syndrome 
treatments (Yusuf et al. 2001; Wiviott et al. 2007; Wallentin et al. 2009).  However, their 
involvement in restenosis and the vascular response to injury was less clear.  In this chapter, 
I demonstrated that P2Y12 indeed mediates the vessel wall response to injury, and show a 
clear relationship between the initial thrombus and subsequent neointima formation.  These 
data reaffirm the importance of P2Y12 inhibitor treatment following PCI in the prevention of 
restenosis and provide a rationale for further investigation into the role of P2Y12 in 
atherogenesis. 
 
In vivo models of thrombosis and neointima formation induce vessel injury via a range of 
methods, including by chemical or mechanical means.  In this study I used the application of 
a 10% w/v ferric chloride solution, which results in vessel denudation following ferric ion 
oxidation of endothelial cells (Tseng et al. 2005), and causes the rapid formation of occlusive 
thrombi (Kurz et al. 1990; Farrehi et al. 1998).  Although traditionally employed in thrombosis 
research, ferric chloride injury has also been used to study neointima formation (Zhu et al. 
2001; Schafer et al. 2002), for which the less thrombogenic mechanical methods of wire 
injury and ligation are usually applied. 
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At 30 minutes and 21 days post ferric chloride injury, thrombus and neointima area were 
assessed, respectively.  Differences observed in vessel CSA represented the variation in 
animal size between groups, and so the thrombus or neointima to media ratios were 
calculated to account for these differences.  P2Y12-deficiency led to a substantial reduction 
in thrombus and neointimal area, the effects of which were reproduced by treatment with the 
P2Y12 antagonist, clopidogrel.  Furthermore, as P2Y12 is expressed on VSMCs as well as 
platelets (Wihlborg et al. 2004), bone marrow transplants revealed that platelet, but not 
vessel wall, P2Y12 was responsible for potentiating neointima formation. 
 
The effects of P2Y12-deficiency or inhibition on thrombosis have been reported previously 
(Andre et al. 2003; Wang and Xu 2005); however, a role for P2Y12 in neointima formation 
had, until now, only been inferred from clinical trial data, demonstrating a reduction in repeat 
vessel revascularisation post-PCI following clopidogrel (Mehta et al. 2001; Steinhubl et al. 
2002), ticagrelor (Wallentin et al. 2009), or prasugrel treatment (Wiviott et al. 2007).  
Neointima development is characterised by the accumulation and proliferation of VSMCs 
and macrophages within the vessel intima, and a role for platelets in this process has been 
implicated in several studies.  Transgenic mouse lines have revealed P-selectin is required 
for neointima formation, and cite its role in mediating leukocyte rolling and adhesion as the 
mechanism by which it promotes neointima (Manka et al. 2001).  Further investigation 
demonstrated platelet, rather than endothelial, P-selectin was responsible for these effects 
(Manka et al. 2004).  By enabling the formation of platelet-leukocyte conjugates, P-selectin 
allows leukocyte arrest onto thrombus, at the site of injury, and subsequent infiltration.  
Furthermore, P-selectin is required for the deposition of platelet RANTES onto the surface of 
leukocytes and the endothelium, which further promotes leukocyte recruitment (Schober et 
al. 2002).  Investigation into the expression of another chemokine revealed MCP-1 binds to 
the surface of platelets and results in monocyte arrest onto these cells (Schober et al. 2004).  
Platelets also induce VSMC migration and proliferation through release of PDGF (Schini-
Kerth et al. 1997; Massberg et al. 2003), and blockade of PDGF via antibody treatment has 
been attributed to a reduction in neointima (Ferns et al. 1991). 
 
From this evidence it is clear that platelets have a substantial role to play in promoting 
neointima formation through the recruitment of leukocytes, by deposition of chemokines 
RANTES and MCP-1, and enabling their adhesion onto thrombus at the site of injury via P-
selectin.  In addition, platelets induce mitogenic effects on VSMCs by release of growth 
factors.  It is apparent that these platelet effects commence from the initial thrombus 
formation at the site of vascular injury, allowing the infiltration of leukocytes and VSMCs, and 
thus causing the eventual remodelling of thrombus into neointima.  By inhibiting P2Y12 using 
clopidogrel, thrombosis is virtually abolished and, with little thrombus present, all ensuing 
platelet-mediated effects on neointima development are eliminated.  Short-term clopidogrel 
treatment demonstrated that P2Y12 inhibition is only required at the time of injury to instigate 
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these effects, highlighting the innate relationship between thrombosis and neointima 
formation.  This is supported by similar data showing a single treatment with either a P-
selectin or PSGL-1 antibody at the time of vessel injury was sufficient to cause a reduction in 
later neointima formation, due to the blockade of platelet interactions with the vessel wall 
and leukocytes (Phillips et al. 2003). 
 
However, it must also be noted that clopidogrel binds irreversibly to the P2Y12 receptor, and 
so its inhibitory effects would have been sustained for several days after the final dose, 
despite only short-term treatment, until clopidogrel-bound platelets were removed naturally 
from the body.  Clopidogrel activity is therefore dependent on platelet turnover.  This is 
highlighted by Gurbel et al. who compared the offset of platelet inhibition by clopidogrel and 
ticagrelor, i.e. how these drugs wore off over time, in the ONSET/OFFSET clinical study 
(Gurbel et al. 2009).  Following a final dose of drug, platelet inhibition was sustained for a 
longer period in patients that had received clopidogrel, compared to those that were given 
the reversible drug ticagrelor, in which the antiplatelet effects diminished at a much quicker 
rate.  Further work into the relationship between the timing of P2Y12 inhibition and neointima 
formation, using ticagrelor, has been pursued by our group and confirms that P2Y12 
inhibition is indeed required at the time of injury, both before and immediately after, in order 
to prevent neointimal hyperplasia (Patil et al. 2010).  In addition, the clear role of platelet 
P2Y12 in neointima formation is also evident following a more moderate injury method 
compared to ferric chloride, using the less thrombogenic wire injury model, as demonstrated 
by our group (Evans et al. 2009). 
 
These data demonstrate the crucial role for P2Y12 in the vessel wall response to injury, and 
validate the importance of P2Y12 inhibition in the prevention of thrombosis and restenosis 
following PCI.  Despite evidence to show the clear interaction of platelets with the 
inflammatory response, little is known of their direct impact on atherogenesis.  Given the 
importance of P2Y12 in the development of neointima, I was interested to investigate its role 
in lesion formation using a model of atherogenesis.  In the following chapter, I discuss the 
development of a novel ApoE/P2Y12 double knockout mouse colony in which to test this 
hypothesis. 
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Given that platelets, and in particular the P2Y12 receptor, are highly influential in the 
development of thrombus and neointima following arterial injury, and that blockade of P2Y12 
leads to a dramatic reduction in both (see Chapter 3), I was interested to further investigate 
the role of P2Y12 in an inflammatory setting, during atherogenesis. 
 
The ApoE
-/-
 mouse is a well-established model for studying atherosclerosis, and is favoured 
due to the similarities seen in lesion composition and development, as compared to human 
disease (Nakashima et al. 1994).  In order to investigate the role of P2Y12 in atherogenesis, 
an ApoE/P2Y12 double knockout (DK) mouse strain was generated from crossing existing in-
house ApoE
-/-
 and P2Y12
-/-
 colonies.  As a novel transgenic line, the phenotype of this strain 
was unknown, and was therefore compared to the ApoE
-/-
 parent line.  This chapter outlines 
the generation of the ApoE/P2Y12 DK colony, and describes the characterisation of the 
physiological and metabolic phenotype of an ApoE/P2Y12 DK mouse. 
 
4.1 Generation of an ApoE/P2Y12 double knockout mouse 
strain 
Established in-house ApoE
-/-
 and P2Y12
-/-
 colonies were crossed to generate F1 and F2 
ApoE/P2Y12 generations.  Offspring were genotyped to select ApoE/P2Y12 DK animals as 
breeding pairs from which to establish the colony. 
 
4.1.1 Genotyping 
PCR was performed using DNA extracted from ear clips and primers specific to both the 
ApoE and P2Y12 genes.  The original ApoE
-/-
 strain, generated by Nobuyo Maeda (Piedrahita 
et al. 1992), and P2Y12
-/-
 strain, by Madhu Chintala (Foster et al. 2001), were developed 
using a neomycin resistance cassette to disrupt the desired gene.  Therefore a set of 3 
primers were used to determine homozygotes and heterozygotes. The first primer was 
common to both wild-type and mutant (knockout) genes; the second was specific to the neo-
insert of the mutant gene, and the third corresponded to only the wild-type gene (see Figure 
4.1a).  In each case, either single (homozygote) or double (heterozygote) bands were 
produced.  The genotype was determined by the length of PCR product. 
 
The primary cross produced an F1 generation that was heterozygous for both the P2Y12 and 
ApoE genes, demonstrated by the presence of a double band, as shown in Figure 4.1b(i) 
(P2Y12 gel not shown).  Heterozygotes were paired to produce an F2 generation and all mice 
4 Physiological and metabolic phenotype of 
the ApoE/P2Y12 double knockout mouse 
during atherogenesis 
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were assessed for ApoE genotype in order to select candidate ApoE
-/-
 mice.  These were 
identified by a single PCR product, 245bp in length, as shown in Figure 4.1b(ii) (lanes 4, 5, 
9, 10, 16, 17 and 19).  Only ApoE
-/-
 mice were then genotyped for the P2Y12 gene to select 
P2Y12
-/-
 animals, denoted by a single band 650bp in length (see Figure 4.1b(iii); lanes 4, 7, 
10, 11 and 14).  The ApoE/P2Y12 DK mice identified were used for establishing the colony. 
 
4.1.2 Genotype frequencies 
The F2 generation, derived from heterozygotes, had 16 possible outcomes, of which only 1 
in 16 would be the desired ApoE/P2Y12 DK genotype (see Figure 4.2a).  The entire F2 
generation (n=119) was genotyped, and the observed and expected frequencies of each 
genotype are shown in Figure 4.2c.  Pearson’s chi-squared test (see Figure 4.2b) was 
applied to test the null hypothesis that genotype frequencies will remain constant within a 
population, as stated in the Hardy-Weinberg principle.  As P<0.05 the null hypothesis was 
rejected (P=0.0366). 
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Figure 4.1 – Generation of an ApoE/P2Y12 double knockout colony. 
 
Mice were genotyped by PCR using primers specific to either the ApoE or P2Y12 gene.  (a) 
The first primer was common to both wild-type (WT) and mutant (KO) genes; the second 
was specific to the neo-insert of the mutant gene, and the third corresponded to only the 
wild-type gene.  In each case, either single (homozygote) or double (heterozygote) bands 
were produced.  The genotype was determined by the length of PCR product, referenced 
against Phix174/HAEIII DNA marker shown in lane 1 of each gel.  (b)(i) ApoE
-/-
 and P2Y12
-/-
 
in-house parent colonies were crossed to produce an F1 generation, heterozygous for both 
the P2Y12 and ApoE genes (ApoE gel shown).  Heterozygotes were paired to produce the 
F2 generation.  (ii) All mice were first genotyped for ApoE to select ApoE
-/-
 mice (lanes 4, 5, 
9, 10, 16, 17 and 19).  (iii) ApoE
-/-
 mice were then genotyped for P2Y12 to select 
ApoE/P2Y12 DK mice for future breeding (lanes 4, 7, 10, 11 and 14). 
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 (a) 
 AP Ap aP ap 
AP AAPP AAPp AaPP AaPp 
Ap AAPp AApp AaPp Aapp 
aP AaPP AaPp aaPP aaPp 
ap AaPp Aapp aaPp aapp 
 
Key:   A – ApoE wild-type allele P - P2Y12 wild-type allele 
   a - ApoE knockout allele  p - P2Y12 knockout allele 
     
     
   (b) 
 
 
 
 
 
 
(c) 
 AAPP AApp AAPp AaPP AaPp Aapp aaPp aaPP aapp 
Oi 15 10 8 18 27 9 19 6 7 
Ei 7.4375 7.4375 14.875 14.875 29.77 14.875 14.875 7.4375 7.4375 
 
 
 
  
Figure 4.2 – Genotype frequencies and Pearson’s chi-squared test of the ApoE/P2Y12 F2 
generation. 
 
(a) An F2 generation was created from crossing the F1 generation of heterozygotes, which 
produced 16 possible outcomes, of which only 1 in 16 was expected to be the desired 
ApoE/P2Y12 DK genotype (highlighted in bold).  Pearson’s chi-squared test (b) was applied to 
test the null hypothesis that genotype frequencies will remain constant within a population 
(Hardy-Weinberg principle).  (c) The observed and expected frequencies of each genotype 
were calculated for the ApoE/P2Y12 F2 population (n=119), and the chi-squared value 
calculated. 
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4.2 ApoE/P2Y12 double knockout mice demonstrate reduced 
platelet reactivity 
The P2Y12 phenotype of platelets from ApoE
-/-
 and ApoE/P2Y12 DK mice was further 
confirmed by a functional assay measuring P-selectin (CD62p) and activated GPIIbIIIa 
receptor (CD41/61) expression in response to TRAP, which acts via the PAR-4 receptor.  
Stimulation via the thrombin receptor induces a strong platelet activation response that leads 
to release of ADP from the platelet dense granules and consequent amplification by P2Y12, 
so that TRAP-induced platelet activation provides a useful measure of P2Y12 inhibition or 
deficiency. 
 
Platelets from ApoE
-/-
 mice displayed high fluorescence of the CD62p and CD41/61 JON-A 
antibodies, demonstrating these platelets expressed high levels of both P-selectin and 
activated GPIIbIIIa receptors (see Figure 4.3a and b).  In contrast, platelets from 
ApoE/P2Y12 DK mice showed attenuated platelet activation, and exhibited much lower 
fluorescence levels, shown as a shift to the left in the fluorescence peaks for each antibody.  
Baseline fluorescence was determined using an isotype (CD62p) or EDTA unstimulated 
control (CD41/61 JON-A). 
 
CD62p and CD41/61 JON-A fluorescence was measured in response to a range of PAR-4 
TRAP concentrations, in addition to a saline control, which showed the cells were not pre-
activated.  Expression was measured as an increase in median fluorescence over baseline.  
At each concentration, ApoE
-/-
 mice demonstrated consistently higher P-selectin (Figure 
4.3c) and activated GPIIbIIIa receptor expression (Figure 4.3d) compared to ApoE/P2Y12 DK 
mice.  This was particularly evident at 3 mmol/L TRAP for which P-selectin median 
fluorescence was 3088 ± 561 vs. 256 ± 38 (ApoE
-/-
 vs. ApoE/P2Y12 DK; P<0.001) and 
GPIIbIIIa median fluorescence was 24502 ± 2284 vs. 4181 ± 481 (P<0.001).  A similar 
response was also seen for 1 mmol/L TRAP.  Attenuated expression of these activation 
markers confirmed a functional platelet deficiency, and demonstrated reduced platelet 
reactivity in ApoE/P2Y12 DK mice.  These results were consistent with our previous findings 
on P2Y12
-/-
 mice (Evans et al. 2009).  
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Figure 4.3 – ApoE/P2Y12 double knockout mice showed reduced expression of platelet 
activation markers. 
 
Blood was taken from ApoE
-/-
 and ApoE/P2Y12 DK mice (n=3), and analysed by flow 
cytometry to assess platelet function, via measurement of (a) P-selectin (CD62p) 
expression and (b) activation of the GPIIbIIIa receptor (CD41/61) in response to PAR-4 
TRAP, a potent platelet agonist.  Baseline fluorescence was determined using (a)(i) 
isotype, or (b)(i) EDTA unstimulated control for the CD62p and CD41/61 antibodies 
respectively.  Representative fluorescence histograms are shown for (ii) ApoE
-/-
 and (iii) 
ApoE/P2Y12 DK mice.  Median fluorescence was measured, and is shown as increase 
over baseline for (c) CD62p and (d) activated CD41/61. Data are mean ± SEM; 
***P<0.001; two-way ANOVA with Tukey’s multiple comparison. 
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4.3 ApoE/P2Y12 double knockout mice gain weight more 
rapidly than ApoE-/- mice when fed a high-fat diet 
Atherogenesis was augmented in ApoE
-/-
 and ApoE/P2Y12 DK mice by feeding a high-fat 
(21% w/w) western diet for 12 weeks.  Additional mice were fed a standard chow (6% w/w 
fat) diet, and all mice were weighed weekly (see Methods, section 2.5). 
 
ApoE/P2Y12 DK mice fed a western diet gained significantly more weight compared to ApoE
-
/-
 mice over 12 weeks (see Figure 4.4a).  Baseline weights were similar for both genotypes 
before feeding commenced: 25.1 ± 0.7 vs. 22.6 ± 0.6 g (ApoE
-/-
 vs. ApoE/P2Y12 DK; P=ns).  
Mice gained weight rapidly thereafter, becoming significantly heavier after 4 weeks on a 
high-fat diet: 33.1 ± 1.0 vs. 28.1 ± 0.6 g; (P<0.01).  Weight gain persisted throughout 12 
weeks of feeding, and continued to diverge from ApoE
-/-
 mice.  After 12 weeks on a western 
diet, ApoE/P2Y12 DK mice weighed 42.5 ± 1.4 g compared to 33.8 ± 0.8 g in ApoE
-/-
 mice 
(P<0.001). 
 
Chow-fed animals gained weight steadily throughout 12 weeks of monitoring, from 25.8 ± 
2.4 vs. 24.5 ± 0.5 g (ApoE
-/-
 vs. ApoE/P2Y12 DK) at baseline, to 31.7 ± 1.4 vs. 31.2 ± 0.9 g at 
week 12.  No significant difference in weight was observed between ApoE
-/-
 and ApoE/P2Y12 
DK mice at any time point (see Figure 4.4b).  Overlaying the weight profiles of mice fed each 
diet, demonstrated that ApoE
-/-
 mice fed a western or chow diet gained weight to a similar 
degree and rate, highlighting the magnitude of weight gain observed in western fed 
ApoE/P2Y12 DK mice (Figure 4.4c).  This significant weight difference was reflected in a 
noticeable size difference compared to ApoE
-/-
 mice (see Figure 4.4e). 
 
With such a significant difference in weight, I was interested to monitor the food consumption 
of a cage of 4 ApoE
-/-
 and 4 ApoE/P2Y12 DK mice fed a western diet for 12 weeks.  No 
difference was seen in the mean total food consumption per mouse (see Figure 4.4d).  
ApoE
-/-
 mice consumed 250 g of western diet each over 12 weeks vs. 266.3 g eaten by 
ApoE/P2Y12 DK mice.  This corresponded to 2.98 g per day for an ApoE
-/-
 mouse and 3.17 g 
per day for an ApoE/P2Y12 DK mouse, compared to a mean daily food intake of 3.26 g for a 
male mouse aged 24 weeks (Evsikova and Svenson 2014), represented by the dashed line 
in Figure 4.4d.  
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Figure 4.4 – ApoE/P2Y12 double knockout mice gained significantly more weight than 
ApoE
-/-
 mice when fed a western diet. 
ApoE
-/-
 and ApoE/P2Y12 DK mice were fed either (a) western (n=16 & 15 respectively) or 
(b) chow diet (n=7) for 12 weeks and weighed weekly.  An overlay of data from both diets 
can be seen in (c).  The food consumption of a cage of 4 mice, of each genotype, fed 
western diet was measured over 12 weeks, and the mean total weight of food consumed 
per mouse calculated (d).  The dashed line represents the mean intake of an average 
male mouse, based on a daily intake of 3.26g/day.  A visible difference in body size (e) 
was noted between ApoE/P2Y12 DK (left) and ApoE
-/-
 mice (right) after 12 weeks of 
feeding a western diet. Data are mean ± SEM; **P<0.01, ***P<0.001; two-way ANOVA 
with Bonferroni’s multiple comparison. 
Source: Mouse Phenome Database. 
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4.4 ApoE/P2Y12 double knockout mice fed a western diet had 
enlarged livers 
Upon dissection, a clear difference in liver size was noted between the 2 genotypes, with 
ApoE/P2Y12 DK mice having noticeably larger livers than their ApoE
-/-
 counterparts (see 
Figure 4.5a).  Weighing each of the main organs revealed no significant difference between 
the heart, lungs, and spleen weight of ApoE
-/-
 and ApoE/P2Y12 DK mice (Figure 4.5b).  
However, ApoE/P2Y12 DK mice had significantly heavier livers than ApoE
-/-
 mice fed a 
western diet: liver weights were 2.169 ± 0.13 vs. 2.588 ± 0.401 g (ApoE
-/-
 vs. ApoE/P2Y12 
DK; P<0.05).  As expected western fed mice had enlarged livers compared to their chow fed 
counterparts: chow ApoE
-/-
 livers were 1.514 ± 0.078 g (vs. western; P<0.001) and chow 
ApoE/P2Y12 DK livers were 1.7 ± 0.089 g (vs. western; P<0.001).  This pattern was also 
reflected when liver weight was calculated as a percentage of the mean body weight (see 
Figure 4.5c).  
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Figure 4.5 – ApoE/P2Y12 double knockout mice fed a western diet had enlarged livers. 
 
The heart, lungs, spleen, and liver were excised from ApoE
-/-
 and ApoE/P2Y12 DK mice 
following 12 weeks of feeding.  (a) Upon dissection, ApoE/P2Y12 DK mice fed a western 
diet appeared to have larger livers (arrow) than those of ApoE
-/-
 mice.  All organs were (b) 
weighed, and (c) calculated as a percentage of mean body weight.  Data are mean ± SEM; 
*P<0.01, ***P<0.001; two-way ANOVA with Bonferroni’s multiple comparison. 
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4.5 The physiological and metabolic phenotype of 
ApoE/P2Y12 double knockout and ApoE
-/- mice is similar 
ApoE
-/-
 and ApoE/P2Y12 DK mice underwent a range of tests to assess both physiological 
and metabolic parameters throughout, and upon the conclusion of, 12 weeks on a western 
diet (see Methods, sections 2.5 and 2.10). 
 
4.5.1 Blood pressure 
Daily systolic and diastolic blood pressure, and pulse readings were taken for ApoE
-/-
 and 
ApoE/P2Y12 DK mice throughout 12 weeks of feeding on a western diet.  Systolic and 
diastolic pressures were averaged to give a mean blood pressure for each genotype, every 
week.  As these parameters are highly sensitive to stress, mice were trained for one week, 
to incorporate these readings into their daily routine.  In addition, care was taken to ensure 
consistent environmental conditions, such as lighting, noise levels, operator, and time of 
day. 
 
Weekly readings for individual mice showed a wide range of mean blood pressures within 
each genotype group (see Figure 4.6a and b).  Individual blood pressures fluctuated from 
week to week, and the wide range of pressures within each group was maintained 
throughout the entire 12 weeks of feeding on a western diet.  The total mean blood pressure 
for each genotype showed the overall trend, and there was no significant difference between 
ApoE
-/-
 and ApoE/P2Y12 DK mice on any week (see Figure 4.6c).  In both genotype groups, 
mean blood pressure rose initially from baseline, at 97.8 ± 2.6 vs. 94.3 ± 1.6 mmHg (ApoE
-/-
 
vs. ApoE/P2Y12 DK), peaking at 106.1 ± 3.3 vs. 99.1 ± 3.8 in week 2, before falling to the 
lowest recorded pressures of 85.3 ± 2.4 vs. 84.5 ± 3.5 mmHg at week 4.  From this time 
point onwards, mean weekly blood pressure increased incremently.  The final mean blood 
pressure, following 12 weeks on a western diet, was 97.9 ± 3.1 mmHg in ApoE
-/-
 mice and 
99.6 ± 2.3 mmHg in ApoE/P2Y12 DK mice. 
 
In addition to blood pressure, the mean pulse rate was also measured, and throughout 12 
weeks of assessment there was no significant difference between ApoE
-/-
 and ApoE/P2Y12 
DK mice (see Figure 4.6d).  The mean pulse rate remained relatively constant throughout, 
ranging between 688-727 beats per minute (bpm) in ApoE
-/-
 mice and 678-730 bpm in 
ApoE/P2Y12 DK mice. 
 
4.5.2 Metabolic studies 
ApoE
-/-
 and ApoE/P2Y12 DK mice underwent glucose (GTT) and insulin tolerance tests (ITT) 
after 10 and 11 weeks, respectively, on a western diet.  For the GTT, mice were fasted 
overnight, and baseline blood glucose levels were 7.91 ± 0.83 vs. 8.91 ± 0.57 mmol/L 
(ApoE
-/-
 vs. ApoE/P2Y12 DK) before receiving a glucose bolus.  Blood glucose levels were 
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recorded thereafter, and showed an increase to 26.4 ± 0.8 vs. 23.34 ± 2.14 mmol/L after 30 
minutes of administration (see Figure 4.7a).  Glucose levels gradually declined back to near 
baseline levels, 9.43 ± 0.49 vs. 10.73 ± 1.37 mmol/L, after 120 minutes. 
 
The following week, mice underwent insulin tolerance testing.  Baseline blood glucose levels 
were 13.91 ± 0.44 vs. 12.3 ± 0.82 mmol/L (ApoE
-/-
 vs. ApoE/P2Y12 DK) before receiving an 
insulin bolus.  Blood glucose levels were recorded thereafter, and showed a steady 
decrease to 6.1 ± 0.66 vs. 7.23 ± 0.52 mmol/L after 40 minutes of administration (see Figure 
4.7b).  Glucose levels gradually increased back to near baseline levels, 9.35 ± 1.44 vs. 
11.23 ± 0.79 mmol/L, after 60 minutes.  Both GTT and ITT revealed no difference in 
response between ApoE
-/-
 and ApoE/P2Y12 DK mice. 
 
After 12 weeks on a western diet, plasma was analysed by ELISA to determine insulin 
levels, and showed that ApoE/P2Y12 DK mice had elevated plasma insulin levels compared 
to ApoE
-/-
 mice (see Figure 4.7c): insulin levels were 1.22 ± 0.2 vs. 3.27 ± 0.61 ng/ml (ApoE
-
/-
 vs. ApoE/P2Y12 DK; P<0.01).  Plasma was sent for biochemical analysis and showed no 
difference between the final plasma glucose levels of ApoE
-/-
 and ApoE/P2Y12 DK mice (see 
Figure 4.7d). 
 
4.5.3 Blood biochemistry 
Plasma from ApoE
-/-
 and ApoE/P2Y12 DK mice was sent for biochemical analysis following 
12 weeks on either a western or chow diet.  The lipid profile, glucose, and liver enzyme 
levels were assessed, and mean values ± SEM are shown in Table 4.1.  As expected, all 
lipid levels were elevated in western fed mice compared to their chow fed counterparts; 
however, no differences were noted when comparing ApoE
-/-
 and ApoE/P2Y12 DK mice on 
the same diet.  Similarly, liver enzymes, aspartate transaminase (AST) and alanine 
transaminase (ALT), were elevated as expected in western fed mice compared to chow fed 
animals.  However, when comparing ApoE
-/-
 and ApoE/P2Y12 DK mice, AST and ALT levels 
were higher in western fed ApoE/P2Y12 DK mice (see Figure 4.8a and b): AST levels were 
116.9 ± 24.9 vs. 177.8 ± 27.5 U/L (ApoE
-/-
 vs. ApoE/P2Y12 DK; P=ns), and ALT levels were 
58.8 ± 16.2 vs. 137.4 ± 27.7 U/L (P<0.05). 
 
4.6 ApoE/P2Y12 double knockout mice possess fatty livers 
ApoE/P2Y12 DK mice fed a western diet had enlarged livers (Figure 4.5b), and elevated AST 
and ALT liver enzyme levels (Figure 4.8a and b) compared to ApoE
-/-
 mice fed the same 
diet.  I therefore stained liver cross-sections with haematoxylin and eosin (H&E) to assess 
tissue architecture (see Figure 4.8c).  H&E staining showed ApoE/P2Y12 DK mice had 
enlarged, irregular hepatocytes with numerous areas once occupied by fat, which had been 
removed during histological processing.  In comparison, ApoE
-/-
 mice had a well-preserved 
tissue architecture with intact, regular hepatocytes and few fatty areas. 
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  Figure 4.6 – Mean blood pressure and pulse rate were similar for ApoE/P2Y12 double 
knockout and ApoE
-/-
 mice fed a western diet for 12 weeks. 
 
Daily blood pressure and pulse rate readings were taken for (a) ApoE
-/-
 and (b) 
ApoE/P2Y12 DK mice (n=8) throughout 12 weeks of feeding on a western diet.  (c) Mean 
blood pressure and (d) pulse rate of each genotype was calculated for each week.   Data 
are mean ± SEM; P=ns; two-way ANOVA with Bonferroni’s multiple comparison. 
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Figure 4.7 – Metabolic studies carried out on ApoE/P2Y12 double knockout and ApoE
-/-
 
mice fed a western diet showed no difference in response to insulin or glucose. 
 
(a) Glucose and (b) insulin tolerance tests were carried out on ApoE
-/-
 and ApoE/P2Y12 
DK mice after 10 and 11 weeks (respectively) of feeding on a western diet (n=8).  Blood 
glucose readings were taken at intervals following either a glucose or insulin challenge.  
Following 12 weeks of feeding, plasma was analysed (c) by ELISA to determine plasma 
insulin levels (n=8 & 7 respectively), and (d) sent for analysis to determine plasma 
glucose levels (n=10).   Data are mean ± SEM; **P<0.01; (a) and (b) two-way ANOVA 
with Bonferroni’s multiple comparison;  (c) Mann-Whitney test; (d) independent samples t 
test. 
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Table 4.1 - Biochemical analysis of plasma from ApoE/P2Y12 double knockout and ApoE
-/-
 mice fed either chow or western diet for 12 weeks. 
 
Data are mean (± SEM); *P<0.05; two-way ANOVA with Tukey’s multiple comparison. 
 
 ApoE
-/-
 
Western 
n=9 
ApoE/P2Y12 DK 
Western 
n=10 
ApoE
-/-
 
Chow 
n=3 
ApoE/P2Y12 DK 
Chow 
n=7 
Cholesterol 
(mmol/L) 
24.356 
(1.859) 
22.820 
(1.587) 
11.067 
(2.298) 
10.614 
(1.014) 
HDL cholesterol 
(mmol/L) 
4.840 
(0.356) 
4.738 
(0.392) 
3.267 
(0.622) 
3.187 
(0.371) 
LDL cholesterol 
(mmol/L) 
14.850 
(0.760) 
15.083 
(1.505) 
6.600 
(1.389) 
5.720 
(0.614) 
Triglycerides 
(mmol/L) 
5.222 
(0.898) 
3.910 
(0.767) 
2.600 
(0.814) 
3.633 
(0.655) 
Total cholesterol/HDL 
5.044 
(0.252) 
4.722 
(0.203) 
3.400 
(0.058) 
3.417 
(0.060) 
Glucose 
(mmol/L) 
13.620 
(0.786) 
11.070 
(1.350) 
8.800 
(0.945) 
9.586 
(0.569) 
AST 
(U/L) 
116.889 
(24.877) 
177.800 
(27.513) 
97.333 
(19.548) 
81.500 
(17.489) 
ALT 
(U/L) 
58.778 * 
(16.160) 
  137.400 * 
(27.665) 
28.667 
(11.319) 
42.429 
(10.781) 
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Figure 4.8 – ApoE/P2Y12 double knockout mice fed a western diet had significantly 
elevated levels of alanine transaminase (ALT) and fatty livers compared to ApoE
-/-
 mice. 
 
Plasma from ApoE
-/-
 and ApoE/P2Y12 DK mice fed either a western (n=9 & 10 
respectively) or chow diet (n=3 & 7 respectively) for 12 weeks was sent for biochemical 
analysis for liver enzymes (a) aspartate transaminase (AST) and (b) alanine 
transaminase (ALT).  (c) Haematoxylin and eosin (H&E) staining of liver cross-sections 
from ApoE
-/-
 and ApoE/P2Y12 DK mice fed a western diet.  Images taken at x200 
magnification, scale bars = 50 µm.  Data are mean ± SEM; *P<0.05; two-way ANOVA 
with Tukey’s multiple comparison. 
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4.7 Summary 
This chapter has outlined the generation of a novel ApoE/P2Y12 double knockout mouse 
strain, and described a range of physiological and metabolic phenotype parameters for 
these mice in comparison to the well-known and well-established ApoE
-/-
 strain.  In 
summary: 
 
 ApoE/P2Y12 DK breeding pairs were genotyped and successfully selected using 
PCR. 
 Pearson’s chi-squared test of the F2 generation genotype frequencies yielded a P 
value marginally less than 0.05, and so the null hypothesis, that genotype 
frequencies remain constant within a population, was rejected. 
 Platelets from ApoE/P2Y12 DK mice demonstrated reduced P-selectin and activated 
GPIIbIIIa receptor expression in response to a platelet agonist, and thus confirmed 
impaired platelet function in these mice. 
 ApoE/P2Y12 DK mice fed a western diet gained significantly more weight than ApoE
-
/-
 mice fed the same diet over 12 weeks.  No weight difference was seen in chow fed 
animals. 
 Dissection revealed western fed ApoE/P2Y12 DK mice also had enlarged livers 
compared to their ApoE
-/-
 counterparts. 
 No differences were noted in blood pressure or metabolic parameters, such as 
glucose and insulin tolerance tests. 
 Plasma insulin levels were elevated in ApoE/P2Y12 DK mice after 12 weeks of 
western diet. 
 Biochemical analysis of plasma showed no difference in the lipid profile of 
ApoE/P2Y12 DK mice compared to ApoE
-/-
 controls.  However, liver enzymes, AST 
and ALT, were elevated in ApoE/P2Y12 DK mice fed a western diet. 
 Histological staining of liver cross-sections revealed western fed ApoE/P2Y12 DK 
mice also had fattier livers than ApoE
-/-
 mice. 
 
4.8 Discussion 
In this chapter, I describe the successful generation of a novel ApoE/P2Y12 DK mouse strain 
to enable studies into the role of P2Y12 in atherogenesis.  In addition, I identify phenotypic 
differences in body and liver weight between ApoE
-/-
 and ApoE/P2Y12 DK mice following 
consumption of a high-fat diet, which raises questions regarding the potential involvement of 
P2Y12 in liver function, lipid levels and appetite, and suggests that P2Y12 deficiency may 
affect areas of animal physiology other than haemostasis. 
 
With the emergence of transgenic mouse strains, the development of the P2Y12
-/-
 mouse 
was a relatively new addition to this ever expanding group (Foster et al. 2001).  Primarily 
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they have been used to study platelet aggregation and thrombosis; yet, despite many other 
platelet atherosclerosis studies having been conducted, P2Y12
-/-
 mice had never been 
employed in this capacity.  I therefore generated a novel ApoE/P2Y12 DK mouse strain in 
order to study the role of P2Y12 in atherogenesis.  At the time of commencing my research 
no other group had generated such a cross; however, a recent paper has been published 
which too developed an ApoE/P2Y12 DK mouse strain, as discussed in later chapters (Li et 
al. 2012). 
 
ApoE/P2Y12 DK mice were generated from parent ApoE
-/-
 and P2Y12
-/-
 lines, which were 
derived from the original founding colonies that had been backcrossed for 10 generations 
onto a C57/BL6 background (Piedrahita et al. 1992; Foster et al. 2001).  To test whether the 
ApoE/P2Y12 DK F2 generation followed Mendelian genetics, in that the genotype frequencies 
would remain constant within the population, as stated by the Hardy-Weinberg principle, I 
performed Pearson’s chi-squared test.  This assessed to what extent the genotype 
frequencies I observed deviated from what would be expected for a population of this size, 
and if this was likely to have occurred by chance, or if another factor was influencing 
genotype frequency in this population.  A significant chi-squared value of 0.0366 was 
calculated, which in turn meant that there was a 3.6% chance that, following the Hardy-
Weinberg principle, this pattern of genotype frequencies occurred at random.  As such the 
null hypothesis, that genotype frequencies remain constant within this population, was 
rejected and so suggests another factor may have affected genotype frequencies. 
 
The Hardy-Weinberg principle is based on the assumption that allele/genotype frequencies 
do not change over time, and from generation to generation within a population.  This also 
assumes there are no other influences on the population, such as natural or sexual 
selection, gene flow, genetic drift, or mutation, which may affect genotype frequencies.  In 
the case of an inbred transgenic mouse strain, where both the ApoE and P2Y12 lines were 
backcrossed onto the same background, it can be assumed that these factors are not at 
play.  Nevertheless, although minimal, the effect of mutations, and the potential for genetic 
drift should be considered.  Another assumption on which the principle is based is that the 
population size is infinite.  When testing the Hardy-Weinberg principle, Pearson’s chi-
squared test is known to be sensitive to both low sample size and low expected frequencies 
(Russell 2002).  In this limited cohort it is very likely, therefore, that small population size, in 
combination with single figure expected frequencies in some groups, contributed to a 
significant chi-squared value. 
 
P-selectin is a platelet activation marker and its expression, determined by flow cytometry, is 
often used as a measure of platelet function (Leytin et al. 2000).  As P2Y12 activation results 
in the amplification of α granule release (Storey et al. 2000), stimulation of platelets via the 
PAR-4 receptor provides a sensitive method to determine P2Y12 function, by the degree of 
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P-selectin expression.  Attenuation of P-selectin expression, in response to PAR-4 TRAP, in 
platelets from ApoE/P2Y12 DK mice demonstrates P2Y12-deficiency, and thus confirms the 
expected platelet phenotype.  These results are consistent with our previous findings (Evans 
et al. 2009). 
 
Although predominantly found on platelets, P2Y12 receptors have now also been identified at 
lower expression levels on VSMCs (Wihlborg et al. 2004), microglial cells (Sasaki et al. 
2003), dendritic cells (Ben Addi et al. 2010), liver cholangiocytes (Masyuk et al. 2008), 
pancreatic islet cells (Lugo-Garcia et al. 2008), and splenic sinus (Uehara and Uehara 2011) 
and vascular endothelial cells (Shanker et al. 2006).  A functional role for P2Y12 in some of 
these cells types is yet to be established; however, it is clear from its wider expression 
pattern that P2Y12-deficiency is no longer limited to affecting platelets alone. 
 
Comparing the physiological and metabolic phenotype of ApoE/P2Y12 DK mice with their 
ApoE
-/-
 counterparts revealed many similarities between the 2 strains; nevertheless, some 
interesting differences emerged when mice were fed a high-fat diet.  In ApoE/P2Y12 DK 
mice, it appeared that P2Y12-deficiency led to an increase in body and liver weight, in 
conjunction with elevated liver enzymes and evidence of fat deposition within the liver tissue, 
with less effect seen in ApoE
-/-
 mice, and no effect in either genotype when fed a chow diet.  
It must also be noted that no such effects have been documented in our own or other 
published studies using P2Y12
-/-
 mice.  Following the original development of the P2Y12
-/-
 
mouse strain, Foster et al. assessed histological cross-sections of the major organs and 
found no abnormalities (Foster et al. 2001).  These data pose the interesting notion that 
P2Y12-deficiency, in cells other than platelets, may influence further physiological systems 
around the body in a diet-dependent manner. 
 
Vascular smooth muscle cell P2Y12 has been shown to mediate cell contraction, and 
promote pro-inflammatory and mitogenic responses in VSMCs (Wihlborg et al. 2004; Rauch 
et al. 2010).  These receptors may contribute to inflammatory responses, such as 
atherogenesis, and this role will be discussed in later chapters; however, vessel wall P2Y12-
deficiency is unlikely to result in such specific, diet-dependent physiological effects in 
ApoE/P2Y12 DK mice.  
 
Microglia are macrophage-like cells, which police the brain and spinal cord for injury and 
infection.  They are also responsible for the removal of apoptotic and necrotic cells, as well 
as modulation of synapses.  In addition, they are also important in the early development of 
the brain in eliminating synapses during brain maturation (Schlegelmilch et al. 2011).  As a 
result of CNS injury, nucleotides are released, and act as signalling molecules for microglia 
(Davalos et al. 2005).  Research into the role of P2Y12 on microglia discovered these 
nucleotides directly activate microglia through the P2Y12 receptor, and mediate chemotaxis 
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in response to injury (Haynes et al. 2006).  Although P2Y12-deficient microglia retained basic 
motility, their ability to migrate in response to nucleotides was eliminated.  The long-term 
physiological and behavioural impacts of diminished microglia response to injury, as a result 
of P2Y12-deficiency, are unknown.  Yet links have been made between microglial function 
and behaviour, demonstrating that deficient microglia-neuron signalling results in impaired 
brain function and altered behaviour (Zhan et al. 2014).  It is not known whether P2Y12-
deficiency directly affects brain development and behaviour; however, given these findings, 
further investigation is warranted.  Nevertheless, microglia P2Y12-deficiency is unlikely to be 
totally responsible for the phenotype I observed, although alterations in appetite and activity 
could influence body weight.  A crude analysis showed no difference in food consumption 
between genotypes, though a more sensitive and accurate investigation, using metabolic 
cages, is necessary to conclude this decisively. 
 
Cholangiocytes are epithelial cells that line the bile ducts, and their function is to modify bile 
composition by regulating water, electrolyte, and organic solute secretion and absorption.  
Cilia on these cells act as mechano- and osmosensory organelles, and regulate bile 
composition via calcium and cAMP signalling (Alpini et al. 1996).  P2Y12 receptors on 
cholangiocyte cilia are thought to act as chemosensors detecting biliary nucleotides, and are 
known to transduce these into a cAMP response (Masyuk et al. 2008).  It is therefore 
plausible that P2Y12-deficiency in the liver may result in impaired sensory function, and 
P2Y12-mediated signalling from cholangiocyte cilia, directly altering bile composition.  
Modifications of this sort could therefore affect both cholesterol excretion in the bile, and lipid 
digestion and absorption in the intestine.  Biochemical analysis of plasma from ApoE/P2Y12 
DK mice showed no overall difference in lipid profile or total cholesterol systemically 
compared to ApoE
-/-
.  However, it must be considered that subtle changes may still have a 
local impact on liver physiology and function, and so offers a potential mechanism by which 
P2Y12-deficiency may lead to lipid accumulation in the liver causing a rise in liver enzymes.   
 
In pancreatic islet cells, P2Y12 is proposed to have a role in stimulation of insulin secretion, 
but its true function has yet to be formally identified (Lugo-Garcia et al. 2008).  Elevated 
baseline insulin levels measured in ApoE/P2Y12 DK mice would lend support to this theory; 
however, no overall effect was seen in the metabolic response of these animals compared to 
ApoE
-/-
 mice, when glucose or insulin tolerance tests were performed.  P2Y12 receptors have 
also been identified in dendritic cells, where they are thought to enhance T-cell activation 
(Ben Addi et al. 2010), and in cultured vascular endothelial cells, where their role is currently 
unknown (Shanker et al. 2006).  Another study also found P2Y12 to be expressed on splenic 
sinus endothelial cells.  These cells control the passage of blood through the splenic cord, 
but in comparison to vascular endothelial cells, they are morphology dissimilar.  P2Y12 
function in these cells is not defined, yet a role in cAMP signalling is postulated (Uehara and 
Uehara 2011).  Several studies have also investigated whether P2Y12 receptors are present 
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on leukocytes and did not find evidence of this (Hollopeter et al. 2001; Zhang et al. 2001; 
Haynes et al. 2006). 
 
This chapter describes the successful development of a novel ApoE/P2Y12 DK mouse strain 
which, as expected, demonstrated functional platelet P2Y12-deficiency.  These data also 
suggest that, given the stimulus of a high-fat diet, P2Y12-deficiency results in distinct 
phenotype differences in ApoE/P2Y12 DK mice compared to their ApoE
-/- 
counterparts.  
Separate to its platelet effects, a potential role for P2Y12 in other cell-types, influencing liver 
function and specifically fat deposition within the liver tissue, was postulated, given the 
evidence of elevated liver enzymes and fatty livers in P2Y12-deficient mice fed a high-fat diet.  
Many other phenotype parameters, however, including metabolic responses, blood 
pressure, and lipid profile, were similar to ApoE
-/-
 mice, and so demonstrated that any non-
platelet P2Y12 differences are relatively limited.  In the following chapter, I go on to 
investigate the role of P2Y12 in atherogenesis using this newly developed mouse strain. 
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The initiation and development of atherosclerotic plaques is a complex inflammatory 
response involving a network of cellular processes (Ross 1999; Libby 2002).  Platelets have 
a fundamental role in atherothrombosis, but their role in atherogenesis is less clear.  They 
are known to interact with the endothelium and leukocytes and, upon activation, can elicit an 
inflammatory response in these cells via both direct adhesion and the release of pro-
inflammatory cytokines (Henn et al. 1998; Gawaz et al. 2000; von Hundelshausen et al. 
2001).  Furthermore, activated platelets can induce mitogenic effects on the vessel wall 
through secretion of growth factors (Schini-Kerth et al. 1997; Massberg et al. 2003).  Several 
studies have investigated various aspects of platelet involvement, including adhesion 
receptors and proteins (Massberg et al. 2002; Burger and Wagner 2003; Huo et al. 2003; 
Bultmann et al. 2010), alluding to the notion that platelet activation potentiates lesion 
development. 
 
Given this evidence, and the importance of P2Y12 in modulating the vessel wall response to 
injury, as demonstrated in Chapter 3 (Evans et al. 2009), I hypothesised that P2Y12 may also 
be important in atherogenesis.  In this chapter I investigated lesion development in 
ApoE/P2Y12 DK mice, to assess the effects of P2Y12 deficiency on atherogenesis.  
 
5.1 ApoE/P2Y12 double knockout mice demonstrate region-
specific differences in lesion development, compared to 
ApoE-/- mice, when fed a high-fat diet 
ApoE
-/-
 and ApoE/P2Y12 DK mice were fed a western or a chow diet for 12 weeks, and 
atherogenesis was assessed in 3 areas of the vasculature prone to atheroma – the thoracic 
aorta, brachiocephalic artery, and aortic sinus (see Methods, section 2.9). 
 
5.1.1 Aortae 
Oil red O staining of whole aortae showed no difference in lesion area, represented as a 
percentage of the total aortic surface area, between ApoE
-/-
 and ApoE/P2Y12 DK mice 
following 12 weeks on either a western or chow diet (see Figure 5.1a and b): lesion area in 
western fed mice was 10.26 ± 0.63 vs. 9.1 ± 0.86% (ApoE
-/-
 vs. ApoE/P2Y12 DK; P=ns)  and 
in chow fed mice was 3.84 ± 0.66 vs. 2.84 ± 0.57% (ApoE
-/-
 vs. ApoE/P2Y12 DK; P=ns).  To 
assess potential region-specific differences in lesion development, atheroma was quantified 
in the aortic arch and descending aorta (see Figure 5.1c).  ApoE/P2Y12 DK mice fed a 
western diet had significantly attenuated atheroma in the aortic arch, which was reduced by 
50% compared to ApoE
-/-
 mice (Figure 5.1d; chow data not shown): aortic arch lesion area 
5 The role of the P2Y12 receptor in 
atherogenesis 
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was 16.67 ± 1.25 vs. 8.54 ± 0.85% (ApoE
-/-
 vs. ApoE/P2Y12 DK; P<0.001).  However, there 
was no significant effect of P2Y12 deficiency in the descending aortae: lesion area was 2.99 
± 0.25 vs. 2.24 ± 0.32% (ApoE
-/-
 vs. ApoE/P2Y12 DK; P=ns). 
 
5.1.2 Brachiocephalic artery 
Cross-sections of the brachiocephalic artery stained with alcian blue/elastic van Gieson 
revealed few lesions in this region of the vasculature, but those present were found close to 
the bifurcation of the vessel.  Western fed mice demonstrated large and complex lesions 
with notable cholesterol clefts and fibrous caps (see Figure 5.2a), whereas chow fed mice 
exhibited much smaller and less complex lesions (images not shown).  Quantification of the 
lesion area, represented as a ratio of the total CSA of the vessel, showed ApoE/P2Y12 DK 
mice fed a western diet had significantly reduced lesion area compared to their ApoE
-/-
 
counterparts (see Figure 5.2b): 0.089 ± 0.015 vs. 0.046 ± 0.007 (ApoE
-/-
 vs. ApoE/P2Y12 DK; 
P<0.05).  No difference was seen in chow fed mice: 0.016 ± 0.011 vs. 0.017 ± 0.007 (ApoE
-/-
 
vs. ApoE/P2Y12 DK; P=ns). 
 
5.1.3 Aortic sinus 
Despite a clear effect of P2Y12 deficiency on lesion development within the aortic arch and 
brachiocephalic artery of western fed mice, no effect was seen in the aortic sinus.  Stained 
cross-sections revealed large and developed lesions within each of the valve leaflets of the 
aortic sinus.  Both genotypes demonstrated highly complex lesions containing numerous 
cholesterol clefts, broken elastic laminae, and fibrous caps (see Figure 5.3a).  Quantification 
of lesion area, represented as a ratio of the aortic sinus CSA, showed no difference in 
atheroma between ApoE
-/-
 or ApoE/P2Y12 DK mice for either diet (see Figure 5.3b): lesion 
area was 0.149 ± 0.015 vs. 0.122 ± 0.016 in western fed mice (ApoE
-/-
 vs. ApoE/P2Y12 DK; 
P=ns) and 0.027 ± 0.003 vs. 0.022 ± 0.006 in chow fed animals (ApoE
-/-
 vs. ApoE/P2Y12 DK; 
P=ns). 
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Figure 5.1 – Oil red O staining showed a significant reduction in lesion formation in the 
aortic arch of ApoE/P2Y12 double knockout mice fed a western diet. 
 
ApoE
-/-
 (n=15) and ApoE/P2Y12 DK (n=18) male mice were fed a western or chow diet for 
12 weeks.  Aortae were (a) stained with oil red O and (b) lesion area was calculated as a 
percentage of total surface area for the whole aorta.  (c) Lesion was also assessed in the 
aortic arch and descending aorta, and (d) quantified for mice fed a western diet.  Data are 
mean ± SEM; ***P<0.001; two-way ANOVA with Bonferroni’s multiple comparison. 
 
 
97 
 
 
  
Figure 5.2 – ApoE/P2Y12 double knockout mice fed a western diet had reduced lesion 
formation, compared to ApoE
-/-
, in the brachiocephalic artery. 
 
ApoE
-/-
 (n=12) and ApoE/P2Y12 DK (n=13) male mice were fed a western or chow diet 
for 12 weeks.  Brachiocephalic arteries were sectioned and (a) stained with alcian 
blue/elastic van Gieson.  Representative cross-sections of western fed mice are 
shown.  Images taken at x100 magnification, scale bar = 100 µm.  (b) Lesion area was 
calculated, and is shown as mean lesion:CSA (cross-sectional area) ratio.  Data are 
mean ± SEM; *P<0.05; two-way ANOVA with Bonferroni’s multiple comparison. 
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Figure 5.3 – No difference in lesion formation, between ApoE
-/-
 and ApoE/P2Y12 
double knockout mice, was seen in the aortic sinus for either diet. 
 
ApoE
-/-
 (n=11) and ApoE/P2Y12 DK (n=14) male mice were fed a western or chow diet 
for 12 weeks.  Each aortic sinus was sectioned and (a) stained with alcian blue/elastic 
van Gieson.  Representative cross-sections of western fed mice are shown.  Images 
taken at x40 magnification, scale bar = 100 µm.  (b) Lesion area was calculated, and is 
shown as mean lesion:CSA (cross-sectional area) ratio.  Data are mean ± SEM; P=ns; 
two-way ANOVA with Bonferroni’s multiple comparison. 
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5.2 Lesion phenotype was similar in both ApoE-/- and 
ApoE/P2Y12 double knockout mice fed a western diet 
As collagen, smooth muscle cell, and macrophage content are key characteristics of 
developing complex and inflammatory lesions, I went on to further stain the aortic sinus 
sections of western fed mice with martius scarlet blue (MSB) for collagen, and for α-smooth 
muscle actin (α-SMA), and macrophage markers, F4-80 and MAC387, using 
immunohistochemistry. 
 
5.2.1 Collagen 
MSB staining provides clear differentiation between fibrin (red) and collagen connective 
fibres (blue).  Staining of the aortic sinus sections showed well-defined bright blue collagen 
staining of the vessel wall and valve leaflets, including large proportions of positive staining 
also within the lesions (see Figure 5.4a).  Higher magnification images from ApoE
-/-
 and 
ApoE/P2Y12 DK mice highlight that the collagen fibres were predominantly located in the 
acellular necrotic core, and towards the cap and shoulder regions of the lesions.  
Quantification of the percentage collagen content within aortic sinus lesions from each 
genotype showed no difference between ApoE
-/-
 or ApoE/P2Y12 DK mice fed a western diet 
(see Figure 5.4b): collagen content was 29.18 ± 4.6 vs. 28.06 ± 3.49% (ApoE
-/-
 vs. 
ApoE/P2Y12 DK; P=ns). 
 
5.2.2 Smooth muscle actin 
Smooth muscle actin immunostaining of aortic sinus sections, using DAB as the substrate, 
revealed brown α-SMA positive cells within the vessel wall.  Positive staining was localised 
to those areas of the vessel wall with visible elastic laminae, but no staining was present in 
the myocardium (see Figure 5.5a).  Negative control sections, where only secondary 
antibody was applied, showed no non-specific binding of the secondary antibody and 
therefore displayed no positive staining.  Higher magnification images (see Figure 5.5b) 
demonstrated many α-SMA positive cells within both ApoE
-/-
 and ApoE/P2Y12 DK lesions, 
located predominantly within the fibrous cap and towards the shoulder regions of the lesions.  
Quantification of α-SMA content within the aortic sinus lesions established no significant 
difference between ApoE
-/-
 and ApoE/P2Y12 DK mice fed a western diet (see Figure 5.5c): % 
α-smooth muscle actin content was 5.63 ± 1.23 vs. 7.03 ± 2.17% (ApoE
-/-
 vs. ApoE/P2Y12 
DK; P=ns).  
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Figure 5.4 – Collagen staining showed no difference in the collagen content of aortic 
sinus lesions from western fed mice. 
 
ApoE
-/-
 (n=11) and ApoE/P2Y12 DK (n=13) male mice were fed a western or chow diet 
for 12 weeks.  (a) Aortic sinus sections were stained with martius scarlet blue, from 
which collagen is stained bright blue.  Representative cross-sections of western fed 
mice are shown.  Images taken at (i) x40 magnification, scale bar = 100 µm and (ii) 
x200 magnification (highlighted area), scale bar = 50 µm.  (b) Collagen content within 
the aortic sinus lesions was quantified, and is shown as a percentage of the total lesion 
area.  Data are mean ± SEM; P=ns; Independent samples t test. 
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Figure 5.5 – No difference was seen in the α-smooth muscle actin content of aortic 
sinus lesions from western fed mice. 
 
ApoE
-/-
 (n=11) and ApoE/P2Y12 DK (n=13) male mice were fed a western or chow 
diet for 12 weeks.  Aortic sinus sections from (i) ApoE
-/-
 and (ii) ApoE/P2Y12 DK 
mice were stained for α-smooth muscle actin using immunohistochemistry, from 
which positive cells are stained brown.  Representative cross-sections of western 
fed mice are shown, including (iii) a negative control.  Images taken at (a) x40 
magnification, scale bar = 100 µm, and (b) x200 magnification (highlighted area), 
scale bar = 50 µm.  (c) Smooth muscle actin content within the aortic sinus lesions 
was quantified, and is shown as a percentage of the total lesion area.  Data are 
mean ± SEM; P=ns; Independent samples t test. 
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5.2.3 Macrophage markers 
Staining for F4/80 and MAC387 macrophage markers by immunohistochemistry, using DAB 
as the substrate, provided inconclusive results.  F4/80 staining of aortic sinus sections 
showed sparse positive staining, with a few distinct positive cells in the cardiac tissue, but no 
staining within the lesions (see Figure 5.6a).  Negative control sections showed no non-
specific binding of the secondary antibody.  Spleen cross-sections showed abundant 
positive staining in the red pulp. 
 
MAC387 staining demonstrated a high level of non-specific staining, as shown in the 
negative control section (see Figure 5.6b).  Despite strong positive staining within spleen 
cross-sections, no specific staining was observed in the aortic sinus.  Pale background 
staining was particularly evident within the acellular necrotic core of the lesions.  
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Figure 5.6 – Staining for macrophage markers, F4/80 and MAC387, within aortic 
sinus lesions provided inconclusive results. 
 
Aortic sinus cross-sections were stained for (a) F4/80 and (b) MAC387 using 
immunohistochemistry, from which positive cells are stained brown.  Representative 
cross-sections of ApoE
-/-
 western fed mice are shown.  (i) & (iii) Images taken at 
x40 magnification, scale bar = 100 µm, and (ii) taken at x200 magnification 
(highlighted area), scale bar = 50 µm. (iv) Spleen positive control sections also 
taken at x200 magnification. 
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5.3 Summary 
This chapter has described the role of the P2Y12 receptor in atherogenesis by examining the 
extent, structure, and composition of atherosclerotic lesions in ApoE/P2Y12 DK mice, and 
assessing their development across several areas of the vasculature prone to disease.  
Results were obtained following 12 weeks on a high-fat western diet.  In summary: 
 
 P2Y12-deficient mice fed a western diet had significantly less atheroma in the aortic 
arch compared to their ApoE
-/-
 counterparts. 
 No difference was observed in the descending aorta, or when assessing lesion area 
across the entire aorta. 
 Western fed ApoE/P2Y12 DK mice also had significantly attenuated atheroma in the 
brachiocephalic artery compared to ApoE
-/-
. 
 However, in the aortic sinus, no difference in lesion formation was noted. 
 Aortic sinus lesions demonstrated a high degree of collagen staining localised 
predominantly to the necrotic core, cap, and shoulder regions of the lesion, although 
there was no overall difference in the percentage collagen content between groups. 
 Smooth muscle actin positive cells were found in high numbers within the cap and 
shoulder regions of aortic sinus lesions from both ApoE
-/-
 and ApoE/P2Y12 DK mice; 
however, no difference in α-SMA content was noted between each group. 
 Macrophage staining provided inconclusive results with no evidence of positive 
staining within the lesions. 
 
5.4 Discussion 
Atherogenesis is a process classically described as involving leukocytes and cells of the 
vessel wall; nevertheless, there is mounting evidence to suggest that platelets should also 
be considered in this ensemble, as their impact on the inflammatory response becomes 
more apparent.  In Chapter 3, I demonstrated that platelet P2Y12 mediated the vessel wall 
response to injury and so may implicate a role for P2Y12 in atherogenesis.  In this chapter, I 
describe a moderate region-specific effect of P2Y12–deficiency on atherosclerotic lesion 
development, which, together with recent findings (Li et al. 2012), suggests a role for platelet 
P2Y12 in established disease. 
 
With α granules packed full of cytokines and membrane adhesion proteins, the pro-
inflammatory capacity of platelets is evident.  Many studies have been conducted to tease 
out their potential role in propagating lesion development, focussing on the mechanisms by 
which platelets interact with the inflammatory system, via adhesion and cytokine release.  
Roles for platelet adhesion proteins and receptors have been implicated, including P-selectin 
(Burger and Wagner 2003; Huo et al. 2003), CD40L (Lievens et al. 2010), GPIb (Massberg 
et al. 2002), and VI (Bultmann et al. 2010).  In addition, the deposition of cytokines, such as 
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RANTES and PF4, by activated platelets onto endothelial and monocyte membranes has 
been associated with increased leukocyte recruitment to atherosclerotic and injured vessels 
(von Hundelshausen et al. 2001; Schober et al. 2002; Huo et al. 2003).  The P2Y12 receptor, 
with its central role in platelet reactivity and, importantly, α granule release, was therefore an 
attractive candidate for investigation, and so formed the basis for this thesis. 
 
Whilst completing my research, Li et al. published data using their own ApoE/P2Y12 DK 
mouse strain, presenting evidence to suggest that platelet P2Y12 indeed promotes lesion 
development, and does this via P2Y12–mediated granule release of P-selectin and PF4, thus 
amplifying leukocyte recruitment (Li et al. 2012).  These findings are consistent with my own 
data which demonstrated that, at an earlier time point in disease, P2Y12 deficiency lead to a 
moderate reduction in atheroma.  However, the magnitude of this attenuation was somewhat 
lesser in my data compared to the effect seen by Li et al. and, furthermore, I observed no 
significant P2Y12 effect in some areas of the vasculature.  In the Li study, a high-fat diet 
similar to our own western diet was used, but mice were fed for 20 weeks as opposed to 12 
weeks, as in my experiments.  This difference in the length of atherogenic stimulus could 
therefore explain the variance in P2Y12-effect on lesion size between these studies, and 
interestingly suggests that platelet P2Y12 may have a greater influence later in disease.   
 
Although P2Y12-deficiency appeared to have only a moderate effect on atherogenesis from 
my data, perhaps the most fascinating finding was that this effect appeared to be regional, 
and dependent on the area of the vasculature.  Lesion area was attenuated in the 
brachiocephalic arteries of mice, but not in the aortic sinus.  Similarly there was no 
difference when assessing the whole aorta; however, a substantial reduction in atheroma 
was identified in the aortic arch.  This indicates that the local vascular environment may 
have been responsible for these regional differences, and so introduces the possibility that 
flow patterns and shear stress may be exacerbating the effects of P2Y12-deficiency on 
atherogenesis. 
 
Oscillatory flow and low shear stress are known to be key factors in determining the location 
of atherosclerotic lesions throughout the vasculature (Ku et al. 1985; Asakura and Karino 
1990).  Lesion prone sites have been shown to not only express high levels of leukocyte 
adhesion molecules, such as VCAM-1 (Nakashima et al. 1998), but also increased vWF 
expression (Theilmeier et al. 2002).  In this particular study, rabbits fed a high-fat diet 
demonstrated both increased vWF and, consequently, platelet adhesion at lesion prone 
sites.  Further investigation discovered GP1b-vWF and P-selectin-PSGL-1 platelet-
endothelial interactions were responsible for these findings.  All of the areas I chose to 
assess for atherosclerotic burden are renowned lesion prone sites, yet despite this, the 
aortic sinus and whole aorta showed no difference in atheroma.  Interestingly, however, the 
brachiocephalic artery and aortic arch, which demonstrated the greatest effect of P2Y12-
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deficiency on atheroma, are perhaps subject to the greatest variations in shear stress (Suo 
et al. 2007).  Given that P2Y12 activation is required for the firm adhesion of platelets to vWF 
(Goto et al. 2002), these sites may reveal the greatest impact of platelet adhesion, or lack of 
in P2Y12-deficient mice, on lesion development and so may explain why the P2Y12 effect was 
most apparent here.  
 
Although it has been documented that platelets adhere to the endothelium of ApoE
-/-
 mice at 
as early as 6 weeks of age and that these interactions precede lesion development 
(Massberg et al. 2002), equally there is much evidence to also support a role for platelets in 
advanced disease.  In addition to the Li study, other mouse models have identified that both 
platelet P-selectin and CD40L not only potentiate atherogenesis, but actively promote a 
mature lesion phenotype, demonstrating a high smooth muscle cell content and evidence of 
lesion calcification (Lutgens et al. 1999; Burger and Wagner 2003; Lievens et al. 2010).  
Indeed the mitogenic effects of PDGF, released from activated platelets, on VSMCs are well 
established (Schini-Kerth et al. 1997; Massberg et al. 2003); yet, α-SMA staining showed no 
difference in smooth muscle cell content in the aortic sinus after 12 weeks on a western diet.  
Lesions in this area were assessed for VSMC and collagen content due to the availability of 
sections and ability to compare similar regions between groups; however, with no difference 
seen in lesion area, phenotype changes in the lesions were unlikely.  Surprisingly, despite 
assessing collagen and macrophage content of the lesions, the Li study did not perform α-
SMA staining. 
 
Collagen content was determined by martius scarlet blue (MSB) trichrome stain, which I 
selected in preference to traditional trichrome stains, such as Masson’s, as it offered clearer 
differentiation between fibrin, collagen, and RBCs, as well as being a reliable and consistent 
staining method.  Aortic sinus lesions showed no difference in collagen content between 
groups at 12 weeks, but in the Li study at 20 weeks, P2Y12-deficiency resulted in an increase 
in collagen within the lesions.  This is a curious finding since collagen synthesis within 
atherosclerotic lesions is mainly associated with VSMCs, specifically their migration (Rocnik 
et al. 1998), and platelets are known to induce this effect.  In addition, TGF-β and PDGF 
have both been shown to induce collagen synthesis by VSMC (Amento et al. 1991).  
Although not the only source for these mitogens, other unique platelet releasates have been 
found within atherosclerotic lesions (Coppinger et al. 2004).  Given this evidence it could be 
deduced that, conversely, platelet activation would in fact increase VSMC migration and 
collagen synthesis, and that P2Y12-deficiency would lead to a reduction in both.  However, 
without knowledge of the smooth muscle cell content of the lesions from the Li study, it is 
difficult to explain their collagen findings.  
 
Macrophages make up a large proportion of the cells within atherosclerotic lesions, and are 
essential in driving the inflammatory microenvironment, promoting migration, proliferation, 
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foam cell formation, and ultimately plaque destabilisation.  With such an important role in 
atherogenesis, I sought to quantify macrophage content within the aortic sinus lesions by 
immunohistochemistry but staining yielded inconclusive results.  Initially I stained for F4/80, 
which is expressed on most tissue macrophages, and obtained positive signals from the 
surrounding cardiac tissue, though none within the lesion itself.  Absence of non-specific 
antibody binding and abundant positive staining of spleen cross-sections, suggested that the 
antibody staining had worked, but yielded no F4/80 positive cells within the lesions. 
 
As several macrophage subtypes have been identified, that express different phenotypes 
and cell markers (Mantovani et al. 2009; Ley et al. 2011), I decided to try another marker 
with a broader expression.  MAC387 is expressed on granulocytes, monocytes, and tissue 
macrophages; however, my staining achieved no positive cells within any of the tissue, 
except in the positive control.  Evidence of non-specific antibody binding in the negative 
control, and background staining in the sinus tissue, suggested the experimental conditions 
were not optimal.  Further workup of this antibody may have yielded positive results, but as 
macrophages are a heterogeneous population, further work using alternative markers such 
as CD68, MAC3 and MOMA-2, is also warranted. 
 
These data suggest P2Y12-deficiency has a moderate regional effect in advanced 
atherogenesis, at 12 weeks on a high-fat diet.  However, the impact of P2Y12 increases as 
disease progresses and a greater role for platelet P2Y12 in late atherogenesis is identified in 
the Li study.  Nevertheless, the influence of VSMC P2Y12 must also be considered when 
interpreting these findings.  Little is known of the effect of vessel wall P2Y12 on 
atherogenesis and so, therefore, I went on to investigate the role of platelet versus vessel 
wall P2Y12 in atherogenesis, using bone marrow transplantations; the results of which are 
discussed in the next chapter. 
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Although predominantly expressed on platelets, P2Y12 is also expressed on vascular smooth 
muscle cells, where it mediates cell contraction (Wihlborg et al. 2004), and promotes pro-
inflammatory and mitogenic responses via a thrombin-induced pathway (Rauch et al. 2010).  
In the previous chapter, I demonstrated that P2Y12 deficiency led to subtle effects on lesion 
development in some areas of the vasculature.  Recent work has suggested that, at a later 
time point in advanced disease, platelet P2Y12 plays a substantial role in the development of 
mature atherosclerotic plaques in a mouse atherosclerosis model (Li et al. 2012).  I 
hypothesised that P2Y12 activation may also be important in promoting early atherogenesis, 
in contrast to later stages of disease when endothelial disruption may promote the role of 
platelets. 
 
In this chapter, I investigated the role of P2Y12 using a model of early atherogenesis, by 
feeding a western diet for 4 weeks, and employed bone marrow transplantations to examine 
the contributions of platelet versus vessel wall P2Y12 to initial lesion formation. 
 
6.1 Transplanted bone marrow-derived platelets expressed 
the donor P2Y12-phenotype 
ApoE
-/-
 and ApoE/P2Y12 DK mice underwent BMT to generate 2 control and 2 chimeric 
groups, deficient in either platelet or vessel wall P2Y12.  The transplantation method I 
employed in this study has successfully been used previously by our group (Chamberlain et 
al. 2006; Evans et al. 2009).  However, to further confirm the bone marrow P2Y12 phenotype 
I assessed the efficacy of transplantation using flow cytometry to measure platelet activation 
markers, P-selectin and activated GPIIbIIIa receptors, in response to PAR-4 TRAP, a potent 
platelet agonist. 
 
Platelets from ApoE
-/-
 mice transplanted with ApoE
-/-
 bone marrow displayed high 
fluorescence of the CD62p and CD41/61 JON-A antibodies, demonstrating these platelets 
expressed high levels of both P-selectin and activated GPIIbIIIa receptors.  In contrast, 
platelets from ApoE
-/-
 mice transplanted with ApoE/P2Y12 DK bone marrow showed 
attenuated platelet activation, and exhibited much lower fluorescence levels, shown as a 
shift to the left in the fluorescence peaks for each antibody (see Figure 6.1a and b). 
 
CD62p and CD41/61 JON-A fluorescence was measured in response to a range of PAR-4 
TRAP concentrations, in addition to a saline control, which showed the cells were not pre-
activated.  Expression was measured as an increase in median fluorescence over baseline, 
determined using an isotype (CD62p) or EDTA unstimulated control (CD41/61 JON-A).  At 
6 The role of platelet versus vessel wall 
P2Y12 in early atherogenesis 
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each concentration, ApoE
-/-
 mice transplanted with ApoE/P2Y12 DK bone marrow 
demonstrated consistently lower P-selectin (Figure 6.1c) and activated GPIIbIIIa receptor 
expression (Figure 6.1d) compared to ApoE
-/-
 controls.  This was particularly evident at 3 
mmol/L TRAP, where P-selectin median fluorescence was 1617 ± 828 vs. 115 ± 41 (ApoE
-/-
 
vs. ApoE/P2Y12 DK bone marrow; P=ns) and GPIIbIIIa median fluorescence was 5027 ± 
2549 vs. 1753 ± 474 (P=ns).  Attenuated expression of these activation markers in ApoE
-/-
 
mice transplanted with ApoE/P2Y12 DK bone marrow confirmed the successful reconstitution 
of P2Y12-deficient donor bone marrow into recipient mice. 
 
6.2 Bone marrow transplanted mice showed no difference in 
blood coagulation parameters 
In order to determine any variation in the potential for thrombin and fibrin generation 
between the BMT mice, I assessed coagulation parameters.  Activated partial 
thromboplastin time (aPTT) and prothrombin time (PT) were measured to assess the 
intrinsic (aPTT) and extrinsic (PT) coagulation pathways, and fibrinogen levels were a 
measure of the final common coagulation pathway.  No differences were found between any 
of the bone marrow chimeric groups for PT, aPTT or fibrinogen levels (see Figure 6.2).  
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Figure 6.1 – ApoE
-/-
 male mice transplanted with ApoE/P2Y12 double knockout bone 
marrow demonstrated attenuated platelet activation markers compared to control mice. 
 
Blood was taken from ApoE
-/-
 mice transplanted with either ApoE
-/-
 or ApoE/P2Y12 DK 
bone marrow (n=3), and analysed by flow cytometry to assess platelet function, via 
measurement of (a) P-selectin (CD62p) expression and (b) activation of the GPIIbIIIa 
receptor (CD41/61) in response to PAR-4 TRAP.  Representative fluorescence 
histograms are shown for (i) ApoE
-/-
 into ApoE
-/-
 and (ii) ApoE/P2Y12 DK into ApoE
-/-
 
mice.  Median fluorescence was measured and is shown as increase over baseline for 
(c) CD62p and (d) activated CD41/61.  Data are mean ± SEM; P=ns; Mann-Whitney 
test (adjusted level of significance P<0.01 for multiple group comparisons). 
 
 
113 
 
  
Figure 6.2 – No differences were found in the coagulation response of bone marrow 
transplanted mice.   
 
Coagulation parameters (a) prothrombin time (PT), (b) activated partial thromboplastin 
time (aPTT), and (c) fibrinogen levels were measured in each of the bone marrow 
transplant chimeric groups: ApoE into ApoE, DK into ApoE, DK into DK, and ApoE into 
DK (n=3, 4, 3 and 5 respectively).  Data are mean ± SEM; P=ns; one-way ANOVA with 
Tukey’s multiple comparison. 
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6.3 Vessel wall, not platelet, P2Y12 potentiates early 
atherogenesis 
Mice were fed a western diet for 4 weeks, following BMT, before lesion area was assessed. 
 
6.3.1 Aortae 
Thoracic aortae stained with oil red O demonstrated a non-significant trend towards reduced 
percentage atheroma in vessel wall P2Y12-deficient mice (see Figure 6.3a and b): lesion 
area was 3.35 ± 0.36% in control mice, 2.14 ± 0.28% in mice with deficient vessel wall and 
platelet P2Y12 (P=0.07 vs. control), and 2.1 ± 0.36% in mice with only deficient vessel wall 
P2Y12 (P=0.056 vs. control).  When assessing the aortic arch alone, atheroma was also 
attenuated in vessel wall P2Y12-deficient mice (see Figure 6.3c): aortic arch lesion area was 
6.7 ± 0.83% in control mice, 4.33 ± 0.4% in mice with deficient vessel wall and platelet P2Y12 
(P=0.033 vs. control), and 4.4 ± 0.54% in mice with only deficient vessel wall P2Y12 
(P=0.039 vs. control).  However, there was no significant effect of vessel wall P2Y12 in the 
descending aortae.  Mice with absence of only platelet P2Y12 exhibited no differences in 
lesion area compared to controls. 
 
6.3.2 Brachiocephalic artery 
Cross-sections of the brachiocephalic artery revealed the presence of few lesions in this 
region of the vasculature.  Those lesions which were visible, were often found close to the 
bifurcation of the vessel, and were small in size, simple in structure and appeared to be of 
an early phenotype.  In some cases, no lesions were detected along the entire length of the 
vessel (see Figure 6.4a).  Quantification demonstrated that mice deficient in vessel wall 
P2Y12 had significantly attenuated atheroma, an effect which was irrespective of platelet 
P2Y12 expression.  Lesion area, represented as a ratio of the total CSA of the vessel, was 
0.027 ± 0.002 in control mice, 0.004 ± 0.003 in mice with deficient vessel wall and platelet 
P2Y12 (P<0.001 vs. control), and 0.006 ± 0.003 in mice lacking only vessel wall P2Y12 
(P<0.001 vs. control) (see Figure 6.4b).  Absence of platelet P2Y12 alone appeared to have 
no effect on lesion size (0.021 ± 0.004; P=ns vs. control). 
 
6.3.3 Aortic sinus 
Analogous results were observed in the aortic sinus, with notably less atheroma observed in 
mice deficient in vessel wall P2Y12 (see Figure 6.5b): aortic sinus lesion area was 0.071 ± 
0.008 in control mice, 0.024 ± 0.003 in mice with deficient vessel wall and platelet P2Y12 
(P<0.001 vs. control), and 0.03 ± 0.006 in mice lacking only vessel wall P2Y12 (P<0.001 vs. 
control).  Again this effect was independent of platelet P2Y12 expression.  In contrast to the 
brachiocephalic artery, the aortic sinus revealed more substantial lesions (see Figure 6.5a); 
however, these too were simple in structure, and considerably less complex than those seen 
after 12 weeks of feeding on a western diet (see Figure 5.3a).   
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  Figure 6.3 – Oil red O staining showed attenuated atheroma in the whole aorta and aortic 
arch region of vessel wall P2Y12-deficient mice. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: ApoE into ApoE, DK into ApoE, DK into DK, and ApoE into DK 
(n=12, 15, 12 and 12 respectively).  Following 4 weeks on a western diet, aortae were (a) 
stained with oil red O, and lesion area calculated as a percentage of surface area for the 
(b) whole aorta, and (c) aortic arch and descending aorta.  Data are mean ± SEM; P=ns; 
(b) one-way ANOVA with Tukey’s multiple comparison; (c) Mann-Whitney test (adjusted 
level of significance P<0.01 for multiple group comparisons). 
 
 
116 
 
  
Figure 6.4 – Attenuated atheroma was seen in the brachiocephalic arteries of vessel 
wall P2Y12-deficient mice, following bone marrow transplantation. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: ApoE into ApoE, DK into ApoE, DK into DK, and ApoE into 
DK (n=10, 13, 8 and 9 respectively).  Following 4 weeks on a western diet, the 
brachiocephalic arteries were sectioned, and (a) stained with alcian blue/elastic van 
Gieson.  Representative cross-sections of each chimeric group are shown.  Images 
taken at x100 magnification, scale bar = 100 µm.  (b) Lesion area was calculated, and 
is shown as mean lesion:CSA (cross-sectional area) ratio.  Data are mean ± SEM; 
*P<0.05, **P<0.01, ***P<0.001; one-way ANOVA with Tukey’s multiple comparison. 
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Figure 6.5 – Lesion formation was significantly attenuated in the aortic sinus of vessel 
wall P2Y12-deficient mice, regardless of platelet P2Y12 expression. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: ApoE into ApoE, DK into ApoE, DK into DK, and ApoE into 
DK (n=13, 14, 9 and 10 respectively).  Following 4 weeks on a western diet, the aortic 
sinus was sectioned, and (a) stained with alcian blue/elastic van Gieson.  
Representative cross-sections of each chimeric group are shown.  Images taken at x40 
magnification, scale bar = 100 µm.  (b) Lesion area was calculated, and is shown as 
mean lesion:CSA (cross-sectional area) ratio.  Data are mean ± SEM; ***P<0.001; one-
way ANOVA with Tukey’s multiple comparison. 
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6.4 Vessel wall P2Y12-deficiency results in an earlier lesion 
phenotype 
As collagen and smooth muscle cell content are key characteristics of developing complex 
lesions, I went on to further stain the aortic sinus sections with martius scarlet blue for 
collagen, and for α-smooth muscle actin by immunohistochemistry. 
 
6.4.1 Collagen 
MSB staining of the aortic sinus sections showed well-defined bright blue collagen staining 
of the vessel wall and valve leaflets.  Higher magnification images of ApoE
-/-
 into ApoE
-/-
 and 
ApoE/P2Y12 DK into ApoE
-/-
 lesions, those mice which did express vessel wall P2Y12, 
showed collagen fibres within the lesions, predominantly located towards the cap and 
shoulder regions (see Figure 6.6b).  However, inspection of lesions from mice lacking vessel 
wall P2Y12, ApoE/P2Y12 DK into ApoE/P2Y12 DK and ApoE
-/-
 into ApoE/P2Y12 DK, showed 
little or no collagen staining within any of the lesions.  Quantification of the percentage 
collagen content within aortic sinus lesions from each group confirmed a non-significant 
trend towards reduced collagen in vessel wall P2Y12-deficient lesions: % collagen was 19.2 
± 4.29 in control mice, 12.08 ± 3.04 in mice lacking only vessel wall P2Y12 and 7.94 ± 1.71 in 
mice with deficient vessel wall and platelet P2Y12 (P=0.08 vs. control; Figure 6.7). 
 
6.4.2 Smooth muscle actin 
Smooth muscle actin immunostaining of aortic sinus sections, using DAB as the substrate, 
revealed brown α-SMA positive cells within the vessel wall.  As typically seen in the aortic 
sinus, positive staining was localised to areas of the vessel wall with visible elastic laminae, 
but no staining was present in the myocardium.  Higher magnification images demonstrated 
again that those mice which expressed vessel wall P2Y12, ApoE
-/-
 into ApoE
-/-
 and 
ApoE/P2Y12 DK into ApoE
-/-
, had α-SMA positive cells within their lesions.  As with the 
collagen staining, these cells were predominantly located towards the cap and shoulder 
regions of the lesions (see Figure 6.8b).  Similarly, mice lacking vessel wall P2Y12, 
ApoE/P2Y12 DK into ApoE/P2Y12 DK and ApoE
-/-
 into ApoE/P2Y12 DK, possessed fewer 
smooth muscle actin positive cells within their lesions.  Quantification of α-SMA content 
within the aortic sinus lesions established again, a non-significant trend towards reduced 
percentage smooth muscle actin in vessel wall P2Y12-deficient lesions: 6.14 ± 1.49% in 
control mice, 8.06 ± 1.36% in mice lacking platelet P2Y12, 2.52 ± 0.6% in mice with deficient 
vessel wall and platelet P2Y12 (P<0.05 vs. platelet P2Y12 deficient mice) and 3.85 ± 0.89% in 
mice lacking only vessel wall P2Y12 (P=0.09 vs. platelet P2Y12 deficient mice; Figure 6.9). 
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Figure 6.6 – Aortic sinus lesions from bone marrow transplanted mice demonstrate 
reduced collagen staining in the lesions of vessel wall P2Y12-deficient mice. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: (i) ApoE into ApoE, (ii) DK into ApoE, (iii) DK into DK, and 
(iv) ApoE into DK, and were fed western diet for 4 weeks.  Representative aortic sinus 
cross-sections stained with martius scarlet blue are shown, in which collagen is stained 
bright blue.  Images taken at (a) x40, scale bar = 100 µm and (b) x400 magnification 
(highlighted area), scale bar = 50 µm. 
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Figure 6.7 – Quantification of collagen content, within aortic sinus lesions, 
demonstrated that vessel wall P2Y12-deficient mice expressed less collagen within their 
lesions. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: ApoE into ApoE, DK into ApoE, DK into DK, and ApoE into 
DK (n=13, 14, 9 and 10 respectively) and were fed western diet for 4 weeks.  Collagen 
content within the aortic sinus lesions was quantified, and is shown as a percentage of 
the total lesion area.  Data are mean ± SEM; P=ns; one-way ANOVA with Tukey’s 
multiple comparison. 
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Figure 6.8 – Bone marrow transplanted mice demonstrate reduced α-smooth muscle 
actin staining in the aortic sinus lesions of vessel wall P2Y12-deficient mice. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: (i) ApoE into ApoE, (ii) DK into ApoE, (iii) DK into DK, and 
(iv) ApoE into DK, and were fed western diet for 4 weeks.  Representative aortic sinus 
cross-sections stained for α-smooth muscle actin using immunohistochemistry are 
shown, in which positive cells are stained brown.  Images taken at (a) x40, scale bar = 
100 µm and (b) x400 magnification (highlighted area), scale bar = 50 µm. 
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Figure 6.9 – Quantification of α-smooth muscle actin, within aortic sinus lesions, 
demonstrated that vessel wall P2Y12-deficient mice had less smooth muscle actin positive 
cells within their lesions. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: ApoE into ApoE, DK into ApoE, DK into DK, and ApoE into DK 
(n=12, 14, 9 and 10 respectively) and were fed western diet for 4 weeks.  Smooth muscle 
actin content within the aortic sinus lesions was quantified, and is shown as a percentage 
of the total lesion area.  Data are mean ± SEM; *P<0.05; one-way ANOVA with Tukey’s 
multiple comparison. 
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6.5 P2Y12 and α-smooth muscle actin dual 
immunofluorescence staining of aortic sinus lesions 
To investigate the localisation of P2Y12 expression within the aortic sinus lesions, I 
developed a dual immunofluorescence staining protocol for P2Y12 alongside a smooth 
muscle cell marker, α-smooth muscle actin.  Few commercial P2Y12 antibodies were 
available, and none had been used on murine tissue or for this purpose.  I opted to use the 
APR-012 P2Y12 antibody from Alomone Labs (Israel).  Various conditions were tested to find 
the optimum staining conditions, and the results can be seen in Figure 6.10. 
 
The α-SMA antibody (green) produced strong positive staining within the vessel wall of the 
aortic sinus.  Some additional positive cells could also be seen in lesions from ApoE
-/-
 into 
ApoE
-/-
 and ApoE/P2Y12 DK into ApoE
-/-
 mice.  As seen with DAB immunostaining, there 
were no positive cells in the lesions of vessel wall P2Y12-deficient mice.  The P2Y12 antibody 
(red) in comparison was very weak, and required a much longer exposure time, indicating a 
lower expression level.  However, a positive signal was seen in the vessel wall, and mirrored 
those areas which were also α-SMA positive.  Interestingly, positive staining could be seen 
in the vessel wall of all groups, despite the ApoE/P2Y12 DK into ApoE/P2Y12 DK and ApoE
-/-
 
into ApoE/P2Y12 DK groups being vessel wall P2Y12-deficient.  Although a weak signal, 
some positive cells could also be seen in the lesions of ApoE
-/-
 into ApoE
-/-
 and ApoE/P2Y12 
DK into ApoE
-/-
 mice.  Negative and single colour control sections show no evidence of non-
specific binding for either antibody.  
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Figure 6.10 – Smooth muscle actin and P2Y12 dual immunofluorescent staining of aortic 
sinus lesions from bone marrow transplanted mice. 
 
ApoE
-/-
 and ApoE/P2Y12 DK male mice underwent bone marrow transplantation to 
generate chimeric groups: (i) ApoE into ApoE, (ii) DK into ApoE, (iii) DK into DK, and 
(iv) ApoE into DK and were fed western diet for 4 weeks.  Representative aortic sinus 
cross-sections are shown, which are stained for (a) DAPI (nuclei, blue), (b) α-smooth 
muscle actin (green), and (c) P2Y12 (red) using immunofluorescence techniques.  (v) 
Negative and (vi-vii) single colour controls are also shown.  Images taken at x200 
magnification, scale bar = 50 µm. 
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6.6 Summary 
The work in this chapter further described the role of P2Y12 in early atherogenesis, using 
bone marrow transplantations to delineate the contribution of platelet versus vessel wall 
P2Y12 receptors in this process.  Results were obtained following 4 weeks on a high-fat 
western diet.  In summary: 
 
 Reduced expression of platelet activation markers, P-selectin and activated 
GPIIbIIIa receptor, in ApoE
-/-
 mice transplanted with ApoE/P2Y12 DK bone marrow 
demonstrated the expected bone marrow P2Y12 phenotype, and thus confirmed the 
efficacy of transplantation. 
 There were no differences in the coagulation response of bone marrow transplanted 
mice. 
 Vessel wall P2Y12-deficient mice had attenuated lesion formation in the whole aorta 
and aortic arch compared to ApoE
-/-
 control mice. 
 In addition, lesion area was significantly reduced in the brachiocephalic arteries and 
aortic sinus of vessel wall P2Y12-deficient mice. 
 The effect of vessel wall P2Y12-deficiency on lesion development appeared to be 
independent of platelet P2Y12 expression. 
 Aortic sinus lesions from mice which expressed vessel wall P2Y12 demonstrated 
collagen fibres within the cap and shoulder regions, and contained an increased 
percentage collagen content than lesions from those mice lacking vessel wall P2Y12, 
where little or no collagen was observed. 
 Similarly, vessel wall P2Y12-deficient mice also had fewer α-smooth muscle actin 
positive cells within their lesions.  
 P2Y12 and α-smooth muscle actin dual staining provided interesting, but 
inconclusive results.  Some weak P2Y12 positive cells were noted in the lesions; 
however, positive staining was also observed in the aortic sinus wall of vessel wall 
P2Y12-deficient mice. 
 
6.7 Discussion 
Fully understanding the role of platelets and P2Y12 in atherogenesis could reveal potential 
mechanisms by which disease progression could be modulated.  In the previous chapter, I 
demonstrated a moderate regional effect of P2Y12–deficiency in established disease; yet 
little is known of its impact in early atherogenesis or likewise, of the role of vessel wall P2Y12 
in this process.  In this chapter, I identify a previously unknown role of vessel wall P2Y12 in 
modulating early atherogenesis, and therefore propose that it is vessel wall, rather than 
platelet, P2Y12 which plays a significant role in the early stages of disease by promoting 
lesion development.   
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To my knowledge, all platelet atherogenesis studies to date model established disease, 
choosing end points from 7 to more than 30 weeks on a chow or high-fat diet (Massberg et 
al. 2002; Burger and Wagner 2003; Hechler et al. 2008; Bultmann et al. 2010).  Cholesterol 
clefts and fibrous caps are common features in these lesions, and are typically associated 
with advanced plaques, including those which are susceptible to endothelial erosion and 
rupture (Stary et al. 1995).  This is true of my findings from the previous chapter, where mice 
fed a western diet for 12 weeks had advanced lesions, and also the Li study which assessed 
atheroma in ApoE/P2Y12 DK mice after 20 weeks on a high-fat diet, similar in composition to 
our own western diet (Li et al. 2012).  I therefore chose to study a much earlier stage of 
atherogenesis, after only 4 weeks of feeding, where I could both accurately measure 
atheroma and also be confident of little risk of endothelial erosion. 
 
To investigate the role of platelet versus vessel wall P2Y12 at this earlier time point, I carried 
out bone marrow transplantations using a method previously employed by our group 
(Chamberlain et al. 2006; Evans et al. 2009).  To further confirm the successful 
reconstitution of donor bone marrow into recipient mice I performed a P-selectin assay to 
assess P2Y12 function, and found ApoE
-/-
 mice transplanted with ApoE/P2Y12 DK bone 
marrow had diminished platelet function as expected, compared to control mice.  These 
results were consistent with our previous findings on P2Y12 mice (Evans et al. 2009). 
 
Recent work by Rauch et al. links P2Y12 expression with VSMC mitogenesis via a thrombin-
induced pathway, and may provide a potential mechanism for the effect I observed (Rauch 
et al. 2010).  Interestingly, following exposure to thrombin, they found P2Y12 surface 
expression being significantly upregulated by nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), and P2Y12-induced mitogenic effects enhanced.  In an 
inflammatory setting such as atherogenesis, where thrombin generation is likely, it is 
probable that P2Y12-potentiated VSMC mitogenesis contributes to lesion progression.  
Indeed, P2Y12-positive VSMCs have been identified within atherosclerotic lesions (Rauch et 
al. 2010).  Furthermore, to eliminate the possible impact of differences in thrombin 
generation on the interpretation of my findings, I conducted PT and aPTT tests and found no 
difference in response between chimeric groups. 
 
Assessing atheroma in transplanted mice following 4 weeks on a western diet demonstrated 
that, in contrast to the Li study, it is vessel wall, rather than platelet, P2Y12 which is important 
in the development of early lesions, but perhaps this balance shifts as disease progresses.  
This hypothesis is supported by my previous work in Chapter 3 showing that platelet, rather 
than vessel wall, P2Y12 plays a profound role in the vessel wall response to injury (Evans et 
al. 2009).  Consideration must also be made for the potential influence of vessel wall P2Y12 
on the results demonstrated by Li et al (Li et al. 2012).  Only ApoE/P2Y12 DK mice were 
chosen as recipients for their bone marrow transplantations and so further investigation 
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looking at the role of vessel wall P2Y12 in later atherogenesis is warranted.  Research into 
the role of the related platelet purine receptor P2Y1 in atherogenesis, which is more widely 
expressed than P2Y12, demonstrated a similar vascular wall effect on atherogenesis, and so 
also supports the need for further exploration in this area (Hechler et al. 2008). 
 
The smaller lesions observed in vessel wall P2Y12-deficient mice suggest that VSMC P2Y12 
expression does influence lesion size, perhaps via VSMC mitogenesis; however, this is yet 
to be explored.  Absence of α-SMA expression within these lesions, compared to positive 
staining seen in those mice which do express vessel wall P2Y12, lends some support to this 
hypothesis, although whether lesion progression is delayed or altered in the absence of 
VSMC P2Y12 remains to be seen.  Indeed, little is known of the true effects of P2Y12 
deficiency on VSMC development, phenotype, or plasticity and so extensive investigation is 
required to find the exact mechanism behind these findings. 
 
Given that P2Y12-positive VSMCs had been identified in human atherosclerotic lesions 
(Rauch et al. 2010), I was interested to investigate the location of these cells, and in relation 
to known VSMC marker, α-SMA.  I therefore chose to use an immunofluorescence staining 
approach.  Having researched into the few commercially available P2Y12 antibodies, I found 
the literature to be very limited, with few of these antibodies having either been tested on 
rodent tissue, or for immunohistochemistry or fluorescence techniques.   However, of these 
antibodies, the APR-012 polyclonal antibody from Alomone Labs had successfully been 
used on both rat spleen and brain tissue for immunofluorescence (Amadio et al. 2006; 
Uehara and Uehara 2011).  I therefore endeavoured to use this antibody, in conjunction with 
the Dako α-SMA antibody, for dual immunofluorescence staining using Alexa Fluor 488 (α-
SMA) and Alexa Fluor 594 (P2Y12) conjugated secondary antibodies. 
 
Despite a weak signal, P2Y12 staining could clearly be seen in the vessel wall which, as 
expected, corresponded to α-smooth muscle actin positive areas.  In addition, some weakly 
positive cells could to seen in lesions from ApoE
-/-
 into ApoE
-/-
 and ApoE/P2Y12 DK into 
ApoE
-/-
 mice, but further work is necessary to improve the P2Y12 staining in order to 
determine whether these are both P2Y12 and α-SMA positive cells.  Negative control 
sections showed no evidence of non-specific binding, yet positive staining could be seen in 
the vessel wall of all chimeric groups, despite some being vessel wall P2Y12-deficient.  Given 
that the biological phenotype of all chimeras were as expected, as is clearly demonstrated in 
the P-selectin data (see Figure 6.1), there is not a clear explanation for these findings.  
However, I postulate that as the P2Y12
-/-
 mice were generated using a neomycin insert into 
the gene, perhaps some protein is still expressed in these mice, but the receptor is not 
functional.  The Alomone P2Y12 antibody is specific to the 2
nd
 intracellular loop of the 
receptor and so, if this amino acid sequence remains, it may explain the positive staining 
seen in these mice. 
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These data demonstrate that vessel wall P2Y12 is important in early atherogenesis and 
potentiates lesion formation, perhaps via VSMC mitogenesis.  In later disease, it seems that 
platelet P2Y12 plays a greater role in determining lesion size and phenotype.  P2Y12 
inhibitors, ticagrelor and clopidogrel, effectively inhibit platelet reactivity and therefore, in the 
following chapter, I went on to investigate whether these were able to block the vessel wall 
P2Y12 effect on early atherogenesis. 
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The P2Y12 antagonist clopidogrel and next-generation agents, such as ticagrelor, are 
routinely used in ACS treatment due to their remarkable effects at preventing thrombosis.  
Given that vessel wall P2Y12 is able to potentiate early atherogenesis; I was interested to 
investigate if these P2Y12 inhibitors were able to modulate the vessel wall P2Y12-mediated 
effect on early atherogenesis in ApoE
-/-
 mice.   
 
In addition, recent data show that ticagrelor also inhibits adenosine re-uptake by RBCs (van 
Giezen et al. 2012), and blocks ADP-induced vasoconstriction in isolated arteries (Hogberg 
et al. 2010; Grzesk et al. 2012).  Furthermore, ticagrelor offers a reduced mortality risk, 
compared to clopidogrel, in patients with acute coronary syndromes (Wallentin et al. 2009), 
but the mechanisms for this mortality reduction remain to be established.  I therefore aimed 
to determine any non-P2Y12-mediated effects of ticagrelor or clopidogrel on early 
atherogenesis in ApoE/P2Y12 DK mice. 
 
7.1 Voluntary drug delivery of ticagrelor and clopidogrel in 
jelly results in effective P2Y12 inhibition 
To investigate the effects of P2Y12 inhibitors on early atherogenesis, mice were given either 
twice-daily doses of ticagrelor (100 mg/kg), daily clopidogrel (20 mg/kg), or mannitol (control) 
in jelly, in addition to a western diet for 4 weeks.  This novel method of voluntary drug 
delivery was adapted from a published method by Zhang (Zhang 2011) and avoided the 
need for  twice-daily gavage, which would have been highly stressful to the animals. 
 
Mice were first trained for a week with jelly only and then switched to a drug-jelly mixture.  All 
responded well, with 77% of mice eating all or >50% of the jelly cube for each dose, 
throughout the 4 weeks of drug treatment.  The remaining 23% of mice did not eat the jelly 
on five or more occasions; however, missed doses were sporadic and interleaved with 
periods where the jelly cubes were consumed.  None of the mice missed every dose.  Of the 
mice which missed five or more doses, all but one was in the ticagrelor treatment group.  
With some mice, particularly those in the ticagrelor group, missing several drug doses, I was 
keen to investigate the efficacy of drug delivery for this method and so assessed platelet 
P2Y12 inhibition by measuring P-selectin expression in response to PAR-4 TRAP. 
 
Platelets from ApoE
-/-
 mice treated with mannitol (control) demonstrated high fluorescence of 
the CD62p antibody in response to 1 mmol/L TRAP, indicating these platelets expressed 
high levels of P-selectin as expected.  In contrast, platelets from ApoE
-/-
 mice treated with 
P2Y12 antagonists, ticagrelor and clopidogrel, showed attenuated platelet activation and 
7 Effect of pharmacological inhibition of 
P2Y12 on early atherogenesis 
135 
 
exhibited much lower fluorescence levels, shown as a shift to the left in the P-selectin 
fluorescence peaks (see Figure 7.1a). 
 
Expression was measured as an increase in median fluorescence over baseline, determined 
using an isotype control antibody.  At each concentration, ApoE
-/-
 mice treated with P2Y12 
inhibitors demonstrated lower P-selectin expression (see Figure 7.1b) compared to control-
treated mice.  This was particularly evident in response to 1 mmol/L TRAP for which P-
selectin median fluorescence was 600 ± 87 for ApoE
-/-
 controls, 166 ± 55 for ticagrelor-
treated mice (P<0.001 vs. control), and 141 ± 73 for clopidogrel-treated mice (P<0.001 vs. 
control; Figure 7.1c).  As expected, reduced P-selectin expression was observed in all 
ApoE/P2Y12 DK mouse treatment groups, and there was no additional effect of ticagrelor or 
clopidogrel (see Figure 7.1b and c).  Attenuated expression of these activation markers in 
ApoE
-/-
 mice treated with ticagrelor and clopidogrel verified effective drug delivery and P2Y12 
inhibition.
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Figure 7.1 – ApoE
-/-
 mice treated with ticagrelor or clopidogrel exhibited reduced P-
selectin expression, demonstrating effective platelet P2Y12 inhibition. 
 
Blood was taken from ApoE
-/-
 and ApoE/P2Y12 DK male mice treated with either ticagrelor 
(n=7 & 6 respectively), clopidogrel (n=5 & 6), or mannitol (control; n=7 & 6), and analysed 
by flow cytometry to assess P-selectin (CD62p) expression in response to PAR-4 TRAP. 
(a) Representative fluorescence histograms are shown for ApoE
-/-
 mice from each 
treatment group.  P-selectin expression was measured as median fluorescence, shown as 
increase over baseline, for (b)(i) ApoE
-/-
 and (ii) ApoE/P2Y12 DK mice and (c) in response 
to 1 mmol/L PAR-4 TRAP.  Data are mean ± SEM; ***P<0.001; two-way ANOVA with 
Tukey’s multiple comparison. 
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7.2 Ticagrelor and clopidogrel have no effect on early 
atherogenesis 
ApoE
-/-
 and ApoE/P2Y12 DK male mice were fed either ticagrelor, clopidogrel, or mannitol 
(control) for 4 weeks, in addition to a western diet, to investigate the effects of 
pharmacological inhibition of P2Y12 on early atherogenesis.  Atheroma was assessed in the 
thoracic aorta and aortic sinus. 
 
7.2.1 Aortae 
Whole aortae were stained with oil red O (see Figure 7.2a), and the mean percentage 
atheroma was calculated for each treatment group and genotype.  Ticagrelor or clopidogrel 
treatment had no effect on lesion development, compared to controls, in either ApoE
-/-
 or 
ApoE/P2Y12 DK mice (see Figure 7.2b).  Likewise, further analysis of the aortic arch and 
descending aorta demonstrated no region-specific differences in lesion formation 
(descending aorta data not shown).  A greater spread of data was noted in the aortic arch 
lesion area of ApoE
-/-
 compared to ApoE/P2Y12 DK mice: lesion area was 1.54 ± 0.35% in 
control, 1.9 ± 0.51% in ticagrelor and 0.86 ± 0.24% in clopidogrel treated ApoE
-/-
 mice (all 
P=ns vs. control) vs. 1.38 ± 0.3% in control, 1.8 ± 0.29% in ticagrelor and 1.47 ± 0.28% in 
clopidogrel treated ApoE/P2Y12 DK mice (all P=ns vs. control). 
 
7.2.2 Aortic sinus 
As seen previously with 4 weeks of feeding on a western diet, histological staining revealed 
the presence of small, simple lesions within the aortic sinus (see Figure 7.3).  Quantitative 
analysis demonstrated similar results to the whole aortae and showed no effect of the P2Y12 
inhibitors on atherogenesis in either ApoE
-/-
 or ApoE/P2Y12 DK mice compared to controls.  
However, an overall effect of P2Y12 deficiency on lesion size continued to be observed in the 
presence of the P2Y12 inhibitors, when comparing all ApoE/P2Y12 DK mice with their ApoE
-/-
 
counterparts (Mean lesion:CSA ratio 0.023 ± 0.002 [DK] vs. 0.034 ± 0.002 [ApoE]; P<0.001; 
Figure 7.4). 
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Figure 7.2 – Oil red O staining of whole aortae showed no effect of ticagrelor or 
clopidogrel treatment on lesion formation compared to control mice. 
  
Whole aortae were excised from ApoE
-/-
 and ApoE/P2Y12 DK male mice fed western diet 
for 4 weeks, in addition to either twice daily doses of ticagrelor (100 mg/kg; n=10 & 9 
respectively), daily clopidogrel (20 mg/kg; n=9 & 8), or mannitol (control; n=9).  (a) Aortae 
were stained en face with oil red O, and lesion area quantified in (b)(i) the whole aorta 
and (ii) aortic arch.  Data are mean ± SEM; P=ns; two-way ANOVA with Tukey’s multiple 
comparison. 
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Figure 7.3 – ApoE
-/-
 and ApoE/P2Y12 double knockout mice treated with ticagrelor, 
clopidogrel, or control demonstrated small aortic sinus lesions, but no overall difference 
in the extent of atheroma. 
 
Representative aortic sinus cross-sections stained with alcian blue/elastic van Gieson 
from (a) ApoE
-/-
 and (b) ApoE/P2Y12 DK male mice fed a western diet for 4 weeks in 
addition to either (i) mannitol (control), (ii) ticagrelor, or (iii) clopidogrel treatment.  
Images taken at x40 magnification, scale bar = 100 µm. 
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Figure 7.4 – Ticagrelor or clopidogrel treatment had no effect on lesion 
development in ApoE
-/-
 or ApoE/P2Y12 double knockout mice, but an effect of P2Y12-
deficiency on atheroma was still observed. 
 
Lesion area was quantified in the aortic sinus from ApoE
-/-
 and ApoE/P2Y12 DK male 
mice fed western diet for 4 weeks, in addition to either twice daily doses of ticagrelor 
(100 mg/kg; n=10 & 9 respectively), daily clopidogrel (20 mg/kg; n=9 & 8), or 
mannitol (control; n=9).  Lesion area is shown as mean lesion:CSA (cross-sectional 
area) ratio.  Data are mean ± SEM; P<0.001; Independent samples t test (ApoE vs 
ApoE/P2Y12 DK); P=ns; two-way ANOVA with Tukey’s multiple comparison. 
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7.3 Summary 
This chapter has examined the use of P2Y12 inhibitors, ticagrelor and clopidogrel, in 
modulating early atherogenesis, and investigated both P2Y12- or non-P2Y12-mediated effects 
on this process.  In summary: 
 
 Ticagrelor and clopidogrel treatment yielded a significant reduction in the expression 
of platelet activation marker, P-selectin, in ApoE
-/-
 mice compared to those treated 
with control, demonstrating effective platelet P2Y12 inhibition. 
 Oil red O staining revealed ticagrelor and clopidogrel treatment had no effect on 
lesion formation, compared to control, in the whole aorta of ApoE
-/-
 or ApoE/P2Y12 
DK mice. 
 In addition, there were no region-specific differences in lesion development. 
 Likewise, in the aortic sinus, P2Y12 inhibitors had no effect on lesion area compared 
to control treatment in either ApoE
-/-
 or ApoE/P2Y12 DK mice. 
 An overall effect of P2Y12 deficiency on lesion formation was still observed in the 
aortic sinus, when comparing all ApoE/P2Y12 DK mice with their ApoE
-/-
 
counterparts. 
 
7.4 Discussion 
The potential therapeutic impact of P2Y12 antagonist treatment in the prevention or 
management of atherosclerosis, before the onset of life-threatening acute coronary 
syndromes, is of great interest.  In the previous chapter, I demonstrated that vessel wall, but 
not platelet, P2Y12 potentiated early atherogenesis, which then poses the question, are 
P2Y12 antagonists able to block this vessel wall effect?  In this chapter, I show that ticagrelor 
and clopidogrel effectively inhibited platelet P2Y12, but had no effect on lesion development 
in early atherogenesis.  These findings therefore indicate that prophylactic use of P2Y12 
inhibitors may not be beneficial in preventing early atherosclerotic disease. 
 
In this study, I utilised a novel approach to drug dosing as an alternative to gavage in order 
to minimise animal stress, whilst maintaining a satisfactory level of drug delivery and P2Y12 
inhibition.  The doses used of ticagrelor and clopidogrel were based on previous studies that 
established these as optimal for providing a high, sustained level of P2Y12 inhibition (Evans 
et al. 2009; Patil et al. 2010).  Although the voluntary method of drug delivery did not achieve 
the accuracy and compliance of drug dosage compared to gavage, it did attain a high level 
of platelet P2Y12 inhibition. 
 
Clopidogrel is widely used in ACS treatment, but next-generation agents, such as ticagrelor, 
are increasingly employed due to their superior inhibitory effects, and greater clinical 
efficacy.  Although particularly effective at preventing secondary thrombosis, evidence of 
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their effects on atherogenesis itself is limited, and existing studies offer conflicting results.  
Schulz et al. investigated the effects of prophylactic treatment, with aspirin and clopidogrel, 
on lesion development in ApoE
-/-
 mice and found that whilst these drugs effectively 
prevented thrombosis following plaque rupture, they had no effect on atherogenesis (Schulz 
et al. 2008).  However, a later study published contradictory results showing that mice 
treated with clopidogrel had reduced atheroma, as well as a stable lesion phenotype 
compared to untreated animals (Afek et al. 2009).  With such controversy, I was interested 
to explore whether P2Y12 antagonists were able to inhibit the vessel wall effect on 
atherogenesis, as demonstrated in Chapter 6.  I found that, despite effective platelet P2Y12 
inhibition, neither ticagrelor nor clopidogrel had any effect on lesion development in ApoE
-/-
 
mice after 4 weeks of treatment.  Though whether these drugs are able to penetrate the 
vessel wall, and so would be available to block VSMC P2Y12 receptors, is debatable. 
 
Studies have shown that ticagrelor (Hogberg et al. 2010; Grzesk et al. 2012) and another 
reversibly-binding P2Y12 antagonist, cangrelor (Wihlborg et al. 2004), are able to inhibit 
ADP-induced VSMC contraction, advocating the notion that these drugs are capable of 
binding to, and blocking the action of, VSMC P2Y12 receptors as they similarly do in 
platelets.  However, such experiments were conducted in denuded arteries, therefore 
suggesting these effects may not have been evident when the endothelium was intact, 
although this was not specified.  Interestingly, clopidogrel was shown to have no effect on 
vessel contraction, with the short half-life of the active metabolite being postulated as a 
potential contributory factor to this lack of effect (Wihlborg et al. 2004). 
 
Without evidence to demonstrate whether drugs such as ticagrelor and clopidogrel are able 
to permeate the vessel wall and, if so, at what concentration they effectively inhibit P2Y12-
mediated effects in VSMCs, it is difficult to draw conclusions from my findings.  Nonetheless, 
it can be deduced that, at doses which yield high levels of platelet P2Y12 inhibition, ticagrelor 
and clopidogrel are unable to inhibit VSMC P2Y12-mediated effects on atherogenesis, 
whether this be via actual lack of effect on the cells or an inability of the drugs to physically 
reach the receptor.  Further investigation is needed to elucidate the action of these agents 
on VSMC P2Y12 receptors in vivo, and deduce their ability to penetrate the endothelium.  
 
In addition to its effects on platelets, ticagrelor has also been shown to block adenosine re-
uptake by RBCs (van Giezen et al. 2012), and so may have other, non-P2Y12-mediated 
effects on the vessel wall, which I was keen to explore further.  Uptake of adenosine is a 
process by which extracellular levels of this important purine are regulated.  Adenosine 
signalling evokes physiological effects in many tissues including the heart, and an 
accumulation of adenosine also protects against tissue damage following ischaemia or 
inflammation (Noji et al. 2004).  Acting on the vessel wall, adenosine is a vasodilator and is 
known to induce nitric oxide production in both VSMC (Dubey et al. 1998) and endothelial 
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cells (Smits et al. 1995), which suppresses expression of leukocyte adhesion molecules, 
such as VCAM-1 (De Caterina et al. 1995).  Adenosine has also been shown to inhibit 
VSMC proliferation (Garg and Hassid 1989), all of which are important processes in the 
initiation and progression of atherogenesis.  Furthermore, the PLATO clinical study showed 
that ticagrelor offered a reduced mortality risk from non-cardiovascular causes, compared to 
clopidogrel (Wallentin et al. 2009) and, additionally, ticagrelor treated patients were less 
likely to experience pulmonary adverse events such as infection and sepsis (Storey et al. 
2012).  The mechanisms for these beneficial effects though, remain to be established.   
 
Therefore given the potential athero-protective effects of ticagrelor, I chose to investigate 
non-P2Y12-mediated effects of ticagrelor and clopidogrel on atherogenesis using 
ApoE/P2Y12 DK mice.  However, neither ticagrelor nor clopidogrel treatment had any effect 
on lesion development after 4 weeks of treatment.  As these mice were P2Y12-deficient, drug 
activity could not be assessed via P-selectin expression.  Nevertheless, given that these 
mice were treated and monitored alongside ApoE
-/-
 mice, which achieved effective platelet 
P2Y12 inhibition using the same treatment regime, it can be assumed that they also had a 
similar level of drug activity.  These findings therefore indicate that any non-P2Y12-mediated 
effects of ticagrelor and clopidogrel are insufficient to influence lesion development, and so 
do not effect atherogenesis at this early stage.  Consideration must also be made for the 
possible effects of P2Y12 deficiency on VSMC development and behaviour in this model, 
which may negate the vessel wall response to adenosine. 
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Preventing blood loss and maintaining haemostasis via thrombosis is the primary function of 
the platelet; however, further insight has shown these cells can impact upon processes far 
beyond the blood clot.  The purinergic receptor P2Y12, responsible for amplifying and 
sustaining the platelet activation response, is perhaps arguably the most important of the 
many platelet receptors due to its profound influence on platelet reactivity.  In addition, new 
roles for P2Y12 receptors that are expressed on other cell types are beginning to emerge.  
With the availability of highly effective inhibitors, P2Y12 offers a promising target for disease 
management, and may hold the key to mediating the role of P2Y12 in processes such as 
atherogenesis. 
 
In this thesis, I have demonstrated that platelet P2Y12 is crucial in modulating the vessel wall 
response to injury.  Conversely, through the development of a novel ApoE/P2Y12 DK mouse 
strain, I have discovered that vessel wall, but not platelet, P2Y12 is important in early 
atherogenesis and potentiates initial lesion formation.  However, the P2Y12 inhibitors, 
ticagrelor and clopidogrel, were ineffective at blocking this vessel wall P2Y12 effect on early 
atherogenesis. 
 
There is an increasing body of evidence demonstrating how individual platelet proteins and 
adhesion receptors, such as P-selectin, CD40L, and GPVI, contribute to lesion development 
in atherogenesis (Burger and Wagner 2003; Bultmann et al. 2010; Lievens et al. 2010).  
Platelets are known to interact with the inflammatory system via leukocytes, and cells of the 
vessel wall via cytokine and mitogen release, as a result of platelet activation.  Therefore, as 
a central regulator of platelet reactivity, the P2Y12 receptor was felt to be crucial in 
modulating these effects and, as such, studies into the role of platelet P2Y12 in 
atherogenesis were greatly anticipated.  However, my findings have challenged this 
paradigm, revealing instead a novel role for vessel wall P2Y12 in early lesion development.  
Together with existing literature, these findings offer new insights into the respective roles of 
platelet and vessel wall P2Y12 receptors in atherogenesis, and how the influence of these 
cell types may change over time as disease progresses.  Therefore, to summarise this 
current knowledge, I propose a suggested timeline of P2Y12 involvement in atherogenesis, 
as demonstrated in murine studies (see Figure 8.1). 
 
 
Figure 8.1 – Timeline of P2Y12 involvement in atherogenesis. 
8 General discussion 
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In the early stages of disease, after 4 weeks on a western diet, vessel wall P2Y12 plays a 
significant role in lesion development, whereas platelet P2Y12 has little effect (see Chapter 
6).  At 12 weeks, when vessels demonstrate characteristics of more advanced disease, the 
influence of P2Y12 is less apparent, except in areas of the vasculature exposed to turbulent 
flow, where P2Y12 is still important in lesion progression.  As discussed in Chapter 5, this 
may reflect an increasing impact of platelet adhesion on atherogenesis, and suggests a 
lesser role of vessel wall P2Y12 at this stage.  In later disease, following 20 weeks on a high-
fat diet, Li et al. document that platelet P2Y12 exerts a prominent effect in promoting 
advanced lesion development (Li et al. 2012).  This is further supported by my own findings, 
which demonstrate a profound role for platelet P2Y12 in the vessel wall response to injury 
through mediating thrombus and neointima formation (see Chapter 3). 
 
It is clear that vessel wall and platelet P2Y12 appear to have a greater impact at opposing 
stages of disease, but how they mediate their effects is not yet fully appreciated.  A recent 
study into VSMC P2Y12 expression and function, however, may provide a potential 
mechanism, having revealed that P2Y12 promotes VSMC mitogenesis in response to 
thrombin (Rauch et al. 2010).  Furthermore, P2Y12 expression was found to be regulated by 
the pro-inflammatory transcription factor, NF-κB.  In advanced disease, platelet P2Y12 has a 
more prominent role, where it appears platelet interactions with the inflammatory system 
become more important to lesion growth, and where endothelial erosion is more likely to 
occur.  Though, exactly when the balance switches from vessel wall to platelet P2Y12 is not 
clear, and further investigation into what influences this process is of great interest. 
 
Given that ticagrelor and clopidogrel were unable to inhibit the vessel wall P2Y12 effect on 
early atherogenesis (see Chapter 7), but are known to be extremely effective inhibitors of 
platelet P2Y12, fully understanding the timeline of P2Y12 involvement in atherogenesis could 
have beneficial consequences to both disease treatment and management.  These findings 
indicate that P2Y12 inhibitors may not offer a therapeutic strategy for the prevention of 
atherosclerosis in people without evidence of atherosclerotic disease.  However, where 
disease is apparent, a greater role of platelets is implicated at this stage, and so indicates 
that commencing P2Y12 inhibitor treatment earlier than when it’s conventionally given, 
following atherothrombosis, may be advantageous in managing lesion progression.  
Nevertheless, caution must be exercised before considering the prophylactic use of these 
drugs, and the overall preventative benefit versus bleeding risk fully assessed.  Indeed, one 
such clinical study of clopidogrel plus aspirin, versus aspirin treatment alone, in patients with 
existing CVD and those which were asymptomatic but high-risk, demonstrated no overall 
effect of clopidogrel in preventing future CV events, yet indicated a moderate increased 
bleeding risk (Bhatt et al. 2006).  Sub-group analysis did, however, show a marginal benefit 
of clopidogrel treatment for those with existing disease, but not in asymptomatic patients, 
who demonstrated increased bleeding complications.  Clearly further investigation is 
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necessary to clarify the full effect of antiplatelet drugs, including the new P2Y12 antagonist 
ticagrelor, on primary prophylaxis in patients with existing disease, to determine when this 
treatment would be indicated and, furthermore, to study their direct effects on lesion 
progression. 
 
It must also be noted that, although clopidogrel is known to produce a consistently high level 
of platelet P2Y12 inhibition in mice, the response in humans, particularly those with CAD, is 
much more variable (Gurbel et al. 2003).  The incidence of clopidogrel ‘non-responders’ is 
well-documented, and is a known risk factor for stent thrombosis (Gurbel et al. 2005; Mega 
et al. 2010).  In light of my findings on the innate relationship between P2Y12 inhibition, 
thrombosis and neointima formation, my data also suggest that inadequate P2Y12 inhibition 
may have an adverse impact on the risk of restenosis in patients who respond poorly to 
clopidogrel, and therefore effective P2Y12 inhibition may be beneficial in the prevention of 
restenosis. 
 
The recently resolved crystal structure of P2Y12 in complex with an agonist and antagonist, 
will undoubtedly fuel further interest in P2Y12 inhibitors and their therapeutic use (Zhang et 
al. 2014; Zhang et al. 2014).  Along with the emerging evidence of P2Y12 involvement in 
atherogenesis, this newfound knowledge of the receptor binding sites may therefore drive 
the development of novel agents, and could mark a new era for platelet and potentially 
VSMC P2Y12 inhibitors in disease prevention. 
 
8.1 Limitations 
The use of animals in the study of human diseases offers an inherent limitation to the 
conclusions which may be drawn from such research, including this thesis.  There are many 
arguments both for and against the suitability and relevance of animal models in research.  
Anatomical and genetic differences between species pose the greatest challenge, in addition 
to the ability to mimic those diseases which are largely human-specific.  This is particularly 
evident in murine models of atherogenesis, as mice appear to be naturally resistant to 
atherosclerosis and require genetic manipulation of either the LDL receptor or ApoE gene in 
order to develop the disease.  With the addition of a high-fat diet, disease progression is 
vastly accelerated in comparison to humans; however, atherosclerotic lesion structure and 
location are very similar, particularly in ApoE
-/-
 mice (Nakashima et al. 1994).  When 
interpreting findings it must therefore be considered that this research was conducted in a 
non-human species, and so any conclusions drawn may not directly translate into human 
disease.  Yet given the challenges posed by animal models, their advantages far outweigh 
any potential drawbacks by providing a valuable insight into disease processes not offered 
by in vitro assays alone.  In particular, transgenic mouse lines enable the full impact of 
individual proteins and receptors, such as P2Y12 to be revealed, something which cannot be 
achieved in larger animal models. 
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Ferric chloride is a useful vessel injury model, which is quick to perform, is not technically 
difficult as the vessel remains intact and, as a consequence, has a high success rate.  
However, the extent of injury is not always consistent, and can also result in damage to the 
surrounding tissue.  As injury is inflicted via oxidation rather than by mechanical means, the 
ensuing tissue factor release is much greater than would occur in a wire injury model, and so 
perhaps does not provide the ideal conditions in which to accurately model PCI-induced 
injury.  Despite this, it does yield a reliable method for inducing thrombus and neointima 
formation, and has revealed the dominant effect of platelet P2Y12 on these processes, which 
can then be further investigated in restenosis models. 
 
Performing a dihybrid cross for the generation of a novel transgenic mouse line requires 
many resources, and is both a time-consuming and costly undertaking.  With the time 
constraints of this project and given the knowledge that both parent strains had already been 
backcrossed 10 generations with C57/BL6 mice, and so should have an identical genetic 
background, we chose not to pursue further backcrossing in the ApoE/P2Y12 DK colony 
generated for this thesis.  However, in an ideal scenario, where time limitations and 
resources were not an issue, this strain would too have been backcrossed to fully ensure a 
common genetic background.  Furthermore, given that the significant chi-squared value 
obtained for the F2 generation was likely to have been due to small population size, in 
hindsight a greater number of breeding pairs would have been advantageous to more 
accurately assess the genotype frequencies in this population. 
 
Phenotype differences in weight gain and liver function between ApoE/P2Y12 DK and ApoE
-/-
 
mice, when fed a high-fat diet, raise many questions as to the role of P2Y12 in other cell-
types.  Although P2Y12 function in these cells was discussed in Chapter 4, along with how 
these may have resulted in these phenotype disparities, their overall impact on 
atherogenesis is unknown.  It is unlikely that P2Y12 function in liver, spleen, pancreatic, or 
microglial cells could influence lesion development, given that systemic lipid and cholesterol 
levels were unaltered and metabolic function was similar, nevertheless this should be 
considered when interpreting these findings. 
 
Similarly, following BMT, mice are described as being platelet or vessel wall P2Y12-deficient; 
however, consideration must be made for the potential influence of other P2Y12-expressing 
cells.  Although predominantly expressed on platelets, P2Y12 mRNA has also been 
identified, to a lesser degree, in murine dendritic cells, where it is thought to enhance T cell 
activation (Ben Addi et al. 2010).  The contribution of dendritic P2Y12 receptors to 
atherogenesis is unknown; however, although they too are bone marrow-derived, dendritic 
cells represent only a small population of cells in comparison to platelets (Fearnley et al. 
1999).  Likewise, P2Y12 has been found to be expressed on cultured endothelial cells, but its 
role in these cells is currently unknown.  Therefore, although platelets and VSMCs are the 
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principal source of P2Y12 in the bone marrow and vessel wall, it must be acknowledged that 
they are not the only cell-types to express P2Y12.  Nevertheless, given the evidence, it is 
highly likely that the P2Y12 effects on vessel injury and atherogenesis demonstrated in this 
thesis are platelet and VSMC-mediated. 
 
En face oil red O staining of aortae is a standard technique for the quantification of 
atheroma, but this method is a relatively crude measurement and is not sensitive to the size 
of lesion, rather the lipid content.  As such, the accuracy of this method may be limited by 
residual fatty tissue on the outside of the vessel.  Extensive efforts were made whilst 
dissecting the aortae to remove all fat from the outer surface of the vessel.  Nevertheless, a 
small amount of fat may have remained on the vessel, and may have been counted towards 
positive staining; however, the overall impact of this on the results is expected to be minimal.  
Conversely, quantification of lesion area via histological analysis is considerably more 
accurate, though when assessing long vessels, cross-sections must be made at intervals to 
enable full assessment of the vessel.  This was the case with both the carotid and 
brachiocephalic arteries, and so given the intervals between cross-sections, areas of lesion 
or neointima were inevitably missed, leading to some loss of detail on lesion/neointima size 
and composition.  Despite this, analysis of several sections at regular intervals along the 
length of the vessel, and taking a mean value, still provides a relatively accurate overview of 
injury or atheroma within the vessel, and is a sensitive method to detect significant effects of 
gene deficiency on these processes. 
 
A voluntary method of drug delivery was utilised in Chapter 7 of this thesis as an alternative 
to twice daily gavage.  Ticagrelor, clopidogrel, or mannitol (control) doses were mixed with 
jelly, which could then be presented to the mice as a small jelly cube containing drug.  Mice 
do not eat large quantities of food and, as this was given in addition to western diet ad 
libitum, jelly cubes needed to be as small as possible.  As a result, to achieve the required 
dosage, drug concentrations were relatively high and so may have affected the taste of the 
jelly.  Some mice, particularly in the ticagrelor group, did not take to the jelly doses and 
chose to leave the jelly on several occasions.  However, despite this non-compliance in 
some animals, a high level of platelet P2Y12 inhibition was still achieved, as measured by P-
selectin expression.  I believe this method is extremely useful for long-term dosing studies 
and, following minor modifications, compliance could also be improved.  Mice were trained 
for one week on jelly only, but in future a longer training period may be beneficial.  In 
addition, the method from which this was adapted (Zhang 2011) used added sweeteners.  It 
appears that the addition of the drug alters the taste of the jelly and so using either a more 
concentrated flavour of jelly or adding additional sweeteners may overcome this issue. 
 
150 
 
8.2 Future work 
The findings of this thesis generate many opportunities in which the research could be taken 
further.  Continuation of this work could not only better inform areas of platelet and P2Y12 
research, but also facilitate advancements in disease prevention and management through a 
greater understanding of the cell roles in disease progression.  The following sections outline 
areas in which I feel my research could be elaborated. 
 
Given the clear relationship between thrombus and neointima formation, and the importance 
of platelet P2Y12 in this process, it would be interesting to now test the impact of P2Y12 
inhibitors in a more clinically relevant injury model.  Despite the obvious difficulties involved, 
due to small vessel size, attempts have been made to directly model PCI in rodents, and 
recently murine stenting and balloon angioplasty have successfully been developed (Ali et 
al. 2007; Chamberlain et al. 2010).  Alternatively, the well-established pig angioplasty model 
of restenosis could be employed (Schwartz et al. 1990).  Further investigation into the 
development of restenosis using these models would be of interest, particularly in the 
application of the superior P2Y12 inhibitor ticagrelor in preventing this process. 
 
Likewise, vessel injury models used to study thrombosis and neointima formation have 
largely been performed on healthy vessels, and were therefore executed in non-
inflammatory models.  Previous studies have shown that atherosclerotic ApoE
-/-
 mice 
demonstrate increased neointima formation following injury (Zhu et al. 2000).  This highlights 
the huge impact that a pro-inflammatory environment, which is found particularly in 
atherosclerotic vessels following PCI, may have on neointima formation.  Therefore, 
additional research into the impact of P2Y12 inhibition following arterial injury in a pro-
inflammatory model is merited.  Recently developed mutant pig models of atherosclerosis 
may be particularly useful for such experiments (Jensen et al. 2010; Al-Mashhadi et al. 
2013).  In addition, given the positive impact of P2Y12 antagonists on reducing restenosis in 
animal models, an appropriately powered clinical study into the direct effect of P2Y12 
antagonists on restenosis rates following PCI is also warranted. 
 
Phenotype differences between ApoE/P2Y12 DK and ApoE
-/-
 mice would be of interest to 
explore in more detail.  As mentioned previously, metabolic cages could be employed to 
accurately measure food intake in ApoE/P2Y12 DK mice to study whether increased weight 
gain was due to greater food consumption.  Similarly, the effects of brain P2Y12-deficiency 
on behaviour and activity could be studied, which may shed light on the diet-related weight 
increase, in addition to providing a better understanding of the long-term impact of P2Y12-
deficiency on brain development and function. 
 
At the 3 phases of atherogenesis discussed in this thesis, after 4, 12, and 20 weeks on a 
high-fat diet, it is clear that the influence of platelet and vessel wall P2Y12 evolves, and 
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changes with disease progression.  Between the Li study (Li et al. 2012) and my own, 
snapshots into the cellular roles in atherogenesis are emerging; however, further studies are 
required to build up a detailed picture of P2Y12 involvement throughout disease progression. 
 
Regional differences in lesion development observed in ApoE/P2Y12 DK mice after 12 weeks 
of western diet were postulated to be due to the impact of shear stress on platelet adhesion. 
Flow models have been used previously to investigate the effects of shear on platelet 
adhesion to the endothelium.  This hypothesis could be pursued further using flow models to 
study the effect of varying shear stress on adhesion of P2Y12-deficient platelets to cultured 
endothelial cells and in explanted atherosclerotic vessels. 
 
Macrophage staining of aortic sinus lesions using markers F4/80 and MAC387 proved 
inconclusive.  Results from the MAC387 staining suggested further workup of the antibody 
was required and that modification of the experimental conditions may have yielded more 
definitive results.  Given more time, I would like to have pursued this work and if 
unsuccessful, would have tried alternative markers such as CD68, MAC3 and MOMA-2. 
 
In addition, further smooth muscle actin staining of lesions from ApoE/P2Y12 DK mice fed 
western diet for a longer period of 20 weeks, similar to the Li study, would be of particular 
interest (Li et al. 2012).  Li et al. demonstrated an increase in collagen at 20 weeks in P2Y12-
deficient mice, yet carried out no α-smooth muscle actin staining of their own.  As discussed 
in Chapter 5, this finding appears to be contradictory to my own showing a decrease in 
collagen and α-SMA in the absence of P2Y12 due to a possible reduction in P2Y12-mediated 
VSMC mitogenesis.  Furthermore, the Li study did not investigate the possible effects of 
vessel wall P2Y12 on atherogenesis, and so further bone marrow transplantations would be 
of great interest, given my own findings.  However, research hypotheses must be carefully 
considered in accordance with the 3R’s principles, in order to justify the further use of 
animals, prior to embarking on additional time points and bone marrow transplantations. 
 
Following the discovery that vessel wall P2Y12-deficiency leads to a reduction in atheroma, 
further study is needed to better understand exactly how P2Y12 signalling in these cells 
promotes early atherogenesis.  I postulated this may be due to P2Y12-mediated VSMC 
mitogenesis in light of recent work by Rauch et al., which demonstrated enhanced P2Y12 
expression and P2Y12-induced mitogenic effects in response to thrombin (Rauch et al. 
2010).  Continuation of this in vitro work, including using P2Y12-deficient VSMCs, would be 
of particular interest and may help to address this hypothesis.  Studying mitogenic 
responses in P2Y12-deficient cells following exposure to growth factors and chemokines 
could be performed.  Given that little is known of the effect of P2Y12-deficiency on VSMC 
development and phenotype, further investigation into this is also warranted.  Clarification on 
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the expression of definitive VSMC synthetic and contractile phenotype markers will also aid 
this research. 
 
Identification of P2Y12 within atherosclerotic lesions of bone marrow transplanted mice could 
be confirmed by mRNA expression levels.  Additional workup of the α-SMA/P2Y12 dual 
immunofluorescent staining protocol is also required, and would help determine P2Y12 
expressing VSMCs from platelets that have been incorporated into the lesion.  
Determination of the APR-012 P2Y12 antibody binding site is needed to confirm whether 
positive signals seen in the aortic sinus of vessel wall P2Y12-deficient mice was indeed, as 
postulated the antibody binding to part of the non-functional receptor or due to non-specific 
binding.  If it was the latter, then the use of other P2Y12 antibodies could be pursued. 
 
Despite achieving a high level of platelet-P2Y12 inhibition, ticagrelor and clopidogrel 
treatment did not block vessel wall P2Y12-mediated effects on atherogenesis.  However, this 
lack of effect could be due to the drugs not penetrating the endothelium and so never 
reaching the receptor.  P2Y12 antagonists have been shown to block P2Y12-mediated 
contraction, but these experiments were carried out on denuded vessels.  Further ex vivo 
studies could be carried out using vessels with an intact endothelium, to investigate if these 
drugs are able to penetrate to the receptor.  Additional work utilising labelled inhibitors may 
also be able to measure drug permeability and detect inhibitors bound to VSMC P2Y12. 
 
Finally, given the indication of platelet P2Y12 involvement in late atherogenesis, investigation 
into the effect of P2Y12 antagonists on lesion progression would be of interest and could be 
performed in murine or porcine models of advanced atherosclerosis.  In the long-term, 
clinical studies into the prophylactic use of these drugs in patients with evidence of 
atherosclerotic disease could be investigated, and should assess both any benefit, by a 
reduction in CV events, but also any associated bleeding risk. 
 
8.3 Concluding remarks 
In conclusion, this thesis presents novel findings to support my original hypothesis that the 
P2Y12 receptor is important in modulating the vessel wall response to both injury and 
inflammation.  Furthermore, I describe a previously unknown role of vessel wall, but not 
platelet, P2Y12 in early atherogenesis, which is in contrast to published data that documents 
the involvement of platelet P2Y12 in later atherogenesis and its thrombotic complications (Li 
et al. 2012).  This work emphasises the complexity of cellular roles within atherogenesis, 
and how the nature and impact of these cell populations may change as disease evolves.  
Further investigation is necessary to clarify the full extent to which vessel wall and platelet 
P2Y12 influence atherogenesis throughout the course of disease.  However, it is clear that 
this work offers a new perspective on atherogenesis, and so has great relevance to, and 
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impact on, disease management and prevention, which may alter the therapeutic approach 
to atherosclerosis in the future. 
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10.1 Appendix I – Diets and antibiotic water 
10.1.1 Chow diet 
2018S - Teklad Global 18% protein rodent diet purchased from Harlan (Indiana, IN). 
Autoclaved and stored at room temperature. 
 
Ingredients 
Ground wheat, ground corn, wheat middlings, dehulled soybean meal, corn gluten meal, 
soybean oil, calcium carbonate, brewers dried yeast, dicalcium phosphate, iodized salt, L-
lysine, DL-methionine, choline chloride, thiamine mononitrate, biotin, niacin, vitamin A 
acetate, pyridoxine hydrochloride, vitamin D3 supplement, folic acid, menadione sodium 
bisulphite complex (source of vitamin K activity), calcium pantothenate, vitamin E 
supplement, vitamin B12 supplement, riboflavin, ferrous sulphate, magnesium oxide, 
manganous oxide, zinc oxide, copper sulphate, calcium iodate, cobalt carbonate, chromium 
potassium sulphate, kaolin. 
 
Specification % (w/w) % KCal Kcal/g 
Crude fat 6 17  
Crude protein 18.8 23  
Crude fibre 3.8 /  
Ash 5.9 /  
Carbohydrate 50 60  
*Starch *45   
*Sugar *5   
Digestible energy   3.4 
Metabolised energy   3.3 
 
10.1.2 Western diet 
829100 - Western rodent diet purchased from Special Diet Services (Witham, UK). 
Purified diet, stored at 4°C to prolong shelf-life. 
 
Ingredients 
Sucrose, milk fat anhydrous, casein, maltodextrin, corn starch, cellulose, corn oil, calcium 
carbonate, L-cystine, choline bitartrate, cholesterol (0.15%), antioxidant, AIN-76A-MX, AIN-
76A-VX. 
 
Specification % (w/w) % KCal Kcal/g 
Crude fat 21.4 42 1.93 
Crude protein 17.5 15 0.7 
Crude fibre 3.5 / / 
Ash 4.1 / / 
Carbohydrate 50 43 2 
Energy   4.63 
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10.1.3 Antibiotic drinking water 
Antibiotic stocks 
Neomycin trisulphate salt hydrate (N1876; Sigma, Poole, UK): 0.1 mol/L in 10 mL aliquots  
Polymyxin B sulphate salt (P1004; Sigma): 1 million USP units in 2 mL aliquots 
 
Antibiotic water 
An aliquot of each antibiotic is added to 1 litre of sterile water making the final 
concentrations: 1 mmol/L neomycin, 1000 USP units/mL polymyxin B. 
 
10.2 Appendix II - PCR parameters and buffers 
All reagents listed in Materials (see section 2.3.1), unless otherwise stated. 
 
10.2.1 ApoE PCR parameters 
Reaction mix 
BioMix™ red   12.5 µL 
 Primer 180   0.5 µL 
 Primer 181   0.5 µL        0.4 µmol/L final concentration 
 Primer 182   0.5 µL 
 Sample DNA   2 µL 
 Sterile water   9 µL 
 
Cycle program 
   94°C for 3 minutes (denaturation step) 
   94°C for 20 seconds (denaturation step) 
     X 35  68°C for 40 seconds (annealing step) 
   72°C for 2 minutes (elongation step) 
   72°C for 7 minutes (final elongation step) 
   4°C holding temperature 
 
10.2.2 P2Y12 PCR parameters 
Reaction mix 
25 mmol/L nucleotides       0.2 µL       0.2 mmol/L final concentration 
25 mmol/L MgCl2       1.5 µL       1.5 mmol/L final concentration 
GoTaq® DNA polymerase (5 U/µL)   0.2 µL       1 unit 
5 x GoTaq® green buffer      5 µL     1 x final concentration 
Primer NEO        0.3 µL       0.25 µmol/L final concentration 
Primer DP308        0.93 µL     0.75 µmol/L final concentration 
Primer DP310        0.93 µL     0.75 µmol/L final concentration 
Sample DNA        2 µL 
Sterile water      13.94 µL 
 
Cycle program 
94°C for 3 minutes (denaturation step) 
   94°C for 30 seconds (denaturation step) 
     X 35  62°C for 30 seconds (annealing step) 
   72°C for 1 minute (elongation step) 
   72°C for 7 minutes (final elongation step) 
   4°C holding temperature 
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10.2.3 Agarose gels 
ApoE - 1.5% w/v gel: 2.25 g agarose to 150 mL TAE buffer  
P2Y12 - 2% w/v gel: 3 g agarose to 150 mL TAE buffer 
 
In each case, the agarose/TAE mixture was heated in a microwave on full power for 2 
minutes until the agarose had dissolved and the liquid was clear.  The solution was cooled 
before adding 10 µL ethidium bromide.  The gel poured and allowed to set for 1 hour before 
placing in an electrophoresis tank.  The gel was submerged in TAE buffer before loading 
samples. 
 
10.2.4 TAE buffer 
To make x 50 stock: 2 mol/L Tris (hydroxymethyl) methylamine (VWR, Lutterworth, UK) 
28.55 mL glacial acetic acid (100% v/v) (VWR) 
50 mmol/L EDTA (pH 8.0) (Sigma) 
Make up to 500 mL with distilled water 
Dilute with distilled water to x 1 working solution. 
 
10.2.5 DNA marker 
1 µL Phix174/HAEIII marker + 3 µL orange/green 6x loading dye + 14 µL sterile water 
 
10.3 Appendix III – Histology and immunohistochemistry 
All reagents listed in Materials (see section 2.8.1 and 2.9.1). 
 
10.3.1 Fixatives 
Neutral buffered formalin (10% v/v) 
To make 1 litre:    4 g sodium phosphate [NaH2PO4] 
7.1 g di-sodium hydrogen orthophosphate [Na2HPO4] 
100 mL formaldehyde (37% w/v) 
900 mL distilled water 
 
Paraformaldehyde in PBS (PFA) (4% w/v) 
To make 100 mL:  4 g paraformaldehyde 
    100 mL PBS 
 
Run the bottle under a hot tap to heat the solution to approximately 60°C.  Then add several 
drops of sodium hydroxide [NaOH] to raise the solution to pH 7.0.  The solution should now 
become clear. 
 
10.3.2 Dehydration protocol 
Tissue is placed in plastic histological cassettes and submerged in increasing concentrations 
of alcohol for 1 hour per grade alcohol (50%, 70%, 90%, 100% and 100% v/v ethanol), 
including a change of ethanol after the first 100% step.  Tissue is then placed in a 1:1 
mixture of ethanol (100%) and xylene for 1 hour.  Followed by 2 x 1 hour steps in xylene, 
with a change of liquid after the first xylene step.  Tissue is then placed in molten paraffin 
wax and left in an oven (60°C) overnight. 
 
To ensure successful infiltration of the wax into the tissue, molten wax should only be held at 
1-2°C above its melting point.  In this case the melting point was 58°C and so the wax oven 
was set to a maximum temperature of 60°C.  Storing wax at much higher temperatures 
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above its melting point, for prolonged periods of time, can alter the properties of the wax and 
in my experience reduce the ability of the wax to infiltrate the tissues.  Further preventative 
measures include replacing molten wax every 6 months and avoid allowing the wax to set 
and re-melt. 
 
10.3.3 Histological staining protocols 
10.3.3.1 Oil red O 
Making oil red O stain 
1. Add 1 mL distilled water to 99 mL isopropanol (Propan-2-ol). 
2. Add oil red O powder to the solution until it is saturated. 
3. Filter the saturated solution using Whatman® grade 1 filter paper. 
4. Dilute the final stain to 60% v/v using distilled water. 
 
Staining protocol 
1. Carry out the staining process in individual 1.5 mL eppendorf tubes. 
2. Rinse aortae in distilled water followed by 60% v/v isopropanol for 2 minutes. 
3. Immerse in oil red O for 10-15 minutes. 
4. Rinse in 60% v/v isopropanol for 2 minutes, followed by distilled water. 
 
10.3.3.2 Alcian blue/elastic van Gieson (EVG) 
Staining protocol 
1. Dewax slides for 10 minutes in xylene and rehydrate through graded alcohols 
(100%, 90%, 70% and 50% v/v ethanol) for 2 minutes each, finishing in water. 
2. Oxidise with aqueous potassium permanganate (0.25% w/v) for 3 minutes, then 
rinse in water. 
3. Bleach with oxalic acid (1% w/v) for 3 minutes, then rinse in water. 
4. Stain nuclei with Carazzi’s haematoxylin for 2 minutes. 
5. Differentiate with acid alcohol (1% v/v HCl in 70% v/v ethanol) for 5 seconds. 
6. “Blue” with hot running tap water for 5 minutes. 
7. Stain with alcian blue (1% w/v in 3% aqueous acetic acid) for 5 minutes. 
8. Rinse in water, followed by 95% v/v ethanol. 
9. Stain with Miller’s elastin stain for 30 minutes. 
10. Differentiate in 95% ethanol and rinse in water. 
11. Stain with Curtis’ modified van Gieson reagent (10 mL 1% w/v ponceau S in 90 mL 
saturated aqueous picric acid, 1ml glacial acetic acid) for 6 minutes, then rinse in 
water. 
12. Dehydrate through graded alcohols (reverse step 1) ending in xylene. 
13. Mount with coverslips using DPX resin. 
 
Interpretation 
Elastin coarse and fine fibres   Blue/black 
Acid mucopolysaccharides   Black 
Collagen      Red 
Muscle      Yellow 
 
10.3.3.3 Haematoxylin and eosin (H&E) 
Staining protocol 
1. Dewax slides for 10 minutes in xylene and rehydrate through graded alcohols 
(100%, 90%, 70% and 50% v/v ethanol) for 2 minutes each, finishing in water. 
2. Stain with Carazzi’s haematoxylin for 2 minutes, then rinse in water. 
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3. Stain with eosin (1% w/v) for 30 seconds. 
4. Rinse briefly in water and quickly dehydrate through graded alcohols for 30 seconds 
each step, beginning at 90% ethanol and ending in xylene. 
5. Mount with coverslips using DPX resin. 
 
10.3.3.4 Martius scarlet blue (MSB) 
Staining protocol 
1. Dewax slides for 10 minutes in xylene and rehydrate through graded alcohols 
(100%, 90%, 70% and 50% v/v ethanol) for 2 minutes each, finishing in water. 
2. Stain with celestine blue (1% w/v) for 5 minutes. 
3. Stain with Harris’ haematoxylin for 5 minutes, then rinse in water. 
4. Differentiate in acid alcohol (1% v/v HCl in 70% v/v ethanol) for a few seconds and 
then ‘blue’ in tap water for 5 minutes. 
5. Rinse in 95% v/v ethanol. 
6. Stain with martius yellow (0.5% w/v martius yellow, 2% w/v phosphotungstic acid in 
95% ethanol) for 2 minutes and rinse in water. 
7. Stain with ponceau de xylidine (1% w/v ponceau de xylidine in 2% v/v glacial acetic 
acid) for 10 minutes. 
8. Differentiate in 1% w/v phosphotungstic acid for 5 minutes and drain (do not wash in 
water). 
9. Stain with methyl blue (5% w/v methyl blue in 10% v/v glacial acetic acid) for 10 
minutes. 
10. Rinse in 1% v/v glacial acetic acid for 10 minutes. 
11. Dehydrate in 100% v/v ethanol, then xylene for 2 minutes each. 
12. Mount with coverslips using DPX resin. 
 
Interpretation 
Nuclei      Black/purple 
RBCs      Yellow 
Fibrin      Red 
Collagen/adventitia/connective tissue  Bright blue 
Smooth muscle     Pink/red 
 
10.3.4 Immunohistochemistry protocols 
Reagents 
Vectastain® ABC-HRP reagent - Add 1 drop each of reagent A and B into 2.5 mL PBS 
(make 30 minutes prior to use). 
SigmaFAST™ DAB - Add one DAB and one urea hydrogen peroxide tablet to 15 mL water. 
 
General staining protocol 
1. Dewax slides for 10 minutes in xylene and rehydrate through graded alcohols 
(100%, 90%, 70% and 50% v/v ethanol) for 2 minutes each, finishing in water. 
2. Block endogenous peroxidases by incubation in 3% v/v hydrogen peroxide in PBS 
for 10 minutes, then rinse in water. 
3. Antigen retrieval step if necessary. 
4. Block non-specific secondary antibody binding with 1% w/v skimmed milk powder in 
PBS for 30 minutes at room temperature. 
5. Tip off milk buffer (don’t wash) and blot away excess.  
6. Incubate with primary antibody. 
7. Wash in 3 changes of PBS, for 5 minutes each. 
179 
 
8. Incubate with biotinylated secondary antibody (1:200 dilution in PBS) for 30 minutes 
at room temperature. 
9. Wash in 3 changes of PBS, for 5 minutes each. 
10. Incubate with Vectastain® ABC-HRP reagent for 30 minutes at room temperature. 
11. Wash in 3 changes of PBS, for 5 minutes each. 
12. Add DAB substrate for 5 minutes and rinse in water. 
13. Counterstain using Carazzi’s haematoxylin for 1 minute and rinse in water. 
14. Dehydrate through graded alcohols (reverse step 1) ending in xylene. 
15. Mount with coverslips using DPX resin. 
 
10.3.4.1 α-Smooth muscle actin (α-SMA) 
Primary antibody 
Mouse monoclonal anti-human α-smooth muscle actin (M0851); 1:150 dilution in PBS for 1 
hour at room temperature. 
 
Secondary antibody 
Biotinylated goat anti-mouse IgG secondary antibody. 
 
10.3.4.2 F4/80 
Primary antibody 
Rat anti-mouse F4/80 (ab6640); 1:100 dilution in PBS, overnight at 4°C. 
 
Secondary antibody 
Biotinylated goat anti-rat IgG secondary antibody. 
 
Antigen retrieval 
Incubate in citrate buffer for 20 minutes at 95°C.  Cool for 20 minutes at room temperature, 
then permeabilise by incubation in 0.5% v/v triton X-100 in PBS for 10 minutes at room 
temperature. 
 
Citrate buffer (10 mmol/L, pH 6.0) 
    2.1 g citric acid monohydrate 
    900 mL distilled water 
 
Adjust pH to 6.0 using 2 mol/L sodium hydroxide [NaOH], then dilute to 1 litre for use. 
 
10.3.4.3 MAC387 
Primary antibody 
Mouse monoclonal anti-human MAC387 (M074701); 1:100 dilution in PBS for 1 hour at 
room temperature. 
 
Secondary antibody 
Biotinylated goat anti-mouse IgG secondary antibody. 
 
Antigen retrieval 
Incubate in 0.1% w/v trypsin in TBS (pH 8.0) for 10 minutes at 37°C.  Tip off trypsin and add 
PBS to stop digestion. 
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10.3.5 P2Y12 / α-smooth muscle actin immunofluorescence protocol 
Primary antibodies 
Mouse monoclonal anti-human α-smooth muscle actin (M0851). 
Rabbit polyclonal anti-P2Y12 (APR-012). 
 
Secondary antibodies 
Alexa Fluor® 488 goat anti-mouse IgG, H+L, highly cross adsorbed (A-11034). 
Alexa Fluor® 594 goat anti-rabbit IgG, H+L, highly cross adsorbed (A-11037).  
 
Staining protocol 
1. Dewax slides for 10 minutes in xylene and rehydrate through graded alcohols 
(100%, 90%, 70% and 50% v/v ethanol) for 2 minutes each, finishing in water for 5 
minutes. 
2. Block non-specific secondary antibody binding in blocking buffer (5% v/v goat 
serum, 1% w/v BSA, 0.5% v/v triton in PBS) for 30 minutes at room temperature. 
3. Tip off blocking buffer (don’t wash) and blot away excess. 
4. Incubate with α-smooth muscle actin (1:150) and P2Y12 primary antibodies (1:100) 
in dilution buffer (1% w/v BSA, 0.5% triton v/v in PBS) overnight at 4°C. 
5. Wash in 3 changes of PBS, for 5 minutes each. 
6. Incubate with fluorescent secondary antibodies (1:200 dilution with 1% w/v BSA in 
PBS) in the dark for 1 hour at room temperature. 
7. Wash in 3 changes of PBS, for 5 minutes each. 
8. Mount with coverslips using Vectashield® mounting medium with DAPI, seal with 
nail varnish and keep in the dark. 
 
10.4 Appendix IV – In vitro assays 
All reagents listed in Materials (see section 2.10.1). 
 
10.4.1 HEPES-Tyrode’s (HT) buffer 
To make 2 litres: 15.15 g Sodium chloride [NaCl] 
   1.48 g Sodium bicarbonate [NaHCO3] 
   0.4176 g Potassium chloride [KCl] 
   0.218 g Potassium phosphate [KH2PO4] 
   2.04 g Dextrose (D-glucose) 
4.78 g N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid            
(HEPES) 
   2 L ultra pure water 
 
